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Abstract 
 
Mycobacterium tuberculosis (TB), the causative agent of tuberculosis, is responsible for over 
one million deaths per annum, a substantive proportion of these due to multidrug resistant or 
extensively drug resistant strains. The available antibiotics are rapidly becoming ineffective 
due to the development of resistance mechanisms by the pathogen. Considering this, there is 
an urgent need for novel and highly effective new TB drugs, with novel modes of action. The 
peptidogycan (PG) layer in the cell wall has emerged as a rich area for drug discovery. It 
undergoes constant reconstruction by penicillin binding proteins (PBPs) and other enzymes to 
allow for cell growth and division, while preventing lysis. In this study, we characterize the 
function of two Low Molecular Mass PBPs, known as D,D-carboxypeptidases (D,D-CPases, 
MSMEG_6113 and MSMEG_2433) in Mycobacterium smegmatis, a model organism for TB 
research. Using a bacterial two hybrid system, we demonstrate that MSMEG_2433 interacts 
with PonA1 (A High Molecular Mass PBP involved in PG synthesis) and FtsH (An AAA 
family protease and a member of the divisome complex). We also demonstrate that 
MSMEG_6113 forms a complex with FtsI (A High Molecular mass PBP and also part of the 
divisome complex) and a cell division control protein, Cdc48. We demonstrate that the two 
D,D-CPases associate with their partnering proteins via their C-terminal transpeptidase 
domain. The importance of these identified interactions for cell division and growth was 
tested through deletion of partnering proteins from the mycobacterial genome, particularly 
FtsI and Cdc48. FtsI is essential for mycobacterial growth in vitro as demonstrated by the 
inability to recover mutants through allelic exchange by homologous recombination, while 
Cdc48 is dispensable for growth. We noted morphological and cell division defects in the 
Cdc48 deletion mutant strain. The absence of Cdc48 results in bulging, kinking and chaining 
phenotypes, in addition to misplacement of the FtsZ ring. Collectively, our observations 
describe the presence of novel PG hydrolysing protein complexes that may mediate essential 
steps in PG synthesis and bacterial proliferation. Targeting these complexes may provide an 
attractive avenue for the development of novel TB therapeutics.  
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1. Introduction 
1.1. Tuberculosis 
Tuberculosis (TB) is an airborne infectious disease caused by the human pathogen 
Mycobacterium tuberculosis (Mtb) discovered in 1882 by Robert Koch. The disease has been 
around for millennia, being recorded as early in history as the Egyptian and Greco-Roman 
civilizations (De Backer et al., 2006). Presently, TB still remains a foremost public health 
burden worldwide and the ninth leading cause of death due to bacterial infection, primarily in 
middle and low income countries (WHO, 2017). In 2016 alone, approximately 10.4 million 
new TB cases were reported, with 1.7 million deaths resulting from TB infections (of which 
374 000 and 1.3 million were from HIV positive and HIV negative patients, respectively), 
ranking TB as one of the top 10 causes of death worldwide above HIV and malaria, as 
reported by the World Health Organization (WHO, 2017). TB infection is prevalent in 
developing countries, particularly the Sub-Saharan African countries and the burden is 
heterogeneously distributed in the world (Figure 1.1.). For example, in South Africa TB 
incidence is more than 250 fold greater (˃500 cases per 100 000 population per year) than the 
United States (˂10 cases per 100 000 population per year) (WHO, 2017). It has also been 
reported that TB incidence is nearly 10% higher in men than women (Dye, 2006) and in all 
new cases worldwide, approximately 10% occur in children (Swaminathan and Rekha, 2010).  
South Africa also ranks fourth among the 10 highest drug-resistant TB burdened countries in 
the world, after China, India and Russia (WHO, 2017). The global burden of TB disease in 
these countries is exacerbated by a number of factors that severely compromise current TB 
interventions. These factors include a decline in health care systems, high population density, 
poor socio-economic conditions, co-infection with TB-HIV and the emergence of drug 
resistant TB. Other risk factors that are responsible for driving the TB epidemic include 
malnutrition, which is attributed to nearly 27% of TB cases worldwide, air pollution, 
excessive alcohol, type II diabetes and smoking (Lonnroth et al., 2010). Among the TB risk 
factors, HIV infection is the strongest, with 12% of all new cases of active TB disease and 
25% of all TB-related deaths occurring in HIV-positive individuals (Getahun et al., 2015). 
The majority (75%) of HIV-associated active TB disease cases and deaths occur in Africa 
(Getahun et al., 2015), making TB a particular source of concern in the continent. 
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Figure 1.1: Global estimated TB incidence rates. TB burden is heterogeneously distributed and is prevalent in 
developing countries, particularly the Sub-Saharan African region. Reproduced from Global Tuberculosis 
Report 2017, WHO (2017).  
1.2. TB infection and TB disease 
Mtb is an extremely well adapted human pathogen. On average, an infectious individual 
might infect 3-10 individuals per year (van Leth et al., 2008), of whom only a minority will 
progress to active TB disease. Infection with Mtb can lead to two broad outcomes: 
elimination or persistence of the pathogen and therefore, TB can present as a dynamic 
spectrum, from asymptomatic infection to active TB disease (Esmail et al., 2014). The 
infectious life cycle of Mtb starts with the transmission of the bacilli from a patient with 
active pulmonary TB through the respiratory route, placing their contacts at risk of infection 
(Zumla et al., 2013a).  Infection begins when aerosolized Mtb enters the lungs via inhalation, 
where it reaches the alveolar space and encounters the resident alveolar macrophages 
(Gonzalo-Asensio et al., 2017). These alveolar macrophages internalize the bacilli by 
receptor-mediated phagocytosis and produce pro-inflammatory components, which lead to 
the recruitment of a large number of immune cells (including B cells and T cells) to the 
infection site, thus inducing granuloma formation (Lin et al., 2014; Gonzalo-Asensio et al., 
2017).  
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The granuloma is an organized structure consisting of the infected macrophages surrounded 
by highly differentiated cells such as epithelioid cells, multinucleated giant cells and foamy 
cells, all surrounded by a ring of T lymphocytes (Miranda et al., 2012; Marakalala et al., 
2016). The granuloma creates an immune microenvironment that acts to constrain the 
infection. If the infection is contained by the granuloma without any substantial tissue 
damage or further progression of disease, the person is said to have latent TB infection 
(LTBI). Individuals with LTBI are asymptomatic and nearly 2 billion people (approximately 
one third of the world‟s population) are estimated to harbor LTBI (Gonzalo-Asensio et al., 
2017). It is estimated that 5% to 15% of these individuals have a defined risk of progressing 
to active TB disease throughout their lifetime (Andrews et al., 2012). In a case where the 
granuloma fails to control bacteria, the infection progress to active TB disease. Individuals 
with active TB disease display symptoms such as fever, weight loss, persistent cough and 
fatigue. In the absence of treatment, TB can be frequently fatal and nearly 50% of the people 
who suffer with the disease will die from it (Tiemersma et al., 2011). 
1.3. TB treatment and drug resistance 
Of all the individuals diagnosed with active TB disease annually, 80% of them are infected 
with Mtb strains that are completely susceptible to the available antimicrobials used for TB 
treatment while the remaining proportion (20%) are infected with drug-resistant strains 
(WHO, 2015; Onozaki et al., 2015). Treatment options differ for LTBI, drug-resistant and 
drug-sensitive active TB disease, and it is estimated that nearly 44 million lives were saved 
by TB treatment between the year 2000 and 2016 (WHO, 2017). The recommended treatment 
regimens for LTBI include the use of Isoniazid (INH) for 6-9 months, a combination of INH 
and Rifapentine for 3 months, followed by 3-4 months of INH and Rifampicin (RIF) or 3-4 
months of RIF alone (WHO, 2014). The standard treatment for drug-sensitive TB includes 
chemotherapy for a period of 6 months, using a composition of first line drugs and second 
line drugs. The treatment is made up of a combination of Pyrazinamide (PZA), INH, 
Ethambutol (EMB) and RIF for the initial two months (intensive treatment phase), followed 
by RIF and INH for the next four months (continuation phase) (WHO, 2010; Nahid et al., 
2016). Although the success rate of the 6 months regimen is high, there are several 
limitations to it. A certain fraction of patients develop toxicity symptoms, which when 
combined with the long duration of treatment undermines patient compliance (Pai et al., 
2016). Failure to complete treatment can result in relapse and emergence of drug resistance.  
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The emergence of drug resistance is a major concern. Globally, 3.5% of new active TB 
disease cases and 20.5% of previously treated cases have multi drug- resistant TB (MDR-
TB). MDR-TB is defined as resistance to the 2 most effective first line drugs, RIF and INH. 
A small proportion (9.7%) of MDR-TB cases progress to extensively drug-resistant TB 
(XDR-TB), defined as resistance to 3 or more of the 6 classes of second line drugs (Pai et al., 
2016). Therapeutic options for drug resistant TB are expensive, lengthy, and use highly toxic 
drugs with uncertain efficacy (Koul et al., 2011). In mycobacteria, the emergence of 
resistance to first line drugs is essentially attributed to genetic mutations in various drug 
target-encoding genes. This highlights a crucial demand for identification of novel drug 
targets and the development of highly effective drugs that have the potential to reduce 
duration of TB treatment. The mycobacterial cell envelope discussed below, particularly the 
peptidoglycan layer of the cell wall has emerged as a rich area for drug discovery. 
1.4. The mycobacterial cell envelope 
The mycobacterial cell envelope is made of complex, multiple layers including a capsule-like 
layer, the envelope core/ cell wall and the plasma membrane (Figure 1.2) (Hett and Rubin, 
2008). The outer layer of the cell envelope is a polymer of polysaccharides (mannan, glucan 
and arabinomannan), lipids (lipopolysaccharides, lipooligosaccharides, phospholipids and 
several other lipids) and proteins (Mishra et al., 2011; Lee et al., 2012). The envelope core, 
herein referred to as the cell wall, is required for bacterial growth, cell shape, virulence and it 
plays a significant role in mediating the intrinsic resistance to antibiotics (Bansal-Mutalik and 
Nikaido, 2014). The cell wall consists of a mycolic acids (MAs) layer esterified to the 
arabinogalactan (AG) layer, which is connected to the muramic residue of the peptidoglycan 
(PG) layer through a linker disaccharide (Kaur et al., 2009). MAs have been associated with 
reduction of Mtb-induced host inflammatory response (Hett and Rubin, 2008) and they play a 
principal role in the inherent decreased permeability to small molecules. The AG layer plays 
part in retaining the integrity of the cell envelope and also plays an essential role in regulating 
permeability of the cell by functioning as an anchor for MA layer which is impermeable (Hett 
and Rubin, 2008). PG layer provides the bacterium with strength to withstand the difference 
in pressure between the environment and the interior of the cell and as a result, it is essential 
for bacterial survival. It is also important in maintaining the specific shape of bacterial cells 
(Hett and Rubin, 2008). 
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Figure 1.2: Diagrammatic representation of mycobacterial cell envelope composition. The envelope 
consists of the outer most capsule-like layer (red rectangle), the envelope core (cell wall) which is made up of 
the mycolic acid layer (yellow threads), arabinogalactan layer (orange pentagons) and PG layer represented by 
the green hexagons cross-linked by the stem peptides (dark green lines). The lipid bilayer represented by purple 
circles. Figure drawn by student, adapted from Hett and Rubin (2008). 
One target of TB antimicrobials is the cell wall and many drug compounds that are under 
development or in clinical use target each layer of the cell wall and enzymes associated with 
its synthesis (Zumla et al., 2013b). For example, EMB inhibits the synthesis of AG and 
lipoarabinomannan and INH inhibits MA synthesis. Many antibiotics that are used widely, 
such as D-cycloserine, β-lactams and glycopeptides target various stages of PG synthesis and 
are routinely used to treat many bacterial infections (Zumla et al., 2013b). However, despite 
their widespread use, bacteria have established strategies to deal with the stress created by 
these antibiotics. For example, they mediate β-lactam resistance by expressing penicillin-
insensitive L,D-transpeptidases to form L,D-cross links instead of D,D-cross-links (Magnet et 
al., 2007). They can also confer vancomycin (a glycopeptide that binds the terminal D-Ala-D-
Ala of the stem peptide) resistance by replacing the D-Ala-D-Ala with D-Ala-D-Serine or D-
Ala-D-Lactate (Mainardi et al., 2008). In addition, bacteria activate their cell-wall stress 
stimulon when exposed to antibiotics, leading to overexpression of PG biosynthesis-
associated genes (Steidl et al., 2008). Regardless of all these resistance mechanisms, PG still 
remains an attractive antibacterial target and in order to combat MDR and develop new TB 
drugs, it is essential to have an indepth understanding on how PG is synthesized and 
modified.  
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1.5. Mycobacterial cell growth and division 
One of the many reasons why Mtb remains an extraordinary successful human pathogen is 
that during cell growth and division, mycobacteria produce heterogeneous daughter cells 
(Santi et al., 2013), which further undergo cell wall remodeling during infection, thus 
allowing the bacterium to withstand the stresses encountered during infection (Aldridge et al., 
2012). This facilitates adaptation of the bacteria to the host and could possibly have a major 
role in clinical latency. The bacterial cell proliferation process is divided into two stages, 
where the parental cell first undergoes elongation, then followed by division of the elongated 
cell into two daughter cells. In numerous bacteria, the cell division process is symmetric 
resulting in production of equally sized daughter cells that equally share the contents of the 
mother cell (Typas et al., 2012). However, in mycobacteria, cell growth and division occur in 
an asymmetric manner, producing unequally sized daughter cells (Santi et al., 2013). 
Mycobacteria grow by inserting newly synthesized cell wall subunits at their sub-polar 
regions, and all cells consist of one pole which is inherited from the previous cell division 
(old pole) and one which is synthesized during division, termed new pole (Figure 1.3A and 
1.3B) (Aldridge et al., 2012). In Firmicutes like E. coli, an actin like filament, MreB, 
spatially directs lateral cell wall synthesis. Mycobacteria lack MreB homologues and thus 
elongate by polar growth rather than lateral wall extension (Hett and Rubin, 2008). The polar 
growth in mycobacteria is explained by two models. In the first model, cytokinesis is used to 
explain the asymmetry in the cell division process (Santi et al., 2013). This model proposes 
that both cell poles grow in a symmetric manner until cytokinesis, and from thereon, growth 
starts to occur predominately at the old pole until cell separation, resulting in generation of 
two unequally sized daughter cells (Figure 1.3A) (Santi et al., 2013; Kieser and Rubin, 2014). 
The second model proposes that elongation of the poles occur at different rates throughout 
the cell cycle, with the old pole always elongating faster than the new pole at all stages of the 
process (Aldridge et al., 2012; Santi et al., 2013). Cell division is also asymmetric, generating 
daughter cells of unequal sizes (Figure 1.3B) (Aldridge et al., 2012; Santi et al., 2013; Kieser 
and Rubin, 2014).  
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Figure 1.3: Models of mycobacterial polar growth and cell division. In mycobacteria, cells elongate by 
growing from the tips of their cell poles, and the parent cells consist of an old pole (light pink) and new pole 
(light blue). Cell growth and division result in generation of unequally sized daughter cells. (A) The cell grows 
in a symmetric manner, however, after cytokinesis, growth predominantly takes place at the old pole. 
Constriction of the septum generates two daughter cells that vary in size. (B) Cell elongation occurs at different 
rates throughout the cell cycle, and elongation is much faster at the old pole compared to new pole. In 
mycobacteria, the final stage of division where the cells physically separate is characterized by what is termed 
as V-snapping, which in turn generates two daughter cells that differ in size. Figure drawn by student, adapted 
from (Kieser and Rubin, 2014). 
The cell division process can be divided into several stages: following elongation, the plasma 
membrane is synthesized roughly at mid-cell during cytokinesis, this is then followed by 
septation, where PG septum is synthesized at mid-cell. The cell wall then constricts and the 
septum is hydrolyzed as the daughter cells physically separate. In mycobacterial, cell 
separation is characterized by what is termed the „v-snapping‟ phenotype (Figure 1.3 A and 
B). A large multiprotein complex termed the divisome is responsible for cell division, and it 
consists of a number of proteins coordinating septal PG synthesis and septum splitting during 
cell division (Kieser and Rubin, 2014). Proteins making up the divisome complex include: 
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cytoskeletal-like proteins (FtsZ), structural proteins (SepF, FhaB, CwsA, FtsW, CrgA, FtsQ), 
PG synthases (PonA1, PBPB, PBPA) and PG hydrolases (RipA, RipC, RpfB) (Hett and 
Rubin, 2008; Typas et al., 2012). Septation is initiated by polymerization of FtsZ into a Z-
ring at mid-cell, with several regulatory factors serving to regulate subcellular placement of 
this Z-ring. Once the Z-ring is formed, it facilitates recruitment of structural elements to form 
the divisome. PG synthases synthesize the septal PG, which is then cleaved by the hydrolases 
to physically separate the daughter cells (Kieser and Rubin, 2014). The unique mode of 
elongation and division in mycobacteria generates a population of daughter cells that differ in 
growth rate, cell size, as well as cell wall composition (Singh et al., 2013) and therefore 
contribute to the ability of the pathogen to persist in the host. 
1.6. PG biosynthesis 
PG is made of linear glycan strands that are cross-linked by short stem peptide chains, 
forming a 3D net-like structure that surrounds the bacterial cell. These glycan strands consist 
of alternating N-acetylglucosamine (GlcNAc or NAG) and N-acetylmuramic acid (MurNAc 
or NAM) residues that are connected by β-1,4-glycosydic bonds (Hett and Rubin, 2008; 
Vollmer et al., 2008). The oligopeptide that serve to cross-link the glycan strands is usually a 
pentapeptide made of L-alaline-D-glutamine-meso-diaminopimalate-D-alanine-D-alanine or a 
tretrapeptide in which the terminal D-alanine is removed. The biosynthesis of the PG layer is 
a multistep-process, which is mediated by an array of periplasmic and cytoplasmic enzymes 
(Figure 1.4). The initial stage of PG synthesis occurs in the cytoplasm, with the synthesis of 
UDP-MurNac through a series of steps. The first step involves UDP-GlcNac synthesis from 
fructose-6-phosphate by GlmSMU enzymes and thereafter, UDP-MurNac is synthesized from 
UDP-GlcNac by MurAB enzyme activity (Figure 1.4) (White et al., 2010). Subsequently, the 
aminoligases MurC, MurD, MurE and MurF catalyze the sequential addition of L-Ala, D-Glu, 
m-DAP, and D-Ala-D-Ala dipeptide to UDP-MurNac, respectively, resulting in the formation 
of UDP-MurNac pentapeptide molecule (Figure 1.4) (White et al., 2010; Jankute et al., 
2015).  The subsequent step involves the formation of lipid linked PG intermediates. The 
membrane step starts with the transfer of phosphor-MurNac-pentapeptide of UDP-MurNac 
pentapeptide to decaprenyl-phosphate (a membrane-bound lipid carrier) by the integral 
membrane protein MraY, leading to the formation of lipid I (Figure 1.4). This is followed by 
coupling of GlcNac moiety from UDP-GlcNac to lipid I by the activity of the peripherally 
associated membrane protein MurG, yielding lipid II. Lipid II is then flipped across the inner 
membrane by either RodA or FtsW (Figure 1.4) (Bouhss et al., 2008; Jankute et al., 2015). 
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The final steps of PG synthesis occur in the periplasm, where the newly formed lipid II is 
incorporated into the existing PG by penicillin binding proteins (PBPs) to form a mature PG 
sacculus (Bouhss et al., 2008). 
 
Figure 1.4: Schematic representation of stages of PG biosynthesis. Lipid II production begins in the 
cytoplasm where NAG (light green hexagon) is converted to NAM (dark green hexagon) by MurA and MurB, 
followed by addition of the stem pentapeptide through the enzymatic activities of aminoligases (MurC-MurF). 
In the inner membrane, MurY and MurG catalyze formation of lipid I and Lipid II, respectively. Once lipid II is 
formed, it is flipped to the periplasmic space by the action of a flippase (FtsW/RodA/MurJ), where it gets 
incorporated into the pre-existing PG through the action of PBPs. Figure drawn by student, adapted from (White 
et al., 2010). 
1.7. PG remodelling 
The constant growth and division of the bacterial cell requires continuous remodelling of the 
PG layer to allow for a range of functions including the insertion of new PG units, secretion 
apparatus and pili (Vollmer et al., 2008). The process of PG remodelling is facilitated by a set 
of enzymes termed PG hydrolases. These enzymes play significant roles such as regulating 
cell wall growth, PG turnover during growth, as well as regulating daughter cell separation 
during cell division and autolysis (Lee and Huang, 2013). PG hydrolases have the ability to 
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degrade bacterial PG at different sites (as shown in Figure 1.5). They act on existing amide 
(amidases), glycosidic (glycosidases) and peptide (peptidases) bonds in the PG sacculus 
(Figure 1.5) (Hett and Rubin, 2008). 
  
Figure 1.5: Schematic representation of the PG structure. The diagram displays the site of action (as 
indicated by black arrows) of selected PG hydrolases acting on the amide, glycosidic and peptide bonds. The 4,3 
cross-links are indicated by the yellow dotted line and the 3,3 cross-links are indicated by the blue dotted line. 
PG constituents are indicated as follows: light green hexagon (GlcNAc), dark green hexagon (MurNAc), yellow 
square (L-alanine), red square (D-glutamine), blue square (meso- Diaminopimalate) and orange square (D-
alanine). Figure drawn by student, adapted from (Vollmer et al., 2008). 
N-Acetylmuramyl-L-alanine amidases (amidases) cleave the amide bond between NAM and 
L-alanine of the pentapeptide resulting in separation of the entire stem peptide chain from the 
glycan strand (Uehara and Park, 2007) and are involved in septum cleavage and daughter cell 
separation during the last stages of cell division (Heidrich et al., 2002). Glycosidases are 
involved in cleavage of the glycan backbone and are further divided into three classes: lytic 
transglycosylases, lysozymes and N-Acetylglucosaminidases. The β-1,4 glycosidic bond 
between GlcNac and MurNac can be cleaved differentially by lytic transglycosylases or 
lysozymes, with lysozyme cleavage yielding a product with a terminal reducing MurNac 
residue. Lytic transglycosylase activity results in the formation of 1,6-anhydro ring on the 
MurNac residue due to modification of the MurNac residue during catalysis, permitting 
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glycan bone expansion and insertion of new PG subunits (Vollmer et al., 2008). These 
enzymes are also involved in β-lactam resistance due to the role of the 1,6-anhydro product in 
β-lactamase induction (Tayler et al., 2010). Another group of PG hydrolases are the 
resuscitation promoting factors (Rpfs). Rpfs are functionally and structurally similar to lytic 
transglycosylases and have been shown to play a significant role in reactivation of dormant 
bacteria in vitro (Mukamolova et al., 1998; Kana et al., 2008; Machowski et al., 2014). N-
Acetylglucosaminidases are a class of glycosidases that cleave the glycosidic bonds between 
NAG and NAM residues. This group of enzymes have not been extensively studied however, 
they have been postulated to have a role in cell wall turnover (Vollmer et al., 2008). Further, 
a number of enzymes act on the stem peptide, these are known as peptidases. Peptidases 
cleave within the stem peptide and this includes carboxy- and endopeptidases that hydrolyze 
various D,D- and L,D- bonds in the stem peptide, respectively (Machowski et al., 2014). PG 
hydrolases have the potential to destroy the bacterial cell wall completely if their activity is 
not carefully regulated, hence they are considered potential targets for anti-TB drug 
development (Kumar et al., 2013). 
1.8. Penicillin binding proteins 
Penicillin binding proteins (PBPs) are a large group of cell wall associated enzymes that bind 
β-lactam antibiotics (Sauvage et al., 2008). These periplasmic enzymes are responsible for 
PG synthesis and remodelling by facilitating polymerization of glycan strands and subsequent 
incorporation of the newly synthesized material into the existing wall (Derouaux et al., 2013; 
Ghosh et al., 2008). Based on their mobility during sodium dodecyl sulfate polyacrylamide 
(SDS-PAGE), and their amino acid sequences, these proteins can be divided into 2 broad 
categories: high molecular mass (HMM) PBPs, which are multidimodular PBPs with  
molecular weight of more than 50 kDa and low molecular mass (LMM) PBPs, which have 
molecular mass of less than 50kDa (Sauvage et al., 2008). 
1.8.1. Penicillin-binding (PB) domain and enzymatic activity of PBPs 
PBPs are acyl-serine transferases, the action of which is catalyzed by an active-serine moiety 
(Scheffers and Pinho, 2005; Rossi et al., 2016). The interaction between the PBPs and their 
substrate is mediated by functional motifs that are specific to these enzymes. These motifs 
make up the active site encompassing residues that are broadly conserved in PBPs, including 
a SXXK tetrad which contains the active serine followed by a lysine (1
st
 motif), a SXN triad 
(2
nd
 motif), and a KTG (T/S) triad which makes the 3
rd
 motif (Figure 1.6) (Sauvage et al., 
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2008; Laddomada et al., 2016). It has been hypothesized that these conserved motifs asume 
roughly the same spacing and order along polypeptide chains in different species (Scheffers 
and Pinho, 2005), as they have been identified in various bacterial PBPs including 
Streptomyces K15, PBP4 of Pseudomonas aeruginosa (P. aeruginosa), Bacillus subtilis (B. 
subtilis) PBP4a and Escherichia coli (E. coli) PBP4 (Rossi et al., 2016).The correct 
orientation of these sites is crucial for acetylation and deacetylation reactions to occur. 
 
Figure1.6: Illustration of the active site of penicillin binding (PB) domain. The ribbon structure shows the 
PB domain and conserved motifs of the active site. Highlighted in yellow with black letters is the SxxK motif. 
The SxN motif is highlighted in green with green letters, and the last motif KTS (T/S) is highlighted in cyan 
with white letters. The red letter represents the glycine found in the active site. The active serine residue is 
shown by (*). Reproduced from (Sauvage et al., 2008).  
The reaction catalyzed by PBPs follows a three-step mechanism. In the first step, the enzyme 
and the stem pentapeptide of the PG form a non-covalent Hendri-Michaelis acyl-enzyme 
complex via a tetrahedral intermediate. This is followed by the nucleophilic attack of the 
serine present in the active site of the enzyme on the D-alanyl carbonyl of the terminal D-Ala-
D-Ala peptide bond, resulting in the formation of an acyl-enzyme intermediate and release of 
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the terminal D-Ala (acetylation). The last step which is the deacetylation, consist of either 
hydrolysis reaction called carboxypeptidation, with the release of shortened peptide, or 
endopeptidation reaction, resulting in formation of cross-link with the neighbouring stem 
peptide in PG known as the acceptor strand (Sauvage et al., 2008; Rossi et al., 2016). Β 
lactams that target PBPs mimic the PG D-Ala-D-Ala C-terminus, hence PBPs recognize them 
as substrates and form the acyl-enzyme complex with them. The formation of this stable acyl-
enzyme complex is essentially irreversible. Thus, β-lactams are mechanism-based, covalent 
PBPs inhibitors (Tipper and Strominger, 1965). Alteration in the copy number of PBPs as 
well as their β-lactams affinity can confer β-lactam resistance in a bacterial cell (Henry et al., 
2010). 
1.8.2. High molecular mass PBPs (HMM PBPs)  
 HMM PBPs are responsible for PG polymerization and insertion of newly synthesized PG 
subunits into the pre-existing wall and they have also been shown to play a role in cell 
elongation and septation (Ghosh et al., 2008). HMM PBPs are further divided into subclass A 
and B, depending on the structure of their N-terminal domain and its catalytic activity. Class 
A HMM PBPs are bifunctional enzymes consisting of both the transglycosylase and 
transpeptidase activities, whereas Class B HMM PBPs are monofunctional with only 
transpeptidase activity (Goffin and Ghuysen, 2002). The general topology of HMM PBPs 
consists of a cytoplasmic tail, a transmembrane anchor and two domains connected by a β-
rich linker, located in the periplasm (Figure 1.7) (Macheboeuf et al., 2006; Sauvage et al., 
2008). In both classes, the C-terminal PB domain has a transpeptidase activity and is 
responsible for catalyzing cross-linking of stem peptides between adjacent glycan strands 
(Figure 1.7). In class A, the N-terminal domain has glycosyltransferase activity and is 
responsible for catalyzing the polymerization of glycan chains (Figure 1.7). The N-terminal 
domain of class B HMM PBPs has no catalytic activity and it is hypothesized to have a role 
in cell morphogenesis by interacting with various proteins involved in the cell cycle (Sauvage 
et al., 2008).  
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Figure 1.7: Schematic representation of domain organization of HMM PBPs. (A) Class A HMM PBPs are 
bifunctional, having both glycosyltransferase activity and transpeptidase activity. (B) Class B HMM PBPs are 
monofunctional and they only possess transpeptidase activity. The N-terminal domain of class B HMM PBPs 
has no catalytic activity. Both class A and B PBPs are associated with the membrane through a transmembrane 
anchor. Figure drawn by student. 
Most organisms possess a number of HMM PBPs. Streptococccus pneumoniae (S. 
pneumoniae) possesses three bifunctional class A PBPs, which are dispensable for survival of 
the bacteria, and two essential class B PBPs designated PBP2b and PBP2x, that play a role in 
PG synthesis in the periplasm and formation of the septum, respectively (Sham et al., 2012). 
A low level β-lactam resistance in S. pneumoniae is attributed to mutations in the two class B 
PBPs, and additional mutations in class A PBP1a are required for high level β-lactam 
resistance (Zapun et al., 2008). In B. subtilis, PBP1 is amongst the four class A PBPs and it is 
required for efficient asymmetric septum formation during sporulation (Scheffers and 
Errington, 2004). In addition, B. subtilis has six class B PBPs, with PBP2 playing a role in 
cell division (Daniel et al., 2000). The activities of HMM PBPs have been well defined in E. 
coli, and two of the five (PBP3 and PBP2, both class B PBPs) are essential for cell division, 
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cell elongation and maintenance of the rod shape, respectively (Sauvage et al., 2008). Among 
the three bifunctional class A PBPs (PBP1a, PBP1b and PBP1c) in E. coli, PBP1a and PBP1b 
have the highest synthetic activity, of which at least one of them is required for cell survival 
as they are individually dispensable but simultaneous disruption of the two is lethal for the 
cell (Dӧrr et al., 2014). Mycobacteria possesses 2 class A PBPs, PBP1 (ponA1) and PBP1a 
(ponA2) and both these genes are present in Mtb and Mycobacterium smegmatis (Msm). In 
addition, Msm possesses a third class A PBP-encoding gene, annotated as ponA3. Class B 
PBPs include PBPA, PBPB and PBP-lipoprotein (Machowski et al., 2014; Kieser et al., 
2015a). PBPB (FtsI) is essential for cell survival and it is recruited to the cell division site 
(Datta et al., 2006). 
1.8.3. Low molecular mass PBPs (LMM PBPs) 
LMM PBPs are often termed “accessory cell division proteins” and are involved in cell 
separation, PG maturation and recycling (Eagan and Vollmer, 2013). LMM PBPs are 
generally termed class C PBPs (Sauvage et al., 2008). LMM PBPs are monofunctional, with 
either D,D-carboxypeptidase activity (D,D,-CPase), which cleave of the terminal D-Ala from 
the pentapeptide chain, or they have D,D-endopeptidase activity, which cleaves peptide cross 
bridges (Ghosh et al., 2008; van Heijenoort, 2011). The transpeptidase domain of D,D-CPases 
is located downstream of the signal peptide and they also consist of a C-terminal 
transmembrane or amphipathic helix that allows for membrane association (Figure 1.8) 
(Macheboeuf et al., 2006). 
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Figure 1.8: Schematic representation of domain organization of LMM PBPs. LMM PBPs are generally 
termed class C PBPs, and their structure is different from that of HMM PBPs in that their transpeptidase domain 
is encoded immediately downstream of the signal peptide found in the N-terminus. They are associated with the 
membrane through a transmembrane helix (TM) or an amphipathic helix. Figure drawn by student. 
1.8.3.1. Endopeptidases 
Endopeptidases are enzymes that cleave the peptide cross bridges in the PG (Ghosh et al., 
2008), they cleave diverse D,D- and L,D- bonds within the stem peptide. In B. subtilis, PBP4a 
is the only LMM PBP that has been shown to have endopeptidase activity. PBP4 of 
Staphylococcus aureus (S. aureus) possesses transpeptidase activity that is needed for the 
high degree of cross-linking in the PG of this bacterium (Wyke et al., 1981). E. coli has two 
endopeptidases, PBP4 and PBP7 encoded by dacB and pbpG, respectively. PBP4 of E. coli is 
a bifunctional LMM PBP due to its minimal D,D-CPase activity in addition to its strong 
endopeptidase activity (Ghosh et al., 2008). This enzyme is dispensable for growth and the 
mutants display no growth defects or any detectable morphological changes. However, it has 
been shown that this enzyme has a primary role in repairing and/or regulating excessive 
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and/or inappropriate PG cross-links via its PG hydrolyzing activity (Thunnissen et al, 1995; 
Meberg et al, 2004). The E. coli PBP7 plays a role in septum cleavage and biofilm formation 
(Ghosh et al., 2008; Sauvage et al., 2008). PBP3 and PBP4 of Neisseria gonorrhoeae (N. 
gonorrhoeae) display sequence similarities to E. coli PBP4 and PBP7, respectively. In Vibrio 
cholerae (V. cholerae), VC0632 is more similar to E. coli PBP4, while VC0870 is more 
similar to PBP7 (Mӧll et al., 2015). Endopeptidases play a role in cell shape maintenance in a 
wide variety of bacteria. In mycobacteria, RipA is the most well characterized endopeptidase 
that is essential for growth in vitro (Hett et al., 2007) and it has been associated with 
resuscitation of dormant cells due to its interaction with RpfB and RpfE (Nikitushkin et al., 
2015).  
1.8.3.2. D,D-carboxypeptidases (D,D-CPases) 
D,D-CPases are LMW PBPs that play a role in controlling the level of PG cross-links. This 
set of enzymes is involved in the last step of PG synthesis. They control the degree of PG 
cross-linking in the cell by cleaving off the terminal D-alanine from the side chain of the 
pentapeptide, generating a tetrapeptide stem, which is unable to act as a donor to form 4,3 PG 
cross-links (Egan and Vollmer, 2013). D,D-CPases are known to be important in maintaining 
bacterial cell shape. Although their biochemical activities are well known, their physiological 
roles still remain elusive due to their genetic redundancy. In E. coli the D,D-CPases include 
PBP5, PBP6 and PBP6b/DacD encoded by dacA, dacC and dacD, respectively (Ghosh et al., 
2008). Individual deletion of these genes does not result in any drastic cell growth defects or 
altered cell morphology in E. coli (Denome et al., 1999). Among the three E. coli D,D-
CPases, PBP5 is the most abundant and well characterized. PBP5 has been shown to have a 
role in cell shape maintenance and studies have also pointed out its accessory regulatory role 
in both bacterial cell division and elongation (Ghosh et al., 2008). Mutants lacking PBP5 
display subtle changes in cell shape (Nelson and Young, 2000). In addition, deletion of other 
E. coli D,D-CPases in conjunction with PBP5 results in extensive morphological defects such 
as branches, kinks and bends, which can be restored when PBP5 expression is restored 
(Nelson and Young, 2001). The PBP5-mediated morphological restoration is dependent on 
both the C-terminal domain and the D,D-CPase activity of the enzyme (Nelson and Young, 
2001). Overexpression of PBP5 is detrimental, resulting in conversion of normal rod-shaped 
E. coli cells into spherical form (Santos et al., 2002). All these observations suggest that 
PBP5 is important in stabilizing growth of the cell versus septal PG synthesis (Potluri et al., 
2010). Both E. coli PBP6 and PBP6b share some degree of sequence homology with PBP5, 
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however, PBP6 displays weaker D,D-CPase activity towards other substrates when compared 
to PBP5. Although the three E. coli D,D-CPases share similar primary structures, they are 
likely to have distinct functions in vivo during the different growth phases (Ghosh et al., 
2008). 
N. gonorrhoeae has two D,D-CPases (PBP3 and PBP4), and PBP3 is involved in PG 
biosynthesis (Stefanova et al., 2003). Similar to the bifunctional E. coli PBP4, PBP3 of N. 
gonorrhoeae possesses weak endopeptidase activity in addition to its strong D,D-CPase 
activity (Stefanova et al., 2003). V. cholerae encodes two D,D-CPases (VC0947 encoded by 
dacA-1 and VCA0270 encoded by dacA-2), which are highly similar to E. coli PBP5 as they 
share 60% sequence similarities with PBP5 at the protein level (Chowdhury and Ghosh, 
2011). DacA-1 is believed to be the principal D,D-CPase in V. cholera and its deletion leads 
to altered cell morphology and severe growth impairment (Mӧll et al., 2015). In B. subtilis, 
PBP5 (dacA), PBP5
*
 (dacB) and DacF display D,D-CPase activities. PBP5 is the major D,D-
CPase in B. subtilis expressed during lag phase and promotes PG maturation (Ghosh et al., 
2008). PBP5* is highly expressed during sporulation and it plays a role in the synthesis of 
spore cortex, whereas DacF is expressed within the forespore during the early stationary 
phase and it is believed to have a role in PG modification during sporulation (Popham et al., 
1999). S. pneumoniae possesses a single D,D-CPase (PBP3), which plays a role in directing 
cell division proteins to the septum, with PBP3 mutants displaying cell division defects 
(Morlot et al., 2004). Listeria monocytogenes (L. monocytogenes) PBP5 regulates cell wall 
thickness and deletion of this enzyme results in altered cell morphology (Korsak et al., 2005). 
In mycobacteria, the biological roles of D,D-CPases has not been well defined.  Mtb has three 
D,D-CPase homologues: Rv3627c, Rv2911(encoded by dacB2) and Rv3330 (encoded by 
dacB1). In Msm, MSMEG_6113 is the equivalent of Rv3627c, MSMEG_1661 is the 
equivalent of Rv3330, MSMEG_2432 and MSMEG_2433 are Rv2911 duplicates 
(Machowski et al., 2014). In addition, Msm has a distinct D,D-CPase, annotated as 
MSMEG_1900. Studies conducted in our laboratory have shown that MSMEG_6113 is 
essential and that MSMEG_2433 is expressed at comparatively higher transcript abundance 
compared to other D,D-CPases in Msm (Ealand et al., unpublished).  
Considering these collective findings, D,D-CPases are considered to be genetically redundant 
and highly conserved in a number of bacteria, implying that they have important but 
unrecognized physiological roles. The possible interaction of mycobacterial D,D-CPases with 
19 
 
other proteins in the cell, particularly HMW PBPs, may point to additional roles of these D,D-
CPases in maintaining cell wall homeostasis. This MSc dissertation was aimed at addressing 
this knowledge gap.  
1.9. Hypothesis and research motivation 
Putative interacting partners of two Msm D,D-CPases designated MSMEG_6113 and 
MSMEG_2433 have been identified in a screen conducted in our laboratory using a bacterial 
two-hybrid system called the mycobacterial protein fragment complementation (M-PFC) 
assay. The M-PFC assay that was used to screen the Msm library identified 10 and 20 
potential interacting partners for MSMEG_6113 and MSMEG_2433, respectively. 
Interestingly, a number of these partners were key regulators of cell division and elongation. 
It was therefore hypothesized that mycobacterial D,D-CPases play a significant role in cell 
growth, particularly in cell elongation and division, through interaction with various protein 
partners. To test this, we proposed to first confirm the putative D,D-CPase-interacting 
partners identified in the above-mentioned screen using full-length constructs. To test the 
importance of the interaction for cell division and growth, we propose to delete some of the 
interacting partners from the mycobacterial genome. 
1.10. Aims and objectives 
1.10.1. Aim 
Considering the broad number of distinct proteins that were identified as interacting partners 
of the two D,D-CPases, combined with the predicted importance of these partners in PG 
synthesis and proliferation, the main aim of this study was to investigate the functional role of 
the two mycobacterial D,D-CPases through interaction and gene knockout studies. 
1.10.2. Specific objectives 
 To confirm interaction of MSMEG_6113 and MSMEG_2433 with their putative 
partnering proteins using M-PFC assay. 
 To determine domains of the two D,D-CPases that are responsible for interaction with  
selected protein partners. 
 To create Msm knockout mutant strains lacking selected protein partners. 
 To perform phenotypic characterization of the resulting mutants using microscopy 
and microbiological assays. 
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2. Materials and methods 
2.1. Databases and bioinformatics tools used 
Various databases and bioinformatics tools were used throughout this study to obtain 
genomic DNA and amino acid sequences, and to analyze genes and proteins of interest. Table 
2.1 illustrates databases and bioinformatics tools used in this study. 
Table 2.1: Bioinformatics tools and databases used to obtain and analyze DNA and protein 
sequences. The table also provides online website addresses. 
Database/bioinformatics 
tool 
Use in the study Address 
SmegmaList This database was used to 
interrogate Msm strain 
mc
2
155 gene and protein 
sequences of interest. 
ch/smegmalist.html 
 
 
 
TubercuList This database was used to 
interrogate Mtb strain 
H37RV gene and protein 
sequences of interest. 
http://tuberculist.epfl.ch 
 
BioCyc This database was used to 
interrogate transcriptional 
units and operonic 
structures of genes of 
interest. 
https://biocyc.org 
 
pFam This database was used to 
identify functional 
domains in protein 
sequences on interest.  
http://pfam.xfam.org/ 
 
STRING This database was used to 
investigate known and 
predicted physical (direct) 
and functional (indirect) 
protein-protein interaction 
https://string-db.org 
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of the D,D-CPases 
studied.   
NCBI BLAST Basic Local Alignment 
Search Tool was used to 
identify genes that encode 
for selected partnering 
proteins in Msm genome 
and related organisms. 
https://www.ncbi.nlm.nih.gov/BLAST 
 
MUSCLE 
Clustal Omega 
The two tools were used 
to identify regions of 
similarity among various 
amino acid sequences of 
selected D,D-CPases 
partnering proteins by 
aligning the multiple 
sequences. Also used for 
phylogenetic tree 
generation.  
www.ebi.ac.uk/Tools/msa/muscle 
www.ebi.ac.uk/Tools/msa/ClustalO 
 
I-TASSER The Iterative Threading 
ASSEmbly Refinement 
server was used to predict 
three dimensional 
structure models and 
function of selected 
partnering proteins. 
http://zhanglab.ccmb.med.umich.edu/I-
TASSER/ 
 
SignalP 4.1 The server was used to 
identify signal peptides 
within amino acid 
sequences of interest, as 
well as predicting the 
signal peptide cleavage 
sites. 
http://www.ebs.dtu.dk/services/signalP/ 
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2.2 Chemicals and reagents used 
Enzymes used throughout this study for DNA manipulation purposes were supplied by 
Roche, Fermentas and New England Biolabs (NEB), unless otherwise stated. Reagents for 
Media and solution preparation were obtained from Sigma Aldrich and Thermo Fischer 
Scientific (Appendix A). All primers were synthesized by the Inqaba Biotech group 
(Appendix B). 
2.3 Bacterial strains and plasmids constructed and/or used 
All plasmids and bacterial strains generated/used throughout this study are listed in Table 2.2 
and Table 2.3., respectively. For all strains, glycerol freezer stocks were made using 66% 
glycerol (1:1 volume) and were stored in -80 °C. 
Table 2.2. Plasmids constructed and/or used in this study 
Plasmids Description Source/reference 
p2NIL E. coli cloning vector. Kan
R
 Parish and 
Stoker, 2000 
pGOAL17 Plasmid carrying lacZ-bla-sacB genes as PacI 
cassette. Amp
R
 
Parish and 
Stoker, 2000 
pMV306H E. coli-Mycobacterium integrating shuttle vector, 
integrating at the L5 attB site in the genome of 
mycobacteria. Hyg
R
 
H. Boshoff 
pUAB300 E. coli- Mycobacterium episomal shuttle vector 
carrying N-terminal mDHFR fragment 1 and 2, 
together with the glycine linker. Hyg
R
 
Singh et al., 2006 
pUAB400 E. coli- Mycobacterium integrating shuttle vector 
carrying N-terminal mDHFR fragment 3. Kan
R
 
Singh et al., 2006 
p2NILcdc48 Derivative of p2NIL carrying the ΔMSMEG_0858 
deletion allele. The deletion allele was generated by 
deleting 2040 bp (amino acid 34-679) from 
MSMEG_0858. Kan
R
 
This study 
p2NILftsI Derivative of p2NIL carrying the ΔMSMEG_4233 
deletion allele. The deletion allele was generated by 
deleting 1749 bp (amino acid 34-582) from 
This study 
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MSMEG_4233. Kan
R
 
p2NILcdc48_Pac Derivative of p2NILcdc48 carrying the lacZ and 
sacB genes from pGOAL17. Kan
R 
This study 
p2NILftsI_Pac Derivative of p2NILftsI carrying the lacZ and sacB 
genes from pGOAL17. Kan
R
 
This study 
pMV306Hcdc48 Derivative of pMV306H carrying MSMEG_0858 
wild type allele and the upstream native promoter 
region. Hyg
R 
This study 
pMV306HftsI Derivative of pMV306H carrying MSMEG_4233 
wild type allele and the upstream native promoter 
region. Hyg
R
 
This study 
pUAB300+6900 Derivative of pUAB300 carrying full length copy 
of MSMEG_6900. Hyg
R
 
This study 
pUAB300+4227 Derivative of pUAB300 carrying full length copy 
of MSMEG_4227. Hyg
R
 
This study 
pUAB300+0031 Derivative of pUAB300 carrying full length copy 
of MSMEG_0031. Hyg
R
 
This study 
pUAB300+6105 Derivative of pUAB300 carrying full length copy 
of MSMEG_6105. Hyg
R
 
This study 
pUAB300+4233 Derivative of pUAB300 carrying full length copy 
of MSMEG_4233. Hyg
R
 
This study 
pUAB300+0858 Derivative of pUAB300 carrying full length copy 
of MSMEG_0858. Hyg
R
 
This study 
pUAB300+5637 Derivative of pUAB300 carrying full length copy 
of MSMEG_5637. Hyg
R
 
This study 
pUAB300+0365 Derivative of pUAB300 carrying full length copy 
of MSMEG_0365. Hyg
R
 
This study 
pUAB300+6112 Derivative of pUAB300 carrying full length copy 
of MSMEG_6112. Hyg
R
 
This study 
pUAB400+6113 Derivative of pUAB400 carrying full length copy 
of MSMEG_6113. Kan
R
 
This study 
pUAB400+2433 Derivative of pUAB400 carrying full length copy 
of MSMEG_2433. Kan
R
 
This study 
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pUAB400+6900 Derivative of pUAB400 carrying full length copy 
of MSMEG_6900. Kan
R
 
This study 
pUAB400+4227 Derivative of pUAB400 carrying full length copy 
of MSMEG_4227. Kan
R
 
This study 
pUAB400+0031 Derivative of pUAB400 carrying full length copy 
of MSMEG_0031. Kan
R
 
This study 
pUAB400+6105 Derivative of pUAB400 carrying full length copy 
of MSMEG_6105. Kan
R
 
This study 
pUAB400+4233 Derivative of pUA400 carrying full length copy of 
MSMEG_4233. Kan
R
 
This study 
pUAB400+0858 Derivative of pUAB400 carrying full length copy 
of MSMEG_0858. Kan
R
 
This study 
pUAB400+5637 Derivative of pUAB400 carrying full length copy 
of MSMEG_5637. Kan
R
 
This study 
pUAB400+0365 Derivative of pUAB400 carrying full length copy 
of MSMEG_0365. Kan
R
 
This study 
pUAB400+6112 Derivative of pUAB400 carrying full length copy 
of MSMEG_6112. Kan
R
 
This study 
pUAB300+6113 Derivative of pUAB300 carrying full length copy 
of MSMEG_6113. Hyg
R
 
This study 
pUAB300+2433 Derivative of pUAB300 carrying full length copy 
of MSMEG_2433. Hyg
R
 
This study 
pUAB400+6113SP Derivative of pUAB400 carrying 147 bp sequence 
encoding the signal peptide of MSMEG_6113. 
Kan
R
 
This study 
pUAB400+6113TP Derivative of pUAB400 carrying 685 bp sequence 
encoding the transpeptidase domain of 
MSMEG_6113. Kan
R
 
This study 
pUAB400+6113LR Derivative of pUAB400 carrying 611 bp sequence 
encoding the linker region of MSMEG_6113. Kan
R
 
This study 
pUAB400+2433SP Derivative of pUAB400 carrying 90 bp sequence 
encoding the signal peptide of MSMEG_2433. 
Kan
R
 
This study 
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pUAB400+2433TP Derivative of pUAB400 carrying 685 bp sequence 
encoding the transpeptidase domain of 
MSMEG_2433. Kan
R
 
This study 
pUAB400+2433Cter Derivative of pUAB400 carrying the 99 bp 
sequence encoding the C terminal region of 
MSMEG_2433. Kan
R
 
This study 
pMV306H+GFP Derivative of pMV306H carrying the green 
fluorescence protein (GFP). Hyg
R
 
CBTBR 
pMV306H+FtsZGFP Derivative of pMV306H carrying the full copy of 
ftsZ gene tagged with green fluorescence protein 
(GFP). Hyg
R
 
CBTBR 
Amp
R
: Ampicillin resistance, Hyg
R
: Hygromycin resistance, Kan
R
: Kanamycin resistance, 
GFP: Green fluorescence protein, attB: tRNA
GLY
 attachment site. 
Table 2.3. Bacterial strains generated and/or used in this study 
Strain Description Source/reference 
E. coli DH5α SupE44 Δlacu169 hsdR17 recA1 
endA1 gyrA96 thi-1 relA1  
Promega, 
Madison, W1 
mc
2
155 Efficient Msm ATTCC 607 
transformation mutant. 
Snapper et al., 
1990 
mc
2
155::pUAB400(pUAB300) Derivative of mc
2
155 carrying the 
pUAB400 plasmid integrated at 
the attB site, and the episomal 
pUAB300 plasmid, Kan
R
Hyg
R
 
D.B. Ralefeta 
(CBTBR) 
mc
2
155::pUAB5439(pUAB3145) Derivative of mc
2
155 carrying the 
pUAB400+5439 plasmid and the 
pUAB300+3145 plasmid. 
Kan
R
Hyg
R
 
D.B Ralefeta 
(CBTBR) 
mc
2
155::pUAB6113(pUAB4233) Derivative of mc
2
155 carrying the 
pUAB400+6113 plasmid and the 
pUAB300+4233 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113(pUAB0858) Derivative of mc
2
155 carrying the This study 
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pUAB400+6113 plasmid and the 
pUAB300+0858 plasmid. 
Kan
R
Hyg
R
 
mc
2
155::pUAB6113(pUAB5637) Derivative of mc
2
155 carrying the 
pUAB400+6113 plasmid and the 
pUAB300+5637 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113(pUAB0365) Derivative of mc
2
155 carrying the 
pUAB400+6113 plasmid and the 
pUAB300+0365 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113(pUAB6112) Derivative of mc
2
155 carrying the 
pUAB400+6113 plasmid and the 
pUAB300+6112 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433(pUAB6900) Derivative of mc
2
155 carrying the 
pUAB400+2433 plasmid and the 
pUAB300+6900 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433(pUAB4227) Derivative of mc
2
155 carrying the 
pUAB400+2433 plasmid and the 
pUAB300+4227 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433(pUAB0031) Derivative of mc
2
155 carrying the 
pUAB400+2433 plasmid and the 
pUAB300+0031 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433(pUAB6105) Derivative of mc
2
155 carrying the 
pUAB400+2433 plasmid and the 
pUAB300+6105 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433SP(pUAB4227) Derivative of mc
2
155 carrying the 
pUAB400+2433SP plasmid and 
This study 
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the pUAB300+4227 plasmid. 
Kan
R
Hyg
R
 
mc
2
155::pUAB2433TP(pUAB4227) Derivative of mc
2
155 carrying the 
pUAB400+2433TP plasmid and 
the pUAB300+4227 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433Cter(pUAB4227) Derivative of mc
2
155 carrying the 
pUAB400+2433Cter plasmid and 
the pUAB300+4227 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433TP(pUAB6900) Derivative of mc
2
155 carrying the 
pUAB400+2433TP plasmid and 
the pUAB300+6900 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB2433Cter(pUAB6900) Derivative of mc
2
155 carrying the 
pUAB400+2433Cter plasmid and 
the pUAB300+6900 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113SP(pUAB0858) Derivative of mc
2
155 carrying the 
pUAB400+6113SP plasmid and 
the pUAB300+0858 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113TP(pUAB0858) Derivative of mc
2
155 carrying the 
pUAB400+6113TP plasmid and 
the pUAB300+0858 plasmid.  
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113SP(pUAB4233) Derivative of mc
2
155 carrying the 
pUAB400+6113SP plasmid and 
the pUAB300+4233 plasmid. 
Kan
R
Hyg
R
 
This study 
mc
2
155::pUAB6113TP(pUAB4233) Derivative of mc
2
155 carrying the 
pUAB400+6113TP plasmid and 
the pUAB300+4233 plasmid. 
This study 
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Kan
R
Hyg
R
 
∆cdc48 Derivative of mc2155 carrying an 
unmarked in frame deletion in 
cdc48 (MSMEG_0858). 
Constructed by electroporation of 
the p2NILcd48_Pac plasmid into 
mc
2
155 strain. 
This study 
∆cdc48::cdc48 Genetically complemented 
derivative of ∆cdc48 carrying a 
full length copy of cdc48 
integrated at the attB site. 
Constructed by electroporation of 
pMV306cdc48 into the ∆cdc48 
strain. Hyg
R
  
This study 
mc
2
155::FtsZ_GFP Derivative of mc
2
155 expressing 
FtsZ_GFP fusion protein. 
Constructed by electroporation of 
the pMV306H+FtsZ_GFP 
plasmid into mc
2
155. Hyg
R
  
This study 
∆cdc48::FtsZ_GFP Derivative of ∆cdc48 expressing 
FtsZ_GFP fusion protein. 
Constructed by electroporation of 
the pMV306H+FtsZ_GFP 
plasmid into ∆cdc48. HygR  
This study 
Hyg
R
: Hygromycin resistance, Kan
R
: Kanamycin resistance, GFP: Green fluorescence 
protein, attB: tRNA
GLY
 attachment site. 
2.4. Bacterial strains culture conditions 
2.4.1 Growth conditions for E. coli DH5α and derivative strains 
E. coli strains were grown on Luria-Bertani agar (LA) or in Luria- Bertani broth (LB) 
supplemented with appropriate antibiotics at the following concentrations: 100 µg/ml 
Ampicillin (Amp), 200 µg/ml Hygromycin (Hyg), and 50 µg/ml Kanamycin (Kan). 
Incubation at 37 °C was used for cultures carrying plasmids ˂ 8 kbp and cultures carrying 
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plasmids ˃ 8 kbp were incubated at 30 °C, with shaking at 250 rpm, to prevent plasmid 
rearrangement. 
2.4.2 Growth conditions for Msm and derivative strains 
Msm strains were grown on Middlebrook 7H10 solid media supplemented with 0.2 % 
glucose, 0.5 % glycerol, 0.085% NaCl (herein referred as 7H10 agar), and appropriate 
antibiotics at 37 °C or in Middlebrook 7H9 liquid media supplemented with 0.2% glucose, 
0.085% NaCl, 0.5% glycerol, 0.05% Tween 80 (herein referred to as 7H9) and appropriate 
antibiotics at 37 °C with shaking at 100 rpm unless stated otherwise. The concentrations of 
antibiotics used were as follows: 50 µg/ml Hyg and 25 µg/ml Kan. 
2.5 Nucleic acid extractions  
2.5.1. E. coli plasmid DNA extractions 
2.5.1.1. Small scale plasmid DNA extraction 
The alkaline lysis mini-preparation method (Birnboim and Doly, 1979) was used for small 
scale plasmid DNA extraction from E. coli DH5α derivative strains carrying plasmids of 
interest. The strains were grown at 37 °C overnight in 2 ml LB media supplemented with 
appropriate antibiotics. Cells were then harvested by centrifugation at 12 470 x g and the 
pellets were re-suspended in 100 µl of solution I. Thereafter, 200 µl of solution II (Table A2) 
was added, mixed by inversion and incubated at room temperature for 5 min. This was 
followed by addition of 150 µl solution III to the mixture and incubation on ice for 5 min. 
The suspensions were then centrifuged for 10 min and the supernatant was transferred to a 
clean Eppendorf tube, followed by addition of 3 µl of RNAseA (10 mg/ml) and incubation 
for 15 min at 42 °C. Plasmid DNA was then precipitated by adding 600 µl of isopropanol to 
the mixture and centrifugation at 12 470 x g for 30 min. The isopropanol supernatant was 
then discarded and the pellet was washed with 70 % ethanol and dried using an Eppendorf 
concentrator 5301. The pellet was resuspended in nuclease free water and quantified using 
the Nanodrop spectrophotometer (NanoDrop technologies) and stored at 4 °C until further 
use. 
2.5.1.2. Large scale plasmid DNA extraction 
Bulk DNA extractions were done using the Macherey-Nagel Nucleobond plasmid DNA 
extraction Kit and following manufacturer‟s instructions. Briefly, the strains were grown at 
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37 °C overnight in 50-100 ml LB supplemented with appropriate antibiotics. Cells were then 
harvested by centrifugation at 4 500 x g for 15 min at 4 °C. The supernatant was discarded 
and the pellet was resuspended in 8 ml of cell lysis buffer to lyse the cells. The cell lysate was 
incubated at room temperature for 5 min. Thereafter, 8 ml of neutralization buffer was added 
to the sample, mixed thoroughly until the solution turned colorless. The column and the filter 
paper were first equilibrated with 12 ml of equilibration buffer. This was followed by 
addition of the clarified cell lysate, which passed through the column. Subsequently, the 
column was washed with 5 ml of equilibration buffer. The filter was then removed and the 
column was washed for the second time to remove impurities with 8 ml wash buffer. The 
plasmid DNA was eluted from the column by addition of 5 ml elution buffer and eluate was 
then collected into a clean tube. This was followed by precipitation of the plasmid DNA by 
addition of 3.5 ml isopropanol and centrifugation at 4 500 x g for 30 min at 4 °C. The DNA 
pellet was washed with 2 ml of 70 % ethanol and was dried using Eppendorf concentrator 
5301. The pellet was resuspended in nuclease free water and quantified using the Nanodrop 
spectrophotometer (NanoDrop technologies) and stored at 4 °C until further use. 
2.5.2. Mycobacterial chromosomal DNA extractions 
2.5.2.1 Small scale chromosomal DNA extraction 
The colony boil method (Tortoli et al., 2001) was used for extraction of chromosomal DNA 
from Msm mc
2
 155 and derivative strains. Half a colony was scraped from solid media and 
resuspended in 50 µl of dsH2O. Thereafter, 50 µl of chloroform was added to the suspension 
and mixed by vortexing. The mixture was then incubated at 95 °C for 5 min, followed by 
centrifugation at 12 470 x g for 5 min. The aqueous layer was then transferred into a clean 
tube and used as template for PCR. 
2.5.2.2. Large scale chromosomal DNA extraction 
The Cetyltrimethylammonium bromide (CTAB) method was used for bulk extraction of 
chromosomal DNA from Msm and derivative strains as previously decribed by Wilson 
(1997). The strains were first grown for two days at 37 °C on 7H10 agar. The cells were 
scraped off the plate and resuspended in 500 µl of TE buffer. The cells were then heat killed 
by incubation at 65 °C for 20 min, followed by addition of 70 µl lysozyme (10 mg/ml) and 
incubation at 37°C for an hour. Thereafter, 6 µl of proteinase K (10 mg/ml) and 70 µl of 10 
% SDS were mixed into the suspension and the mixture was incubated for 2 hours at 65 °C. 
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This was followed by addition of 100 µl of NaCl (5M) with mixing, followed by addition of 
80 µl of pre-warmed (65 °C) CTAB/NaCl. The suspension was then incubated at 65 °C for 
10 min. An equal volume of chroroform: isoamyl alcohol (24:1 v/v) was added, mixed 
vigorously and centrifuged at 1 470 x g for 5 min at room temperature. The top aqueous layer 
was transferred into a fresh Eppendorf tube and the DNA was precipitated by addition of 600 
µl isopropanol and centrifugation at 12 470 x g for 20 min. The pellet was then washed with 
1 ml of 70 % ethanol by centrifugation at 12 470 x g for 3 min, dried using an Eppendorf 
concentrator 5301, resuspended in nuclease free water and quantified by the Nanodrop 
spectrophotometer (NanoDrop technologies) and stored at 4 °C until further use.   
2.6 DNA manipulations 
2.6.1 DNA amplification by Polymerase Chain Reaction (PCR) 
Table 2.4 shows parameters used for primer design using the online Primer3 program 
(http://bioinfo.ut.ee/primer3). 
Table 2.4: Parameters used for primer design 
 Size (bp) Tm (°C) %GC 
Minimum 18 55 55 
Maximum 25 63 65 
Optimum 23 60 62 
 
2.6.1.1. Roche Faststart Taq PCR 
The Roche Faststart Taq DNA polymerase protocol was used by following the 
manufacturer‟s instructions for PCR screening of clones and confirmation of gene deletion 
mutants. PCR reactions were set up using the following components: 5 µl of 10X 
recommended buffer, 10 µl 5x GC buffer, 2.5 µl of forward and reverse primer to a final 
concentration of 1 µM each, 8 µl of dNTPs to a final concentration of 0.2 µM, 2 U Taq 
polymerase, and 50- 100 ng of template DNA. The final reaction volume was made up to 50 
µl with nuclease free water. The reactions were incubated in a thermocycler (Bio-Rad 
laboratories) using the following cycling conditions: 4 min of initial denaturation at 95 °C, 30 
cycles of 30 sec of secondary denaturation at 95 °C, 45 sec of annealing at 65 °C, 1 min of 
extension at 72 °C and 10 min of final extension at 72 °C. 
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2.6.1.2 Q5 high-fidelity PCR 
Q5 High-fidelity DNA polymerase (NEB) was used for high-fidelity PCR by following the 
manufacturer‟s instructions for amplification of DNA fragments used for cloning purposes. 
PCR reactions were set up using the following components: 10 µl of 5X Q5 reaction buffer, 
10 µl 5X high GC enhancer, 2.5 µl of forward and reverse primer to a final concentration of 
0.5 µM each, 1 µl of dNTPs to a final concentration of 200 µM, 0.5 µl Q5 High-Fidelity 
DNA polymerase, 50- 100 ng of template DNA, made up with nuclease free water to a final 
reaction volume of 50 µl. The reactions were incubated in a thermocycler (Bio-Rad 
laboratories) using the following cycling conditions: 30 sec of initial denaturation at 98 °C, 
35 cycles of 10 sec of secondary denaturation at 98 °C, 30 sec of annealing at 70 °C, 30 sec 
of extension at 72 °C and 2 min of final extension at 72 °C. 
2.6.2. Restriction enzyme digestions 
Restriction enzymes used in this study for digestion of plasmid or PCR DNA were purchased 
either from Roche Applied Science (Roche), Fermentas or New England Biolabs (NEB). 
Restriction digestion reactions were performed as per manufacturer‟s instructions. Briefly, 1 
µg of DNA was digested with 1 U restriction enzyme in 1X recommended buffer and 
addition of sdH2O to a final reaction volume of 20 µl. Reactions were incubated for an hour 
at 37 °C, followed by heat inactivation at 65 °C for 10 min unless advised otherwise by the 
manufacturer. 
2.6.3 Nucleic acid quantification 
Quantification of all DNA was carried out using the Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies), which quantifies DNA by measuring absorbance of the sample at a 
wavelength of 260 nm.  
2.6.4 DNA visualization and purification 
2.6.4.1. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for visualization of DNA. The percentage of agarose in 
gels depended on the molecular weight of the sample/s to be analyzed. Low molecular weight 
DNA was separated by using 2 % agarose gels made in 1X TAE buffer (1 mM EDTA and 40 
mM Tris-acetate) and high molecular weight DNA was separated by using 0.8-1 % agarose 
gels. Electrophoresis was carried out in 1X TAE buffer at 80-90 V in electrophoresis tanks 
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(Bio-Rad laboratories). DNA molecular weight markers were also run on the same gel for 
molecular size estimation of the DNA sample analyzed. Visualization of the gels was 
achieved by the use of SYNGENE G-Box system. 
2.6.4.2 DNA fragment purification 
Fragment purification was performed for either the product of restriction digest of plasmids 
or PCR fragments using the NucleoSpin PCR clean-up and gel extraction kit (Macherey-
Nagel), as per manufacturer‟s instructions. Briefly, DNA was run on an agarose gel and the 
fragment was then excised from the gel. The gel slice was solubilized by mixing with binding 
buffer and incubation at 50 °C for 5-10 min. For PCR fragment clean-up, 1 volume of the 
sample was directly mixed with 2 volumes of the binding buffer. Thereafter, the solubilized 
gel fragment or PCR DNA fragment was loaded into the NucleoSpin column which was 
placed in a collection tube. The sample was then centrifuged for 30 sec at 11 000 x g to allow 
binding of DNA to the column. The flow-through was then discarded and the column was 
washed twice with 700 µl of wash buffer and centrifuged at 11 000 x g for 30 sec. The flow-
through was discarded and the column was dried by centrifugation at 12 470 x g for 1 min. 
This was followed by elution of DNA into a fresh Eppendorf tube by addition of 30 µl of 
elution buffer and centrifugation at 11 000 x g for 1 min. The DNA was stored at 4°C for 
subsequent DNA manipulation steps. 
2.6.5. DNA ends modification   
2.6.5.1. Dephosphorylation of DNA 
Dephosphorylation of the 5‟ends of linearized plasmid DNA was carried out using Antarctic 
Alkaline Phosphatase (NEB). The reaction contained 1 µg of plasmid DNA, 2 µl of Antarctic 
Alkaline Phosphatase buffer, 1 U of Antarctic Alkaline Phosphatase and sdH2O to a final 
volume of 20 µl. The reaction was then incubated for an hour at 37 °C, followed by heat 
inactivation at 65 °C for 20 min. 
2.6.5.2. Phosphorylation of DNA  
Polynucleotide Kinase (NEB) was used for phosphorylation of PCR products. 1 U of 
Polynucleotide Kinase was added to 1 µg of PCR product, 2 µl of Polynucleotide Kinase 
buffer, 2 µl of 10 mM ATP and sdH2O to a final reaction volume of 20 µl. This was then 
incubated for 1 hour at 37 °C and heat inactivation at 65 °C for 20 min. 
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2.6.6. DNA ligation 
DNA fragments were ligated together using T4 DNA ligase (NEB). Ligation reactions 
contained a constant amount of plasmid DNA of 50 ng, desired volume of insert DNA, 1 U of 
enzyme, 2 µl of T4 DNA ligase reaction buffer and sdH2O to a final reaction volume of 20 
µl. This was then incubated at room temperature for 20 min, followed by heat inactivation of 
the enzyme at 65 °C for 10 min. The following equation was used to calculate the amount of 
insert DNA required for 1:1 (vector: insert) ligation reaction. 
Amount of insert DNA (ng) = 50 ng x size of insert (bp) / size of vector (bp) 
2.6.7. DNA sequencing 
All constructs generated in this study by PCR based cloning techniques were sequenced in 
order to confirm that no mutations have been introduced into the gene/region of interest 
during the process. DNA sequencing was done by the DNA Sequencing Facility of 
Stellenbosch University and the sequencing data was analysed using the DNASTAR software 
(DNASTAR). 
2.7. Bacterial transformations 
2.7.1. Preparation and transformation of E. coli chemically competent cells 
E. coli chemically competent DH5α cells were prepared and transformed following the 
protocol previously decribed by Sambrook et al., 1989. A single colony was picked and 
inoculated into 5 ml of LB and incubated at 37 °C overnight. Thereafter, 1 ml of the 
overnight culture was used to inoculate 100 ml of fresh LB and incubated at 37 °C for 3-5 
hours. The sample was then put on ice for 20 min followed by harvesting the cells by 
centrifugation at 4 500 x g for 10 min at 4 °C. The pellet was then resuspended in 10 ml of 
ice cold CaCl2 (0.1 M) and chilled on ice for 20 min. The cells were then harvested as before, 
resuspended in 5 ml of CaCl2 and kept on ice or used immediately for transformation. 
Transformation of the chemically competent cells was done by mixing 100 µl of cells with 
the desired volume of plasmid DNA, followed by incubation on ice for 15 min and 
transformation by heat shock at 42 °C for 90 sec. Subsequently, cells were chilled on ice for 2 
min and recovered with 800 µl of warm LB. Following this, cells were incubated for an hour 
at 37 °C with 100 rpm shaking. Cells were then selected on LA media supplemented with 
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appropriate antibiotics and incubated overnight at 37 °C to allow for selection of positive 
transformants. 
2.7.2. Preparation and transformation of Msm electro-competent cells 
Msm competent cells were prepared as previously described by Larsen (2002). Briefly, 50-
100 ml of fresh 7H9 media was inoculated with a starter culture, followed by growth to an 
OD600 of 0.5-0.8 at 37 °C. Cells were then harvested by centrifugation at 4500 x g for 10 min 
at 4 °C, followed by three washes with gentle resuspension in 30 ml ice cold 10 % glycerol 
and centrifugation as before. Following the washing steps, cells were resuspended in 3 ml 
10% glycerol and kept on ice until used. 
For electroporations, 400 µl of the cells was mixed with 1 µg of plasmid DNA and 
transferred into a pre-chilled 0.2 cm GenePulser cuvette (BioRad). The BioRad GenePulser 
X-Cell
TM
 system (BioRad) was used to perform electroporations under the following 
parameters: Voltage 2 500 V, Capacitance 25 µF, Resistance 1000 Ω and Distance 0.2 cm. 
Following pulsing, cells were rescued with 800 µl of LB, transferred into a fresh tube and 
incubated at 37 °C for 3-16 hours. This was followed by selection of the cells on 7H10 media 
supplemented with appropriate antibiotics for 3-7 days at 37 °C. 
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2.8. Confirmation of D.D-CPase interacting partners and determination of D,D-CPase 
domains responsible for interaction 
Figure 2.1. gives a diagrammatic representation of the work done in this study. 
Figure 2.1: Diagrammatic representation of experimental layout of interaction work done in this study. 
Identified partnering proteins were first confirmed and evaluated by M-PFC assay and STRING analysis. 
Thereafter, few partners were selected and verified using full length clones, followed by identification of D,D-
CPase interacting domains as well as functional analysis of the selected partners through bioinformatics. 
Sections refer to the relevant sections of the materials and methods. 
2.8.1. Confirmation of D,D-CPase interacting partners 
To confirm previously identified putative interacting partners of MSMEG_6113 and 
MSMEG_2433, the mycobacterial protein fragment complementation (M-PFC) two-hybrid 
system was used as previously described (Singh et al., 2006). This system is based on 
functional rearrangement of two murine dihydrofolate reductase (mDHFR) domains (an 
adenine binding domain (F[2]) and a discontinuous domain (f[1]& f[3]) which are 
autonomously tagged to two proteins to test interaction when co-transformed into 
mycobacteria. Where there is interaction between the two proteins, the mDHFR domains 
reassemble into a functional enzyme that hydrolyses trimethoprim (trim), thus allowing for 
Confirmation of 
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M-PFC assay using 
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Evaluation of interacting 
partners using STRING 
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selection of positive interacting partners on trim supplemented media (Figure 2.2). Briefly, 
the ORFs of the genes of interest were cloned separately into pUAB400 and pUAB300 
plasmids as described in section 2.6.6., and the resulting constructs were confirmed by 
sequencing before subsequent use. The plasmids were then co-transformed into wildtype 
mc
2
155 following the protocol outlined in section 2.7.2. The resulting transformants were 
subsequently picked, resuspended in 1 ml fresh 7H9 broth and inoculated onto 7H10 agar 
supplemented with Hyg (50 µg/ml), Kan (25 µg/ml) and trim (7.5 µg/ml) and incubated at 37 
°C for 7 days to allow for selection of positive interaction. To confirm the functionality and 
efficacy of the M-PFC system, the prey and the bait vectors carrying Rpf interacting protein 
A (RipA) and resuscitation promoting factor B (RpfB), respectively, were used as positive 
controls based on proven interaction (Hett et al., 2007; Hett et al, 2008). In addition to the 
wildtype mc
2
155, the empty vector strains were used as negative controls. 
 
Figure 2.2:  Schematic diagram demonstrating the M-PFC assay principle. When interacting proteins A and 
B are fused with mDHFR subunits (F1,2) and (F3) and co-transformed into mycobacterial cell, the subunits 
reassemble into a functional protein which hydrolyses trim,  thus allowing for survival of the transformants on 
trim plates. In a case where the proteins do not interact, reconstitution of the mDHFR activity does not occur 
thus no growth is observed on the plates. Figure drawn by student, adapted from (Singh et al., 2006). 
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2.8.2. Determination of D,D-CPase domains responsible for interaction 
To determine D,D-CPase domains that are responsible for interaction with the partnering 
proteins, sequences encoding functional domains found in D,D-CPases were cloned 
separately into pUAB400 plasmid and then co-transformed with pUAB300 prey constructs 
into wildtype mc
2
155 and positive interactions were selected as previously described. For 
MSMEG_6113, the sequences encoding signal peptide (SP) and the transpeptidase domain 
(TP) were cloned separately into pUAB400. The resulting constructs (pUAB400+6113SP, 
pUAB6113+ 6113TP) were then co-transformed with the previously generated pUAB300 
constructs carrying selected partnering proteins (FtsI [MSMEG_4233] and Cdc48 
[MSMEG_0858]). The same procedure was followed with MSMEG_2433, where sequences 
encoding signal peptide, transpeptidase domain and the C-terminal region (Cter) were 
individually cloned into pUAB400, and then co-transformed with pUAB300 constructs 
carrying PonA1 (MSMEG_6900) and FtsH (MSMEG_6105). Positive interaction was scored 
as growth on 7H10 plates supplemented with Kan, Hyg and trim. The same controls that were 
used above, were also used for this assay.  
2.9. Knockout mutant generation and phenotypic characterization  
The flowchart in Figure 2.3 summarizes the steps involved in generation of knockout mutant 
strains, from suicide vector construction to characterization of these strains. 
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Figure 2.3:  Flowchart summarizing the steps involved in generation of knockout mutant strains, from suicide 
vector construction to characterization of the strains. Sections refer to the relevant sections of the materials and 
methods. 
2.9.1. Generation of Msm mutant strains 
The two-step allelic exchange by homologous recombination (Gordhan and Parish, 2001) was 
used for generation of Msm knockout deletion mutants. A schematic representation of this 
approach is shown in Figure 2.4. This method involves suicide vector  construction, where 
homologous sequences of the downstream and the upstream region and a small fragment of 
the 5‟ and 3‟ ends of the gene of interest are fused together and cloned into the vector. The 
vector also contains selectable markers (aph and lacZ) to allow for selection of single cross-
over (SCO) recombinants and the sacB gene, which serves as a counter-selectable marker 
facilitating a second cross-over event. The vector is incorporated into the genome of Msm by 
homologous recombination with either the upstream or downstream region resulting in a SCO 
strain carrying both the wildtype and mutated copies of the gene (identified as blue colonies 
growing on 7H10 plates supplemented with Kan and X-gal). The second cross-over event can 
either occur in the same homologous region as the first cross-over, generating a wildtype 
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strain, or it can occur in the opposite homologous region resulting in the generation of the 
mutant strain carrying the inactive copy of the gene of interest (identified as white colonies 
growing in the presence of X-gal and sucrose). 
 
 
Figure 2.4: Schematic representation of the two step allelic exchange by homologous recombination 
procedure. The suicide vector carrying a truncated version of the gene of interest as well as marker genes is 
incorporated into wildtype mc
2
155 strain by homologous recombination with either the upstream or downstream 
region resulting in a SCO strain carrying both the wildtype and mutated copy of the gene. A double crossover 
event results in generation of either a wildtype gene or a knockout mutant. US and DS represents the upstream 
and downstream regions, respectively. ∆ indicates a mutant gene. Figure drawn by student, adapted from 
(Gordon and Parish, 2011). 
2.9.2. Generation of MSMEG_0858 and MSMEG_4233 knockout mutants 
Primers were designed to amplify the upstream (1500 bp) and the downstream (1500 bp) 
regions flanking the gene of interest along with 99 bp of the 5‟end of the gene and 99 bp of 
the 3‟end of the gene. The regions were amplified following the protocol outlined in section 
2.6.1.2. and the resulting PCR fragments were cloned into the p2NIL plasmid as per protocol 
outlined in section 2.6.6. to generate  suicide vector. In addition to this, the counter-selection 
marker gene, sacB (encoding levansucrase), and selectable marker gene lacZ (encoding β-
galactosidase) were excised from pGOAL17 plasmid as a single linear fragment (termed the 
PAC cassette) and cloned into the PacI site of the suicide vector. The resulting construct was 
electroporated into wildtype mc
2
155 according to the protocol outlined in section 2.7.2. The 
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transformants were selected on 7H10 agar supplemented with Kan (25 µg/ml) and 2 % X-gal 
and incubated at 37 °C for 3-5 days. SCO strains were identified as blue colonies growing on 
Kan due to the presence of Kan marker (aph) and the lacZ, encoding β-galactosidase, which 
hydrolyses X-gal resulting in production of blue pigment. SCOs were then selected and 
grown overnight in 5 ml of 7H9 broth containing Kan (25 µg/ml) at 37 °C. This was then 
used to inoculate 5 ml of fresh 7H9 broth and grown at 37 °C overnight in the absence of 
antibiotics to allow for the second cross-over event to occur, resulting in loss of the suicide 
vector. Cells were harvested by centrifugation at 12 470 x g for 10 min and the pellet was 
resuspended in 500 µl of fresh 7H9, from which 100 µl was used to prepare a dilution series 
from 10
-1
-10
-7
. From this, 100 µl of each dilution were selected on two sets of 7H10 plates, 1 
set containing only 2 % X-gal and another set containing 2 % X-gal and 5% sucrose. The 
sacB gene encodes the enzyme levansucrase which degrades sucrose, resulting in production 
of toxic levans that kills the cells retaining the suicide vector. Cells that have undergone a 
successful second cross-over event are able to grow in the presence of sucrose due to the loss 
of the sacB gene and emerge as white colonies growing on 7H10 agar supplemented with 
sucrose. These white colonies were then picked, resuspended in 50 µl of 7H9 broth and 10 µl 
of the suspension was spotted onto two sets of 7H10 plates, 1 set with 2 % X-gal only and the 
other set with 2% X-gal and Kan (25 µg/ml) to ensure that the vector backbone has been lost. 
White colonies that did not grow on Kan were picked and taken forward for PCR screening to 
confirm the genotype. 
2.9.3. Genotypic confirmation of the parental and mutant strains by Southern blot 
analysis 
Southern blot analysis was performed to confirm the genotype of the mutant strains generated 
in this study. Southern blot analysis can disclose details about DNA size, abundance and 
identity. This technique involves separation of DNA fragments based on size by gel 
electrophoresis, transferring and immobilization of the separated fragments onto a 
nitrocellulose membrane, followed by hybridization with a chemiluminescent labelled 
sequence-specific probe, extensive washing and chemiluminescent detection of labelled 
hybridized DNA bands using X-ray films. A brief description of the steps involved in this 
method are shown in Figure 2.5 and discussed in the sections below. For detailed solution 
recipes used for Southern blots see Appendix A, (Table A8). 
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Figure 2.5: Diagrammatic representation of the steps involved in Southern blot analysis. The nitrocellulose 
membrane and the UVC 500 Crosslinker were from Amersham Biosciences, the probe labelling kit and all 
hybridizing solutions as well as the hybridizing bag were supplied by Roche. The hybridization oven and the X-
ray films were supplied by Thermo scientific. Figure drawn by student. 
2.9.3.1. Electro-blotting 
Chromosomal DNA was extracted from derivative SCO strains, DCO mutant strains as well 
as the wildtype Msm following the protocol detailed in section 2.5.2.2. Subsequently, 2 µg of 
genomic DNA was digested with 1 U of appropriate restriction enzyme overnight at 37 °C. 
The fragments were separated on 0.8 % agarose gel at 80 V for 2-3 hours, and the gel was 
visualized alongside a ruler using SYNGENE G-BOX system. Following this, the gel was 
soaked in depurination solution for 15 min with shaking. The depurination solution was then 
discarded and the gel was washed twice with sdH2O, soaked in denaturation solution at room 
temperature for 30 min with shaking. The gel was then neutralized by washing in 1X TBE 
buffer. A Hybond
TM
 N-nitrocellulose membrane (Amersham Biosciences) was then overlaid 
with the gel, sandwiched between 2 layers of Whitman filter papers and 2 layers of porous 
sponge, all of which were enclosed in a plastic cassette. This was then transferred into an 
electroblotting unit filled with 1X TBE buffer. The DNA was transferred onto the 
nitrocellulose membrane at 4 °C for 2 hours at 600 mA and 130 V. Following this, the DNA 
was cross-linked to the nitrocellulose membrane by ultra violet radiation using a UVC 500 
Crosslinker (Amersham Biosciences) at 2500 mJ/cm
3
 for 2 min. 
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2.9.3.2. DNA probe labelling 
Probes used for Southern blots were synthesized using the PCR DIG Probe Synthesis Kit, 
following manufacturer‟s instructions (Roche). This kit allows for specific labelling of probes 
by incorporating alkali-labile digoxygenin-labelled dUTP (DIG-dUTP) in place of dTTP into 
the sequence of the probe during PCR reaction. The DIG-labelled and unlabelled PCR 
products were synthesized as indicated in section 2.6.1.1. Incorporation of DIG dUTP into 
the probe sequence was confirmed by running the PCR products on 1 % agarose gel. The 
DIG-labelled DNA fragment is expected to have higher molecular size compared to the 
unlabelled fragment. The probe was then stored at -20 °C until required. 
2.9.3.3. Hybridization 
Following crosslinking, the nitrocellulose membrane was pre-hybridized by placing the 
membrane into a Hybaid HB-OV-BM roller bottle (Thermo Scientific) containing 12 ml of 
DIG Easy hyb solution (Roche) and incubated at 60 °C for 30 min in a Hybaid Micro-4 
hybridization oven (Thermo Scientific). The labelled probe was then denatured at 65 °C for 
10 min, added to the membrane in the hybridization bottle and hybridized overnight at 60 °C. 
Following hybridization, the membrane was washed twice with solution 1 for 5 min at room 
temperature with shaking, followed by two washes with solution 2 for 15 min at 68 °C in the 
hybridization oven. 
2.9.3.4. Immunological detection 
Prior to immunological detection, the membrane was exposed to several wash steps at room 
temperature with shaking. The membrane was first rinsed in wash buffer for 5 min, followed 
by incubation in 1X blocking buffer for 30 min. The membrane was then incubated for 30 
min in 20 ml of 1X antibody buffer and washed twice for 15 min in wash buffer. Following 
this, the membrane was placed in a hybridization bag (Roche) with the DNA side facing up, 
and 1 ml of chloro-5-substituted adamantyl-1,2-dioxetane phosphate (CSPD) substrate was 
spread evenly onto the membrane. Excess CSPD was removed from the hybridization bag 
followed by incubation for 10 min at 37 °C. The membrane was then exposed to X-ray films 
(CL-XposureTm Film, Thermo Scientific) for 30 min. Films were developed manually in the 
darkroom by 30 sec incubation in developing solution, followed by rinsing in sdH2O for 30 
sec,  30 sec incubation in fixing solution and final rinsing in sdH2O for 30 sec. The film was 
then left to dry. 
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2.10. Generation of Msm complemented strains 
To confirm that any phenotypic variation observed from the mutant strains was due to loss of 
functional copy of the gene of interest and not due to polar effects, complemented strains 
were generated where the gene of interest was reintroduced in the background of the mutant 
strain. This was achieved by amplifying the full length copy of the gene of interest together 
with the 200 bp upstream region of the gene to include its native promoter and cloning into 
an integrating vector (pMV306H), which allows for integration of the functional gene into the 
attB (phage attachment) site in the genome of mycobacteria. The resulting complementation 
constructs were then electroporated into mutant strains following the protocol in section 
2.7.2. To confirm that integration of the complementing gene was successful, genomic DNA 
was extracted from the resultant complemented strains as indicated in section 2.5.2.1. and 
used for PCR screening as indicated in section 2.6.1.1. 
2.11. Generation of MSMEG_4233 SCO recombinant (merodiploid) strain  
Failure to generate MSMEG_4233 targeted gene knockout mutant by allelic exchange was 
taken as an indication of the essentiality of MSMEG_4233 gene function, hence a 
merodiploid strain was generated in order to prove the essentiality of this gene and to 
demonstrate that the wildtype copy of the gene can only be inactivated in the presence of a 
second copy of the gene located elsewhere in the genome. A merodiploid strain was 
generated by electroporating MSMEG_4233 complementation vector construct (described 
above in section 2.10.) into the genome of the MSMEG_4233 SCO recombinant strain as per 
protocol in section 2.7.2. A schematic representation of this approach is shown in Figure 2.6. 
This was then followed by extraction of genomic DNA from the resultant merodiploid strain 
as per protocol in section 2.5.2.1 and the DNA was then used for PCR screening as indicated 
in section 2.6.1.1. to confirm successful integration of complementation vector into the SCO 
recombinant strain. 
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Figure 2.6: Schematic representation of integration of pMV306ftsI into the attB site in the genome of 
MSMEG_4233 SCO. The plasmid uses L5 based integration system, where the attachment site (red) integrates 
at the tRNA
Glycine
 (orange) locus on the SCO chromosome, resulting in the incorporation of the plasmid into the 
genome. Shown in blue arrows are the primers used to confirm site specific integration of the plasmid and 
expected amplicon sizes. Figure drawn by student.  
2.12. Generation of MSMEG_4233 mutant in the merodiploid strain 
To generate MSMEG_4233 mutant, the merodiploid strain was grown overnight in 5 ml of 
7H9 broth containing Kan (25 µg/ml) and Hyg (50 µg/ml) at 37 °C. This was then used to 
inoculate 5 ml of fresh 7H9 broth, followed by growth at 37 °C overnight in the absence of 
antibiotics to allow for second cross-over event to occur. Cells were harvested by 
centrifugation at 4000 x g for 10 min and the pellet was resuspended in 500 µl of fresh 7H9, 
from which 100 µl was used to prepare a dilution series from 10
-1
-10
-7
. One hundred µl of 
each dilution was spread on two sets of 7H10 plates, 1 set containing only 2 % X-gal and 
another set containing 2 % X-gal and 5% sucrose and incubated 5-7 days at 37 °C. Colonies 
were subjected to sucrose selection as described in section 2.9.1 and PCR screening was 
performed to confirm the genotype. 
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2.13. Phenotypic analysis of Msm knockout mutant strains 
2.13.1. Growth kinetics analysis 
The growth rate of Msm derivative strains was analyzed in comparison to the wildtype strain 
by performing three independent growth curve experiments in standard 7H9 media. Briefly, a 
pre-culture of each strain was started from 1 ml of frozen culture in 5 ml 7H9 broth 
containing appropriate antibiotics when necessary and incubated at 37 °C overnight with 
shaking at 100 rpm. Each pre-culture was diluted to an OD600 = 0.01 in 50 ml 7H9 broth 
supplemented with appropriate antibiotics and incubated at 37 °C with shaking at 100 rpm. 
Growth rates were determined by recording OD600 at three hour intervals and the data was 
then used to generate scatter plots. In addition to this, colony forming units (CFU) counts 
were enumerated to confirm the number of bacteria. This was done by making 10-fold serial 
dilutions of each strain at each growth phase and plating the dilutions on 7H10 agar plates. 
The plates were then incubated at 37 °C for two days, following which, CFU/ml was 
determined. 
2.13.2. Minimum inhibitory concentration (MIC) determination 
To determine antibiotic MICs of the mutant strains in comparison to the wildtype, bacterial 
strains were grown in 5 ml of 7H9 supplemented with appropriate antibiotics when necessary 
at 37 °C with shaking at 100 rpm to an OD600=0.2-0.3. Serial 2-fold dilutions of the 
antibiotics were added per well in a 96-well plate containing 7H9 broth. Per well, 100 fold 
diluted cultures were added. The plates were incubated for 5-7 days at 37 °C. The tested 
antibiotics and their starting concentrations were as follows: Amoxicilin (512 µg/ml), 
Cycloserine (100 µg/ml), Ethambutol (102.4 µg/ml), Imipenem (100 µg/ml), Isoniazid (250 
µg/ml), Rifampicin (25.6 µg/ml), Teicoplanin (100 µg/ml) and Vancomycin (100 µg/ml). The 
experiment was done in three biological repeats. 
2.13.3. Ethidium bromide diffusion assay 
Ethidium bromide (EtBr) assay was used to determine cell permeability of mutant strains in 
comparison to the wildtype. This technique is based on accumulation of EtBr inside the cell, 
which is a result of the relationship between efflux activity of cell membrane proteins and 
permeability of the cell wall. Briefly, cells were grown in 7H9 with appropriate antibiotics 
when necessary at 37 °C overnight with shaking at 100 rpm to an OD600=0.8. Cell cultures 
were then centrifuged at 4500 x g for 5 min, the supernatant was discarded and the pellet was 
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washed in PBS. Subsequently, the pellet was resuspended in PBS supplemented with 0.4 % 
glucose and the OD600 was adjusted to 0.4. From this, a 50 µl aliquot of cell suspension was 
added into a 96-well plate, followed by addition of EtBr at concentrations ranging from 10 – 
0.07 µg/ml. Thereafter, fluorescence was measured every 60 sec using a plate reader 
(excitation: 530 nm, emission: 585 nm) for an hour at 37 °C. Measurements were done in 
triplicates.  
2.13.4. Microscopy 
2.13.4.1. Copper Click reaction with D-alanine analogue (click chemistry) 
To investigate the spatial distribution of PG synthesis in growing cells, the click chemistry 
technique was used. This technique allows for labelling of sites of new PG synthesis by 
incorporating a D-alanine, PG-precursor analogue into the PG during synthesis of the cell 
wall. Briefly, bacterial strains were grown at 37 °C overnight with shaking at 100 rpm to an 
OD600=0.5-0.6. Cells were then harvested by centrifugation at 12 470 x g and then 
resuspended in 1 ml 7H9 broth. Subsequently, 1 µl of 10 M D-alanine analogue stock 
solution was added to the cells, followed by 3 hours incubation at 37 °C with shaking at 100 
rpm. Following incubation, the cells were harvested and washed 3 times in PBSTB buffer 
(1X PBS, 0.05 % BSA and 0.01 % tween20). For copper click reaction to occur, 500 µl of 
PBSTB, 500 µl of 1 M CuSO4, 500 µl of 128 µM TBTA (tris- (benzyltriazolylmrthyl) 
amine), 10 µl of 1.2 mM Sodium ascorbate and 10 µl of 20 µM azido probe were added in 
the order listed and the reaction was allowed to proceed for 60 min at room temperature with 
shaking. Following this, cells were washed 3 times in PBS and 5 µl of the cells was spotted 
onto glass slide with 2 % agarose pad and visualized with the Zeiss Axio Observer Z1 
inverted fluorescent microscope. Analysis of all images taken was done using the ZEN lite 
software. 
2.13.4.2. DMN- Trehalose Staining 
In addition to click chemistry, DMN (4-N,N-dimethylamino-1,8-naphthalimide) -Trehalose 
staining was also used for in vivo staining of the cell wall. This technique makes use of a 
trehalose derivative attached to a dye that yields green fluorescence once incorporated into 
the cell wall. Bacterial strains were grown overnight at 37 °C with shaking at 100 rpm to an 
OD600=0.6. Cells were then harvested by centrifugation at 12 470 x g for 5 min followed by a 
single wash in 100 µl PBS. Thereafter, cells were resuspended in 100 µl fresh 7H9 broth, 10 
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µl of 100 µM DMN-Trehalose stain was added to the cells and incubated for an hour at 37 °C 
with shaking. Following incubation, cells were harvested by centrifugation at 12 470 x g for 5 
min and then resuspended in 50 µl sdH2O. Thereafter, 5 µl of the cells was spotted onto glass 
slide with 2 % agarose pad and visualized with the Zeiss Axio Observer Z1 inverted 
fluorescent microscope and analysis of all images taken was done using the ZEN lite 
software. 
2.13.4.3. Scanning electron microscopy (SEM) 
SEM was conducted in order to characterize the Msm strains based on their surface cell 
morphology. Cells were grown to an OD600 = 0.5-0.8 in 50 ml 7H9 broth supplemented with 
appropriate antibiotics at 37 °C with 100 rpm shaking overnight. Thereafter, cells were 
harvested by centrifugation at 4000 x g for 10 min, followed by washing in 0.01 M PBS 
twice. The cells were then resuspended and fixed in 500 µl of 2.5 % gluteraldehyde at 4 °C 
overnight. Thereafter, cells were harvested and washed 3 times in 1 ml PBS, followed by 
staining with 100 µl of 2 % osmium tetraoxide for an hour at room temperature. Cells were 
then washed twice in PBS and dehydrated by 2 min of resuspension in increasing 
concentrations of ethanol (30 %, 50 %, 70 %, and twice in 100 %). Dehydrated cells were 
stored at room temperature in 100 % ethanol until viewed under SEM. Before imaging, cells 
were spotted on a filter, coated twice with carbon and viewed using the FEI Nova NanoSEM 
320. Preparation of cells for SEM was done by student but imaging was outsourced to 
Miranda Waldron at the Centre of Imaging and Analysis, University of Cape Town. The 
student then analysed the resulting images. 
2.14. FtsZ localization 
For localization of proteins of interest, a previously generated protein fusion (FtsZ_GFP) was 
electroporated into wildtype Msm and derivative mutant strains following the protocol 
outlined in section 2.7.2. The resultant transformants were then grown in 5 ml of 7H9 broth 
containing appropriate antibiotics to an OD600=0.5-0.6 overnight at 37 °C. Subsequently, cells 
were harvested by centrifugation at 12 470 x g for 5 min and resuspended in 50 µl of fresh 
7H9 broth. Following this, 5 µl of the cells was mounted onto a glass slide with 2 % agarose 
pad. The slides were then covered with cover slips and visualized with the Zeiss Axio 
Observer Z1 inverted fluorescent microscope and analysis of all images taken was done using 
the ZEN lite software. 
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3. Results 
3.1. Protein interactions 
The first part of this study was aimed at characterizing the Msm D,D-CPases designated 
MSMEG_2433 and MSMEG_6113, through interaction with their respective partnering 
proteins that were previously identified in screen conducted in our lab using bacterial two-
hybrid system. In this regard, the approach involved confirming interaction between the two 
D,D-CPases with their full-length putative partnering proteins and further characterizing these 
partners through bioinformatics analyses as well as determining interaction domains of the 
two D,D-CPases. 
3.1.1. Confirmation of MSMEG_2433 and MSMEG_6113 interacting partners using the 
M-PFC assay 
The screen conducted in our lab identified 20 and 10 possible interacting partners for 
MSMEG_2433 and MSMEG_6113, respectively. Partial clones of these putative partners 
were obtained and first propagated on 7H10 Hyg/Kan solid media. Colonies that emerged 
were sub-cultured on 7H10 Hyg/Kan media supplemented with trim. Any growth on the 
plates was scored as positive interaction and all tested clones were confirmed as positive, 
Table 3.1. Interestingly, a number of these partners were key regulators of cell elongation and 
division. The assay revealed that MSMEG_6113 and MSMEG_2433 possibly interacts with 
HMM PBPs, which play a significant role in cross-linking PG during the last stages of PG 
synthesis. In addition, the assay also revealed other partners, including proteins of the 
transcriptional and translational machinery (DNA polymerase III subunit delta and RNA 
polymerase sigma factor E), metalloproteases and several hypothetical proteins as possible 
interacting partners of the two D,D-CPases. Table 3.1 and Table 3.2. summarize the results 
obtained using M-PFC assay including all controls used in the assay. Three independent 
assays were conducted to confirm these interactions. In the first assay, colony numbers were 
lower compared to the ones in the second and third assay and this was possibly due to 
experimental errors or variation in electroporation efficiency. 
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Table 3.1: Confirmation of MSMEG_6113 interaction with its putative interacting partners 
including appropriate controls using M-PFC assay. 
 1
st
 assay 2
nd
 assay 3
rd
 assay 
Test Positive 
(+) 
negative 
(-) 
number 
of 
colonies 
Positive 
(+) 
negative 
(-) 
number 
of 
colonies 
Positive 
(+) 
negative 
(-) 
number 
of 
colonies 
mc
2
 155 - 0 - 0 - 0 
mc
2
:: pUAB400 (pUAB300) (-
ve control) 
- 0 - 0 - 0 
mc
2
:: RipA +RpfB (+ve 
control) 
+ 287 + 600 + lawn 
mc
2
::pUAB6113+penicillin 
binding protein B 
(MSMEG_4233) 
+ 610 + lawn + lawn 
mc
2
::pUAB6113+hypothetical 
protein (MSMEG_6112) 
+ 221 + lawn + lawn 
mc
2
::pUAB6113+cell division 
control protein 
(MSMEG_0858) 
+ 456 + lawn + lawn 
mc
2
::pUAB6113+enoyl-CoA 
hydratase/isomerase 
(MSMEG_0259) 
+ 527 + lawn + lawn 
mc
2
::pUAB6113+penicillin 
binding protein 4 
(MSMEG_5637) 
+ 542 + lawn + lawn 
mc
2
::pUAB6113+hypothetical 
protein (MSMEG_0610) 
+ 578 + lawn + lawn 
mc
2
::pUAB6113+hypothetical 
protein (MSMEG_0365) 
+ 511 + lawn + lawn 
mc
2
::pUAB6113+integral 
membrane protein 
(MSMEG_4287) 
+ 622 + lawn + lawn 
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mc
2
::pUAB6113+coniferyl 
aldehyde dehydrogenase 
(MSMEG_2242) 
+ 428 + lawn + lawn 
* The plus (+) sign indicates positive interaction and the minus (–) sign indicates negative or no interaction 
observed using M-PFC assay. 
  
Table 3.2: Confirmation of MSMEG_2433 interaction with its putative interacting partners, 
including appropriate controls using M-PFC assay. 
 1
st
 assay 2
nd
 assay 3
rd
 assay 
Test Positive 
(+) 
negative 
(-) 
number 
of 
colonies 
Positive 
(+) 
negative 
(-) 
number 
of 
colonies 
Positive 
(+) 
negative 
(-) 
number 
of 
colonies 
mc
2
 155 - 0 - 0 - 0 
mc
2
::pUAB400 (pUAB300) (-ve 
control) 
- 0 - 0 - 0 
mc
2
::RipA+RpfB (+ve  control) + 287 + lawn + lawn 
mc
2
::pUAB2433+ UDP-
diphospho- muramoypentapeptide 
beta-acetylglucoseamyl 
transferase (MSMEG_4227) 
+ 298  + lawn + lawn 
mc
2
::pUAB2433+glutamine 
synthetase (MSMEG_3561) 
+ lawn + lawn + lawn 
mc
2
::pUAB2433+RNA 
polymerase sigma factor RpDE 
(MSMEG_1914) 
+ 525 + lawn + lawn 
mc
2
::pUAB2433+hypothetical 
protein (MSMEG_3858) 
+ 527 + lawn + lawn 
mc
2
::pUAB2433+beta lactamase 
(MSMEG_4337) 
+ 596 + lawn + lawn 
mc
2
::pUAB2433+conserved 
hypothetical protein 
(MSMEG_5691) 
+ lawn + lawn + lawn 
52 
 
mc
2
::pUAB2433+tRNA 
pseudouridine synthase A 
(MSMEG_1527) 
+ lawn + lawn + lawn 
mc
2
::pUAB2433+penicillin 
binding protein transpeptidase 
domain protein (MSMEG_0031) 
+ 476 + lawn + lawn 
mc
2
::pUAB2433+transglycosidase 
(MSMEG_6201) 
+ 387 + lawn + lawn 
mc
2
::pUAB2433+penicillin 
binding protein 1(MSMEG_6900) 
+ 532 + lawn + lawn 
mc
2
::pUAB2433+ATP-dependent 
zinc metalloprotease 
(MSMEG_6105) 
+ 566 + lawn + lawn 
mc
2
::pUAB2433+glycosyl 
transferase (MSMEG_4947) 
+ lawn + lawn + lawn 
mc
2
::pUAB2433+UDP-N-
acetylenolpyrovoyl-glucosamine 
reductase (MSMEG_0928) 
+ 406 + lawn + lawn 
mc
2
::pUAB2433+DNA 
polymerase III subunit delta 
(MSMEG_6153) 
+ 591 + lawn + lawn 
* The plus (+) sign indicates positive interaction and the minus (–) sign indicates negative or no interaction 
observed using M-PFC assay. 
  
3.1.2. STRING analysis of MSMEG_6113 and MSMEG_2433 interacting partners. 
In addition to M-PFC assay, MSMEG_6113 and MSMEG_2433 interacting partners were 
evaluated using STRING database (https://string-db.org). The associations in this database 
include direct (physical) interactions and indirect (functional) interactions. A number of 
proteins that were predicted by STRING as possible interacting partners of MSMEG_6113 
and MSMEG_2433 were consistent with those revealed by M-PFC assay. These include 
penicillin binding protein 4 (MSMEG_5637), a hypothetical protein (MSMEG_6112) and 
penicillin binding protein B (MSMEG_4233) for MSMEG_6113 (Figure 3.1.). For 
MSMEG_2433, penicillin binding protein A (MSMEG_0031), penicillin binding protein 1 
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(MSMEG_6900) and UDP-diphospho- muramoylpentapeptide beta N-
acetylglucosaminyltransferase (MSMEG_4227) were identified as interacting partners 
(Figure 3.2).  
 
 
Figure 3.1: MSMEG_6113 interacting protein partners revealed by String analysis. The nodes represent 
proteins and the lines represent protein-protein associations, with known interactions represented by turquoise 
lines. Blue, green and red lines represent predicted interaction obtained by gene co-occurrence, gene 
neighbourhood and gene fusions respectively. The other associations are represented by black and yellow lines. 
https://string-db.org accessed on 1 June 2016. 
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Figure 3.2: MSMEG_2433 interacting protein partners revealed by String analysis. The nodes represent 
proteins and the lines represent protein-protein associations, with known interactions illustrated by purple and 
turquoise lines. Blue, green and red lines represent predicted interaction obtained by gene co-occurrence, gene 
neighbourhood and gene fusions respectively. The other associations are represented by black and yellow lines. 
https://string-db.org accessed on1 June 2016. 
3.1.3. Cloning of genes encoding D,D-CPases and their selected partners into M-PFC 
bait and prey vectors 
The screen that identified these interactions made use of a DNA library consisting of genomic 
fragments. As such, fragments of the putative proteins were identified as possible interacting 
partners. To further confirm interactions, the genes encoding full length proteins were cloned 
for M-PFC analysis. For this component, five MSMEG_6113 interacting partners were 
selected including penicillin binding protein B (PBPB) also known as FtsI, cell division 
control protein 48 (Cdc48), penicillin binding protein 4 (PBP4), hypothetical proteins 
MSMEG_0365 and MSMEG_6112. In addition, four MSMEG_2433 partnering proteins 
were also selected including penicillin binding protein 1 (PonA1), penicillin binding protein 
A (PBPA), ATP-dependent zinc metalloprotease (FtsH) and UDP-diphospho-
muramoylpentapeptide beta N-acetylglucosaminyltransferase (MurG). The rationale for 
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selecting these included a demonstrated role in cell wall biology or cell division/elongation. 
Two hypothetical proteins were chosen as exploratory objectives. The ORFs of the genes 
encoding the above selected proteins and the two D,D-CPases were cloned separately into 
pUAB300 (prey) and pUAB400 (bait) vectors respectively, following the protocol outlined in 
section 2.6.6. Prior to cloning, the genetic integrity of the vectors was confirmed by extensive 
restriction digest (results shown in Appendix C1, C2). The resulting constructs were analyzed 
by restriction profiling and further confirmed by sequencing. Restriction analysis of all 
constructs yielded the expected banding patterns (see appendix C4-C14). Sequencing 
revealed no mutations. 
3.1.4. Confirmation of MSMEG_2433 and MSMEG_6113 interacting partners by M-
PFC assay using full length clones 
Electroporation of the Msm mc
2
155 strain with the above generated constructs was performed 
following the protocol outlined in section 2.7.2. to generate mc
2
155 strains carrying both 
tagged derivatives of D,D-CPases and their selected partners. The strains were then 
propagated on 7H10 media containing Kan/Hyg. All strains grew on 7H10 Kan/Hyg plates, 
indicating the presence of the constructs carrying the desired genes. To test for protein 
interactions, colonies were picked from the above plates and resuspended in 1 ml fresh 7H9 
media, then sub-cultured on 7H10 Kan/Hyg media supplemented with trim and incubated for 
4-5 days at 37°C. Colony growth on the plates was scored as positive interaction and all 
tested strains were positive. The mc
2
155 cells only control (A in Figure 3.3) and the empty 
vector control mc
2
 155::pUAB400(pUAB300) (C in Figure 3.3 ) tested negative as expected 
(Table 3.3. and Figure 3.3.). The mc
2
155::RipA+RpfB positive control (B in Figure 3.3) 
showed strong interaction between the two proteins as indicated by the number of colonies 
and the time at which colonies emerged (two days post incubation) (Table 3.3. and Figure 
3.3). Numerous studies have demonstrated interaction between RipA and RpfB and this 
interaction has been shown to play important role in various cell division processes (Hett et 
al., 2007; Hett et al., 2008). MSMEG_6113 was shown to interact strongly with 
MSMEG_6112 (E in Figure 3.3) (Table 3.3 and Figure 3.3). This strong interaction between 
MSMEG_6113 and MSMEG_6112 (HP) may be due to the fact that the genes encoding the 
two proteins are found next to each other in an operon. MSMEG_2433 was able to interact 
strongly with FtsH and PBPA (Table 3.3. and Figure 3.3.). Strong interaction is indicated by 
bacterial lawn while weak interaction is demonstrated by less number of colonies formed. 
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Table 3.3: Interaction of MSMEG_6113, MSMEG_2433 and their selected putative 
partnering proteins.  
Test strains Positive (+)/ 
negative (-) 
Number of 
colonies* 
(A) mc
2
 155 - 0 
(B) mc
2
 155:: RipA+ RpfB + lawn 
(C) mc
2
 155:: pUAB400 + pUAB300 - 0 
(D) mc
2
 155:: pUAB6113 + PBPB/FtsI + 414 
(E) mc
2
 155:: pUAB6113 + hypothetical protein (HP) 
(MSMEG_6112) 
+ lawn 
(F) mc
2
 155:: pUAB6113 + Cdc48 + 420 
(G) mc
2
 155:: pUAB6113 + hypothetical protein (HP) 
(MSMEG_0365) 
+ 428 
(H) mc
2
 155:: pUAB6113 + PBP4 + 312 
(I) mc
2
 155:: pUAB2433 + FtsH + lawn 
(J) mc
2
 155:: pUAB2433 + MurG + 368 
(K) mc
2
 155:: pUAB2433 + PonA1 + 392 
(L) mc
2
 155:: pUAB2433 + PBPA + lawn 
*The table shows results observed using M-PFC assay including test strains and appropriate controls. Colony 
numbers indicate the strength of the observed interactions. 
 
Figure 3.3: Protein interaction between MSMEG_6113, MSMEG_2433 and their selected partners in 
Msm using the M-PFC assay. Msm cells were transformed with M-PFC plasmids, transformants were selected 
on 7H10 plates supplemented with Kan/Hyg, and later sub-cultured onto 7H10 Hyg/Kan plates containing 7.5 
µg/ml trim. (A) Wildtype mc
2
155 cells only negative control, (B) RipA+ RpfB positive control, (C) empty 
vector negative control, (D-H) MSMEG_6113 positive interacting partners, (I-L) MSMEG_2433 positive 
interacting partners. The plates were incubated for 5 days. 
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3.1.5. Cloning of genes encoding functional domains of the two D,D-CPases into M-PFC 
bait vector 
3.1.5.1. Cloning of genes encoding signal peptide and transpeptidase domain of 
MSMEG_6113 into pUAB400 
After confirming the interactions, we next sought to determine which regions in the D,D-
CPases interact with the partnering proteins. The ORFs of the genes encoding the signal 
peptide (SP) and the transpeptidase (TP) domain of MSMEG_6113 were cloned separately 
into the M-PFC bait vector pUAB400, following the protocol outlined in section 2.6.6. A 
selected clone per construct was verified by restriction profiling with at least 6 restriction 
enzymes (Figure 3.4. and 3.5.) and further confirmed by sequencing (results not shown). 
Restriction enzymes used for profiling pUAB400+6113SP construct yielded the expected 
banding patterns with the exception of NspI which had an extra band and this could be due to 
the star activity of the enzyme (Figure 3.4C). An unexpected cleavage pattern was observed 
with pUAB400+6113TP where digestion by AatII yielded aberrant bands (Figure 3.5B) 
however, sequencing results of these constructs revealed no mutations (data not shown), this 
construct was used for further works.  
 
See figure legend on the next page 
Pagepage 
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Figure 3.4: Restriction profile of pUAB400+6113SP. (A) Domain organization of MSMEG_6113 indicating 
the location of the signal peptide and cloning of the signal peptide into pUAB400. (B) Plasmid map of the final 
pUAB400+6113SP construct used for transformation. (C) 0.8 % agarose gel indicating expected DNA band 
sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) Acc65I, lane (4) BamHI, 
lane(5) MscI, lane (6) NruI, lane (7) NspI, lane (8) XbaI. (D) Table showing restriction enzymes used for 
profiling and the expected fragment sizes. 
 
Figure 3.5: Restriction profile of pUAB400+6113TP. (A) Domain organization of MSMEG_6113 indicating 
the location of the transpeptidase domain and cloning of the transpeptidase domain into pUAB400. (B) Plasmid 
map of the final pUAB400+6113TP construct used for transformation. (C) 0.8% agarose gel indicating expected 
DNA band sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) 
NotI, lane(5) NruI, lane (6) NspI, lane (7) PstI, lane (8) SmaI. (D) Table showing restriction enzymes used for 
profiling and the expected fragment sizes. 
3.1.5.2. Cloning of genes encoding signal peptide, transpeptidase domain and C-
terminal region of MSMEG_2433 into pUAB400 
As with MSMEG_6113, the domains in MSMEG_2433 were investigated for their ability to 
interact with putative interacting partners. For this, the region encoding the signal peptide, 
transpeptidase domain and the C-terminal region of MSMEG_2433 were separately cloned 
into the M-PFC bait vector pUAB400 following the protocol outlined in section 2.6.6. A 
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selected positive clone per construct was verified by restriction analysis following the 
protocol outlined in section 2.6.2. (Figure 3.6., 3.7. and 3.8.) and further confirmed by 
sequencing, which revealed that no mutations had occurred in the cloned regions during PCR 
(results not shown). Restriction enzymes used for profiling the constructs yielded the 
expected banding patterns with the exception of NspI which had an extra band in all cases 
and this again was attributed to star activity (Figure 3.6B and 3.8B). Digestion by AatII 
yielded unexpected cleavage pattern (Figure 3.6B, 3.7B and 3.8B) whereby the aberrant AatII 
site was mapped to the vector backbone and not the region of interest.  
  
 
Figure 3.6: Restriction profile of pUAB400+2433SP. (A) Domain organization of MSMEG_2433 indicating 
the location of the signal peptide and cloning of the signal peptide into pUAB400. (B) Plasmid map of the final 
pUAB400+2433SP construct used for transformation. (C) 0.8% agarose gel indicating expected DNA band 
sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) NruI, 
lane(5) NspI, lane (6) PvuI, lane (7) SmaI, lane (8) XbaI. (D) Table showing restriction enzymes used for 
profiling and the expected fragment sizes. 
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Figure 3.7: Restriction profile of pUAB400+2433TP. (A) Domain organization of MSMEG_2433 indicating 
the location of the transpeptidase domain and cloning of transpeptidase domain into pUAB400. (B) Plasmid 
map of the final pUAB400+2433TP construct used for transformation. (C) 0.8% agarose gel indicating expected 
DNA band sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) 
Acc65I, lane(5) NcoI, lane (6) NotI, lane (7) SmaI, lane (8) XbaI. (D) Table showing restriction enzymes used 
for profiling and the expected fragment sizes. 
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Figure 3.8: Restriction profile of pUAB400+2433Cter. (A) Domain organization of MSMEG_2433 indicating 
the location of the C-terminal region and cloning of C-terminal region into pUAB400. (B) Plasmid map of the 
final pUAB400+2433Cter construct used for transformation. (C) 0.8% agarose gel indicating expected DNA 
band sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) NruI, 
lane(5) NspI, lane (6) PvuI, lane (7) SmaI, lane (8) XbaI. (D) Table showing restriction enzymes used for 
profiling and the expected fragment sizes. 
3.1.6. Determination of MSMEG_6113 and MSMEG-2433 interacting domains 
To determine the interacting domains of MSMEG_6113 and MSMEG_2433, co-
electroporation of mc
2
155 with the above generated constructs was performed following the 
protocol outlined in section 2.7.2. These generated mc
2
155 strains carrying both tagged 
derivatives of selected partnering proteins and functional domains of MSMEG_6113 and 
MSMEG_2433 were then propagated on 7H10 media containing Kan/Hyg. All strains grew 
on 7H10 Kan/Hyg plates, indicating the presence of the constructs carrying the desired genes. 
To test for protein interaction, colonies were picked from the above plates and resuspended in 
1 ml fresh 7H9 media then sub-cultured on 7H10 Kan/Hyg media supplemented with trim 
and incubated for 4-5 days at 37°C. Positive interaction was scored as growth observed on 
the plates. The mc
2
155 cells only control (A in Figure 3.9) and the empty vector control 
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mc
2
 155::pUAB400(pUAB300) (B in Figure 3.9) tested negative as expected (Table 3.4. and 
Figure 3.9.). Of all the constructs tested for MSMEG_6113, the signal peptide and the 
transpeptidase domain were sufficient for interaction with Cdc48 and FtsI. However, signal 
peptide interaction was slightly weaker than that of the transpeptidase domain (Figure 3.9 D, 
E, F, and G). Of  all the constructs tested for MSMEG_2433, only the constructs containing 
the transpeptidase domain were sufficient for interaction with FtsH and PonA1 (Figure 2.9 I 
and K), while constructs containing the C-terminal region failed to interact (Figure 3.9. J and 
L). These results revealed that the two D,D-CPases most likely interact with their partners at 
the transpeptidase domain responsible for cleaving PG crosslinks. 
Table 3.4: Interaction of MSMEG_6113 SP and TP domain with Cdc48 and FtsI, as well as 
that of MSMEG_2433 SP, TP domain and C-ter region with FtsH and PonA1.  
Test strains Region tested Positive (+)/ 
negative (-) 
Number of 
colonies 
(A) mc
2
 155 - - 0 
(B) mc
2
 155:: pUAB400 + pUAB300 - - 0 
(C) mc
2
 155:: RipA + RpfB - + lawn 
Full-length MSMEG_6113  Not tested Not tested 
(D) mc
2
 155:: pUAB6113SP + Cdc48  + lawn 
(E) mc
2
 155:: pUAB6113TP + Cdc48  + lawn 
(F) mc
2
 155:: pUAB6113SP + FtsI  + lawn 
(G) mc
2
 155:: pUAB6113TP + FtsI  + lawn 
Full-length MSMEG_2433  Not tested Not tested 
(H) mc
2
 155:: pUAB2433SP + FtsH  + 480 
(I) mc
2
 155:: pUAB2433TP + FtsH  + lawn 
(J) mc
2
 155:: pUAB2433Cter + FtsH  - 0 
(K) mc
2
 155:: pUAB2433TP + 
PonA1 
 + lawn 
(L) mc
2
 155:: pUAB2433Cter + 
PonA1 
 - 0 
*The table shows results observed using M-PFC assay including appropriate controls. Colony numbers indicate 
the strength of the observed interactions.The D,D-CPase region tested for interaction is also shown, the plus (+) 
sign indicates positive interaction and the minus (–) sign indicates negative or no interaction observed using M-
PFC assay. The full-length MSMEG_6113 and MSMEG_2433 were not tested and their domain organizations 
were only included in the table to show the spatial location of the regions tested. 
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Figure 3.9: Protein interaction between MSMEG_6113, MSMEG_2433 domains and their selected 
partners in Msm using the M-PFC assay. Msm cells were transformed with M-PFC plasmids, transformants 
were selected on 7H10 plates supplemented with Kan/Hyg, and later sub-cultured onto 7H10 Hyg/Kan plates 
containing 7.5 µg/ml trim. (A) Wildtype mc
2
155 cells only negative control, (B) empty vector negative control 
(C) RipA+ RpfB positive control, (E-L) Tested MSMEG_6113 and MSMEG_2433 domains with selected 
partners. The plates were incubated for 7 days.  
 
3.1.7. Bioinformatics analyses of selected MSMEG_6113 and MSMEG_2433 partnering 
proteins (Cdc48, FtsI, FtsH and PonA1) 
3.1.7.1. Sequence alignment of Cdc48, FtsI, PonA1 and FtsH in various rod shaped 
bacteria 
Our analysis thus far confirmed various interacting partners for MSMEG_6113 and 
MSMEG_2433 and also highlighted what domains are required for interaction. We next 
turned our attention to detailed bioinformatics analysis of the putative interacting partners. To 
identify conserved catalytic residues within the selected protein partners, clustalO analysis 
(www.ebi.ac.uk/Tools/msa/ClustalO) was conducted using amino acid sequences from each 
protein. The sequences were compared with those of commonly studied rod-shaped bacteria 
including Mtb, E. coli, B. subtilis, M. leprae, M. bovis and M. marinum by conducting a 
clustalO alignment. Alignment of Cdc48 proteins revealed that the GxGK (T/S) motif (also 
known as the ATP-binding motif or A-box) is conserved throughout the different species 
(Figure 3.10 A). FtsI and PonA1 alignments confirmed the presence of all three conserved 
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catalytic motifs (SxxK, SxN and KTG (T/S) of PBPs (Figure 3.10 B and Figure 3.10 C) and 
these motifs occurred in the same position across the different organisms assessed. Alignment 
analysis of amino acid sequences of the FtsH protein revealed the presence of three conserved 
motifs including the two ATP-binding motifs (GPPGTGKT and IIFVDEID), the AAA family 
signature motif (GVILIAATNRPDILDPALLRPGR) and Zn2+-binding motif (HEGGH). 
These motifs shared 100% identity at the amino acid level with Mtb FtsH protein (Figure 3.10 
D). The alignments indicated that all residues responsible for the coordinated activities of 
these proteins are highly conserved across the different organisms particularly in 
mycobacteria, suggesting that they could have similar physiological roles in different 
mycobacterial species.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 A: Comparison of the conserved Msm Cdc48 sequence with other Cdc48 homologues. Shown 
is the amino acid sequence alignment of Ms (Msm), MMAR (M. marinum), Mt (Mtb) and Mb (M. bovis). Two 
conserved ATP-binding motifs A-box (first and second last row) and B-box (last raw) are highlighted in yellow 
shading. www.ebi.ac.uk/Tools/msa/ClustalO accessed on 20/06/2017. 
Ms        LDEWLRLSLDEPELLKTLGATPHLGVLVSGPAGVGKATMVRAVCASRRVVELDGPEVGAL 
MMAR      LTEWLKLALDEPHLLQSLGAGTNLGVLVSGPAGVGKVTLVRAVCAGRRLVELDGPEVGAL 
Mt        LTEWLKLALDEPHLLQTLGAGTNLGVLVSGPAGVGKATLVRAVCDGRRLVTLDGPEIGAL 
Mb        LTEWLKLALDEPHLLQTLGAGTNLGVLVSGPAGVGKATLVRAVCDGRRLVTLDGPEIGAL 
          * ***:*:****.**::***  :*************.*:***** .**:* *****:*** 
 
Ms        QVDERLRSVTSAVAAVTESGGVLFIADVDALLPAGNEMRPPEPVATLILAELRKAVATPG 
MMAR      APENRLKAVASAVATVRDGGGVLLITDVDALLPAT-----AEPVAALILGELRTAVATDG 
Mt        AAGDRVKAVASAVQAVRHEGGVLLITDADALLPAA-----AEPVASLILSELRTAVATAG 
Mb        AAGDRVKAVASAVQAVRHEGGVLLITDADALLPAA-----AEPVASLILSELRTAVATAG 
             :*:::*:*** :* . ****:*:*.******       ****:***.***.**** * 
 
Ms        VAFIATSAVPENVDARLRAPEVCDRELGLSLPDATARRSLLEMLLRGVPSEDLDLGDIAD 
MMAR      VVLIATTAAPDQLDARLRAPDLCDRELGLPLPDAATRKALLEALLRHVPTGDLDIDEIAS 
Mt        VVLIATSARPDQLDARLRSPELCDRELGLPLPDAATRKSLLEALLNPVPTGDLNLDEIAS 
Mb        VVLIATSARPDQLDARLRSPELCDRELGLPLPDAATRKSLLEALLNPVPTGDLNLDEIAS 
          *.:***:* *:::*****:*::******* ****::*::*** **. **: **::.:**. 
 
Ms        HTPGFVVADLAAVVREGALRAAARASSSDDDPVLRHADLEGALTVIRPLSRSASEEVSVG 
MMAR      RTPGFVVADLAALLREAALRAASRASTDGQPPELNQEDLLGALTVIRPLSRSASSEVAVG 
Mt        RTPGFVVADLAALVREAALRAASRASADGRPPMLHQDDLLGALTVIRPLSRSASDEVTVG 
Mb        RTPGFVVADLAALVREAALRAASRASADGRPPMLHQDDLLGALTVIRPLSRSASDEVTVG 
          :***********::**.*****:***:..  * *.: ** **************.**:** 
 
Ms        SVTLDDVGDMVETKRALTEAVLWPLQHPDTFSRLGIDPPRGVLLYGPPGCGKTFVVRALA 
MMAR      SITLDDVGDMAQAKQALTEAVLWPLQHPDTFARLGVEPPRGVLLYGPPGCGKTFVVRALA 
Mt        DVTLDDVGDMAAAKQALTEAVLWPLQHPDTFARLGVEPPRGVLLYGPPGCGKTFVVRALA 
Mb        DVTLDDVGDMAAAKQALTEAVLWPLQHPDTFARLGVEPPRGVLLYGPPGCGKTFVVRALA 
          .:********. :*:****************:***::*********************** 
 
Ms        SSGRLSVHAVKGSELMDKWVGSSEKAVRELFARARDSAPSLVFLDEIDALAPRRGQNFDS 
MMAR      STGQLSVHAVKGSELMDKWVGSSEKAVRELFRRARDSAPSLVFLDEVDALAPRRGQSFDS 
Mt        STGQLSVHAVKGSELMDKWVGSSEKAVRELFRRARDSAPSLVFLDELDALAPRRGQSFDS 
Mb        STGQLSVHAVKGSELMDKWVGSSEKAVRELFRRARDSAPSLVFLDELDALAPRRGQSFDS 
          *:*:*************************** **************:*********.*** 
 
Ms        GVTDKVVASLLTELDGIEPLRDVVVLGATNRPDLIDPALLRPGRLERLVFVEPPDAAARR 
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Figure 3.10 B: Comparison of the conserved Msm FtsI sequence with other FtsI homologues. Shown is the 
amino acid sequence alignment of Ms (Msm), Ml (M. leprae) MMAR (M. marinum), Mt (Mtb) and Mb 
(M.bovis). The three conserved motifs of PBPs are also shown. Highlighted in turquoise blue is the SxxK motif 
containing the active serine residue. The SxN motif is highlighted in purple shading and the KTG motif is 
shown in dark blue shading. www.ebi.ac.uk/Tools/msa/ClustalO accessed on 20/06/2017. 
 
Ms        DGSVTYDRGSDGVVIPGSYRNRHDAVDGSTVQLTIDDDIQYHVQQQVQMAKDASGAKNVS 
Ml        DGSVTYDRGSDGVVIPGSYRNRHRAVNGSTVQLTIDDDIQFYVQQQVQQAKNLSGAHNVS 
MMAR      DGSVTYDRGSDGVVIPGSYRNRHKAVHGSTVQLTLDNDIQFYVQQQVQQAKNLSGARNAS 
Mt        DGSVTYDRGSDGVVIPGSYRNRHKAVHGSTVVLTLDNDIQFYVQQQVQQAKNLSGAHNVS 
Mb        DGSVTYDRGSDGVVIPGSYRNRHKAVHGSTVVLTLDNDIQFYVQQQVQQAKNLSGAHNVS 
          *********************** **.**** **:*:***::****** **: ***:*.* 
 
Ms        AVVLDAKTGEVLAMSNDNTFDPSQDIGRQADRQMGNPSVSSPFEPGSVNKIVTAAAAIEN 
Ml        AVVLDAKTGEVLAMANDNTFDPSQDIGRQGGKQLGNLAVSSPFEPGSVNKVITASAVIEY 
MMAR      AVVLDAQTGEVLAMANDNTFDPSQDIGRQGDRQLGNLVVSSPFEPGSVNKIIAAASVIEY 
Mt        AVVLDAKTGEVLAMANDNTFDPSQDIGRQGDKQLGNPAVSSPFEPGSVNKIVAASAVIEH 
Mb        AVVLDAKTGEVLAMANDNTFDPSQDIGRQGDKQLGNPAVSSPFEPGSVNKIVAASAVIEH 
          ******:*******:**************..:*:**  ************:::*::.**  
 
Ms        GLTNPDEVLQVPGSIHMGGVTVRDAWNHGVMPYTTTGVFGKSSNVGTLMLAQRVGPERFY 
Ml        GLSTPDEVLQVPGSIQMGGVSVHDAWEHGVMPYTTTGVFGKSSNVGTLMLAQRVGPERFY 
MMAR      GLSTPDEVLQVPGTIQMGGVTVHDAWGHGVMPYTTTGVFGKSSNVGTLMLAQRVGPERFY 
Mt        GLSSPDEVLQVPGSIQMGGVTVHDAWEHGVMPYTTTGVFGKSSNVGTLMLSQRVGPERYY 
Mb        GLSSPDEVLQVPGSIQMGGVTVHDAWEHGVMPYTTTGVFGKSSNVGTLMLSQRVGPERYY 
          **:.*********:*:****:*:*** ***********************:*******:* 
 
Ms        EMLRKFGLGQRTNVGLPGESSGLLPPIDQWSGSSFSNLPIGQGLSMTLLQMAAMYQTVAN 
Ml        DMVRKFGLGQLTGVGLPGESEGLVPSVDQWSGSTFSNLPIGQGLSTTLLQMTGMYQVIAN 
MMAR      DMVGKFGLGQRTGVGLPGESAGLVPPLDQWSGSTFANLPIGQGLSMTLLQMAGMYQAIAN 
Mt        DMLRKFGLGQRTGVGLPGESAGLVPPIDQWSGSTFANLPIGQGLSMTLLQMTGMYQAIAN 
Mb        DMLRKFGLGQRTGVGLPGESAGLVPPIDQWSGSTFANLPIGQGLSMTLLQMTGMYQAIAN 
          :*: ****** *.******* **:* :******:*:********* *****:.***.:** 
 
Ms        DGVRVPPRIIKSTIAPDGTVTEEERPEGIRVISPETARTLRSMFRSVVQRDPMGVQQGTG 
Ml        DGVRIPPRIIKATNAADGTRTQEPRPDGIRVVSPQTAQTVRQMLRAVVQKDPMGYQQGTG 
MMAR      DGVRIPPRIIKATIAADGTRTEEPRPEGIRVVSAQTAQTVREMLRAVVQRDPMGYQQGTG 
Mt        DGVRVPPRIIKATVAPDGSRTEEPRPDDIRVVSAQTAQTVRQMLRAVVQRDPMGYQQGTG 
Mb        DGVRVPPRIIKATVAPDGSRTEEPRPDDIRVVSAQTAQTVRQMLRAVVQRDPMGYQQGTG 
          ****:******:* * **: *:* **:.***:* :**:*:*.*:*:***:**** ***** 
 
Ms        PQAAVEGYQIAGKTGTAQQINPACGCYYDDVYWITFAGIAPADDPRYVIGIMMDAPQRAA 
Ml        PAAGVSGYQIAGKTGTAQQVNPACRCYFDDVYWITFAGMATVDNPRYVIGTMMDNPERNA 
MMAR      TAAAVPGYQMAGKTGTAQQINPACGCYFDNVYWITFAGLATVDNPRYVIGLMLDNPERNS 
Mt        PTAGVPGYQMAGKTGTAQQINPGCGCYFDDVYWITFAGIATADNPRYVIGIMLDNPARNS 
Mb        PTAGVPGYQMAGKTGTAQQINPGCGCYFDDVYWITFAGIATADNPRYVIGIMLDNPARNS 
            *.* ***:*********:**.* **:*:********:* .*:****** *:* * * : 
 
Ms        DGSPGSSAAPLFHEIASWLLQRHNVPLSPDPGPPLTLQAT 
Ml        DGTPGHSAAPLFHNVAGWLMQRENVPLSPDPGPPLTLQAT 
MMAR      DGTAGHSSAPLFHNIAAWLMQRENVPLSADPGPPLLLQAT 
Mt        DGAPGHSAAPLFHNIAGWLMQRENVPLSPDPGPPLVLQAT 
Mb        DGAPGHSAAPLFHNIAGWLMQRENVPLSPDPGPPLVLQAT 
          **: * *:*****::*.**:**.***** ****** **** 
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Figure 3.10 C: Comparison of Msm PonA1 sequence with other PonA1 homologues. Shown is the amino 
acid sequence alignment of Ms (Msm), Ml (M. leprae) MMAR (M. marinum), Mt (Mtb) and Mb (M. bovis). 
Conserved motifs of PBPs are also shown. Highlighted in turquoise blue is the SxxK motif containing the active 
serine residue and the SxN motif is highlighted in purple shading. www.ebi.ac.uk/Tools/msa/ClustalO accessed 
on 20/06/2017. 
 
Ml        DRAFFCDYVQEYLSRAGISKEQVATGGYLIRTTLDPEVQAPVKAAIDKYASPNLAGISSV 
MS        ----ERQVTNELLDLFDINEQTLNTEGLQITTTIDPKAQEAAVDAVDKYLEGQDPDMRAA 
MMAR      ----ERQVTKELLELFNIDEQTLNTQGLQVTTTIDAQAQQAAEKAVAKYLDGQDPEMRAA 
Mt        ----ERQVTRELLELFNIDEQTLNTQGLVVTTTIDPQAQRAAEKAVAKYLDGQDPDMRAA 
Mb        ----ERQVTRELLELFNIDEQTLNTQGLVVTTTIDPQAQRAAEKAVAKYLDGQDPDMRAA 
                : ..* *.  .*.:: : * *  : **:* :.*  .  *: ** . :   : :. 
 
Ml        MSVIKPGKDAHKVLAMASNRKYGLDLEAGETMRPQPFSLVGDGAGSIFKIFTTAAALDMG 
MS        VVSIDPRTGGIKA-------YY-----GGSDANGFDFAQAGLPTGSSFKVFALVAALQQG 
MMAR      VVSIDPHNGAVRA-------YY-----GGDNANGFDFAQAGLQTGSSFKVFALVAALEQG 
Mt        VVSIDPHNGAVRA-------YY-----GGDNANGFDFAQAGLQTGSSFKVFALVAALEQG 
Mb        VVSIDPHNGAVRA-------YY-----GGDNANGFDFAQAGLQTGSSFKVFALVAALEQG 
          :  *.* ... :.        *     .*.  .   *: .*  :** **:*: .***: * 
 
Ml        MGINAQLDVPPRFQ-AKGLGSGGAKGCPKETWCVVNAGNYRGSMNVTDALATSPNTAFAK 
MS        IGLGYQIDSGPLEVNGIKIGNVEGEGC--------------GTCSIAEALKRSLNTSYYR 
MMAR      IGLGYDVDSSPLTVDGIKITNVEGESC--------------GTCNIAQALKMSLNTSYYR 
Mt        IGLGYQVDSSPLTVDGIKITNVEGEGC--------------GTCNIAEALKMSLNTSYYR 
Mb        IGLGYQVDSSPLTVDGIKITNVEGEGC--------------GTCNIAEALKMSLNTSYYR 
          :*:. ::*  *    .  : .  .:.*              *: .:::**  * **:: : 
 
Ml        LISQVGVGRAV--DMAIKLGLRSYANPGTARDYNPDSNESLADFVKRQNLGSFTLGPIEL 
MS        LMLKLENGPADVAEAAHDAGVA-ESFPGVEHTLSEDGK-------GGPPNNGVVLGQYQS 
MMAR      LMLKLKGGPEAVADAAHQAGIA-TSFPGVPHTLSEDGK-------GGPPNNGIVLGQYQT 
Mt        LMLKLNGGPQAVADAAHQAGIA-SSFPGVAHTLSEDGK-------GGPPNNGIVLGQYQT 
Mb        LMLKLNGGPQAVADAAHQAGIA-SSFPGVAHTLSEDGK-------GGPPNNGIVLGQYQT 
          *: ::  *     : * . *:   : **. :  . *.:            ....**  :  
 
Ml        NALELSNVAATLASGGVWCPPNPIDQLIDRNGNEVAVTT---ETCDQVVPAGLANTLANA 
MS        RVLDMASAYATLAASGVYHKPHFVEKVVNSSGQVLFDASKEDN-GEERIDKAVADNVTSA 
MMAR      RVIDMASAYATLAASGIYHRPHFVQKVVNADGRVLFDASTEDNTGDQRIPKAVADNVTAA 
Mt        RVIDMASAYATLAASGIYHPPHFVQKVVSANGQVLFDASTADNTGDQRIPKAVADNVTAA 
Mb        RVIDMASAYATLAASGIYHPPHFVQKVVSANGQVLFDASTADNTGDQRIPKAVADNVTAA 
          ..::::.. ****:.*::  *: :::::. .*. :  ::   :  :: :  .:*:.:: * 
 
Ml        MSKDAV---GSGTAAGSAGAAGWDLPMSGKTGTTEAHRSAGFVGFTNRYAAANYIYDDSS 
MS        MQPIAGWSRGHNLAGGRPSAAK---TGTVQLGDTGDNRDAWMVGYTPSLSTAVWVGTT-- 
MMAR      MEPIAGYSRGHNLAGGRPSASK---TGTVQLGDTSANRDAWMVGYTPSLSTAVWVGTV-- 
Mt        MEPIAGYSRGHNLAGGRDSAAK---TGTTQFGDTTANKDAWMVGYTPSLSTAVWVGTV-- 
Mb        MEPIAGYSRGHNLAGGRDSAAK---TGTTQFGDTTANKDAWMVGYTPSLSTAVWVGTV-- 
          *.  *    * . *.*  .*:      : : * *  ::.* :**:*   ::* ::      
 
Ml        SPTDLCSGPLRHCGSGDLYGGNEPSRTWFAAMKPIANNFGEVQLPPTDPRYVDGAPGSRV 
MS        ----EGVKPLVNKWGSPIYGSGLPSDIWKATMDGALEGTDVESFPK--PTEIGGYAGVPQ 
MMAR      ----KGDEPLVTASGAPIYGSGLPSDIWKATMDGALKGTEVESFPK--PTEIGGYAGVPA 
Mt        ----KGDEPLVTASGAAIYGSGLPSDIWKATMDGALKGTSNETFPK--PTEVGGYAGVPP 
Mb        ----KGDEPLVTASGAAIYGSGLPSDIWKATMDGALKGTSNETFPK--PTEVGGYAGVPP 
                  **    .. :**.. **  * *:*.   :.     :*   *  :.*  *    
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Figure 3.10 D: Comparison of the conserved Msm FtsH sequence with other FtsH homologues. Shown is 
the amino acid sequence alignment of Ms (Msm), Mt (Mtb), Mb (M. bovis), Ec (E. coli) and Bc (B. subtilis). The 
two conserved ATP-binding motifs are shown in yellow, highlighted in red shading is the AAA signature motif 
and in green shading is the Zn
2+
-binding motif. www.ebi.ac.uk/Tools/msa/ClustalO accessed on 20/06/2017). 
 
Ms     YEIKDFLQNPSRYQALGAKIPKGVLLYGPPGTGKTLLARAVAGEAGVPFFTISGSDFVEM 
Mt     YEIKDFLQNPSRYQALGAKIPKGVLLYGPPGTGKTLLARAVAGEAGVPFFTISGSDFVEM 
Mb     YEIKDFLQNPSRYQALGAKIPKGVLLYGPPGTGKTLLARAVAGEAGVPFFTISGSDFVEM 
Ec     AELVEYLREPSRFQKLGGKIPKGVLMVGPPGTGKTLLAKAIAGEAKVPFFTISGSDFVEM 
Bs     VEVVEFLKDPRKFAELGARIPKGVLLVGPPGTGKTLLAKACAGEAGVPFFSISGSDFVEM 
         *: ::*::* ::  **.:******: ***********:* ********:********* 
 
Ms     FVGVGASRVRDLFEQAKQNSPCIIFVDEIDAVGRQRGAGLGGGHDEREQTLNQLLVEMDG 
Mt     FVGVGASRVRDLFEQAKQNSPCIIFVDEIDAVGRQRGAGLGGGHDEREQTLNQLLVEMDG 
Mb     FVGVGASRVRDLFEQAKQNSPCIIFVDEIDAVGRQRGAGLGGGHDEREQTLNQLLVEMDG 
Ec     FVGVGASRVRDMFEQAKKAAPCIIFIDEIDAVGRQRGAGLGGGHDEREQTLNQMLVEMDG 
Bs     FVGVGASRVRDLFENAKKNAPCLIFIDEIDAVGRQRGAGLGGGHDEREQTLNQLLVEMDG 
       ***********:**:**::**:**:***************************:****** 
 
Ms     FGDRQGVILIAATNRPDILDPALLRPGRFDRQIPVSNPDLAGRRAVLKVHSQGKPIAPDA 
Mt     FGDRAGVILIAATNRPDILDPALLRPGRFDRQIPVSNPDLAGRRAVLRVHSKGKPMAADA 
Mb     FGDRAGVILIAATNRPDILDPALLRPGRFDRQIPVSNPDLAGRRAVLRVHSKGKPMAADA 
Ec     FEGNEGIIVIAATNRPDVLDPALLRPGRFDRQVVVGLPDVRGREQILKVHMRRVPLAPDI 
Bs     FSANEGIIIIAATNRADILDPALLRPGRFDRQITVDRPDVIGREAVLKVHARNKPLDETV 
       *  . *:*:****** *:**************: *. **: **. :*:** :  *:     
 
Ms     DLDGLAKRTVGMSGADLANVINEAALLTARENGTVITGPALEEAVDRVVGGPRRKSRIIS 
Mt     DLDGLAKRTVGMTGADLANVINEAALLTARENGTVITGPALEEAVDRVIGGPRRKGRIIS 
Mb     DLDGLAKRTVGMTGADLANVINEAALLTARENGTVITGPALEEAVDRVIGGPRRKGRIIS 
Ec     DAAIIARGTPGFSGADLANLVNEAALFAARGNKRVVSMVEFEKAKDKIMMGAERRSMVMT 
Bs     NLKSIAMRTPGFSGADLENLLNEAALVAARQNKKKIDARDIDEATDRVIAGPAKKSRVIS 
       :   :*  * *::**** *::*****.:** *   :    :::* *::: *  ::.::: 
 
Ms     EHEKKITAYHEGGHTLAAWAMPDIEPIYKVTILARGRTGGHAVAVPEDDKGLMTRSEMIA 
Mt     EQEKKITAYHEGGHTLAAWAMPDIEPIYKVTILARGRTGGHAVAVPEEDKGLRTRSEMIA 
Mb     EQEKKITAYHEGGHTLAAWAMPDIEPIYKVTILARGRTGGHAVAVPEEDKGLRTRSEMIA 
Ec     EAQKESTAYHEAGHAIIGRLVPEHDPVHKVTIIPRGRALGVTFFLPEGDAISASRQKLES 
Bs     KKERNIVAYHEGGHTVIGLVLDEADMVHKVTIVPRGQAGGYAVMLPREDRYFQTKPELLD 
       : ::: .****.**:: .  : : : ::****: **:: * :. :*. *    :: ::   
 
Ms      RLVFAMGGRAAEELVFRE--PTTGAVSDR-TGTKIARAMVTEYGMSSKLGAVRYGTEHG 
Mt      QLVFAMGGRAAEELVFRE--PTTGAVSDIEQATKIARSMVTEFGMSSKLGAVKYGSEHG 
Mb      QLVFAMGGRAAEELVFRE--PTTGAVSDIEQATKIARSMVTEFGMSSKLGAVKYGSEHG 
Ec      QISTLYGGRLAEEIIYGPEHVSTGASNDIKVATNLARNMVTQWGFSEKLGPLLYAEEEG 
Bs      KIVGLLGGRVAEEIIFGE-VSTGAHNDFQRATNIARRMVTEFGMSEKLGPLQFGQSQGG 
        ::    *** ***:::     :*** .*   .*::** ***::*:*.*** : :. . * 
 
Ms     DPFLGRTMGTQADYSHEVAQIIDDEVRKLIEAAHTEAWEILTEYRDVLDILAGELLEKET 
Mt     DPFLGRTMGTQPDYSHEVAREIDEEVRKLIEAAHTEAWEILTEYRDVLDTLAGELLEKET 
Mb     DPFLGRTMGTQPDYSHEVAREIDEEVRKLIEAAHTEAWEILTEYRDVLDTLAGELLEKET 
Ec     EVFLGRSVAKAKHMSDETARIIDQEVKALIERNYNRARQLLTDNMDILHAMKDALMKYET 
Bs     QVFLGRDFNNEQNYSDQIAYEIDQEIQRIIKECYERAKQILTENRDKLELIAQTLLKVET 
       : **** . .  . *.: *  **:*:: :*:  : .* ::**:  * *. :   *::** 
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3.1.7.2. Domain organization of Cdc48, FtsI, PonA1 and FtsH 
To examine domain organizations of the selected partnering proteins, Pfam analysis 
(http://pfam.xfam.org/) was conducted using amino acid sequences from each protein. The 
results revealed that Cdc48 is a member of the AAA (ATPases associated with various 
cellular activities) family of ATPases due to the presence of two AAA-type ATPase domains, 
D1 (aa 266-319) and D2 (aa 522-653) (Figure 3.11 A). This protein is a magnesium-
dependent ATPase and the two AAA domains are capable of ATP hydrolysis. In addition, the 
Cdc48 protein also comprises of an N-terminal β-barrel domain (aa 24-107) (Figure 3.11 A). 
FtsI, also known as PBPB, is a monofunctional Class B HMM PBP with only transpeptidase 
activity. The FtsI structure comprises of an N-terminal PBP dimer (aa 91-266) and the C-
terminal transpeptidase domain (aa 307-625) (Figure 3.11 B). The transpeptidase domain is 
responsible for catalysing stem peptide cross-links. PonA1 is a bifunctional class A HMM 
PBP. The N-terminus contains transglycosylase domain (aa 117-299) responsible for 
catalysing polymerization of glycan strands (Figure 3.11 C). The transpeptidase domain (aa 
391-669) is also present in the C-terminal region of the protein (Figure 3.11 C). Both 
enzymatic activities of the two domains are required for normal cell growth. Analysis of 
amino acid sequence of FtsH revealed the presence of an N-terminal AAA domain (aa 199-
332) and a C-terminal protease domain (aa 392-601) designated peptidase_M41 domain 
(Figure 3.11 D). Like Cdc48, FtsH also belongs to the AAA family of ATPases. FtsH protease 
activity is stimulated by metal ions such a Zn2+, hence the protein is considered an ATP-
dependent Zn2+ metalloprotease. 
 
  
 
 
Figure 3.11 A: Schematic representation of domain organization of Msm Cdc48 protein. The functional 
domains are represented by different colours. Shown in blue is the N-terminal domain and in red are the two 
AAA domains (D1 and D2). The conserved AAA domains each contain the signature nucleotide binding and 
hydrolysis motifs. Both D1 and D2 domains are capable of ATP hydrolysis however, under physiological 
conditions D1 shows weak ATPase activity. http://pfam.xfam.org/ accessed on 15/05/2017. 
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Figure 3.11 B: Schematic representation of domain organization of Msm FtsI protein. The functional 
domains of the protein are represented by different colours. Shown in green is the N-terminal PBP_dimer and in 
orange is the transpeptidase domain. The N-terminal dimerization domain is highly stable and is implicated in 
polymerization of PBP. The transpeptidase domain is needed for cross linking of septal PG. 
http://pfam.xfam.org/ accessed on 15/05/2017. 
 
 
 
 
 
 
 
Figure 3.11 C: Schematic representation of domain organization of Msm PonA1 protein. The functional 
domains of the protein are represented by different colours. Shown in blue is the N-terminal transglycosylase 
domain and in orange is the transpeptidase domain found in the C-terminal region. Both the transglycosylase 
and the transpeptidase domains covalently incorporate the newly synthesized PG units into the pre-existing PG 
sacculus. Although the transpeptidase domain of PonA1 is dispensable for growth, loss of this protein affects 
antibiotic sensitivity in mycobacteria (Kieser et al., 2015a). http://pfam.xfam.org/ accessed on 15/05/2017.  
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Figure 3.11 D: Schematic representation of domain organization of Msm FtsH protein. The functional 
domains of the protein are represented by different colours. Shown in red is the N-terminal AAA domain and in 
purple is the protease domain. Similar to AAA domain of Cdc48, the AAA domain of FtsH also has ADP bound 
active site and is capable of ATP hydrolysis. The FtsH peptidase domain is involved in efficient protein 
degradation, hence FtsH is involved in the proteolytic degradation of specific integral membrane and 
cytoplasmic proteins that participate in diverse cellular functions. http://pfam.xfam.org/ (15/05/2017). 
 
3.2. Generation of Msm deletion mutants defective in cdc48 and ftsI genes 
The protein interaction and bioinformatics analysis identified several D,D-CPases interacting 
partners with potentially important roles in the mycobacterial physiology. To further probe 
this, the second part of this study was aimed at interrogating the functional roles of selected 
MSMEG_2433 and MSMEG_6113 partnering proteins by generating Msm mutant strains 
lacking genes encoding selected partners through two step allelic exchange by homologous 
recombination. This method involves the construction of a suicide plasmid carrying the 
inactive copy of the gene of interest (Figure 3.12). Initially, this method was planned for use 
to delete all four selected partners, two of MSMEG_2433 (FtsH and ponA1) and two of 
MSMEG_6113 (Cdc48 and FtsI) however, due to time constraints only MSMEG_6113 
partners were taken forward for evaluation. 
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Figure 3.12: Schematic diagram illustrating the general strategy of suicide vector construction using 
cdc48 as an example. Homologous sequences of the downstream and the upstream region and a small fragment 
of the 5‟ and 3‟ ends of the gene of interest are fused together and cloned into the p2NIL plasmid generating 
p2NILcdc48 construct. Subsequently, the Pac cassette from pGOAL17 is ligated into the p2NILcdc48 construct 
generating the final p2NILcdc48_Pac suicide vector construct. 
3.2.1. Construction of cdc48 and ftsI gene deletion constructs 
The suicide vectors were constructed as detailed in section 2.9.2. Briefly, 1500 bp upstream 
and 1500 bp downstream regions flanking the gene of interest along with 99 bp of both the 
5‟end and the 3‟end of the gene were amplified by PCR. The PCR fragments were sub-cloned 
into p2NIL following the protocol in section 2.6.6. A selected clone for each construct was 
verified by restriction profiling with at least 6 restriction enzymes (Appendix C15, C16) and 
further confirmed by sequencing (results not shown). The linearized Pac cassette excised 
from pGOAL17 was cloned into the p2NILcdc48 and p2NILftsI constructs to generate final 
knockout constructs. A single positive clone per construct was selected and verified by 
restriction analysis as outlined in section 2.6.2. (Figure 3.13. and 3.14) and further confirmed 
by sequencing (results not shown). The genetic integrity of the p2NILcdc48_Pac and 
p2NILftsI_Pac constructs was maintained as confirmed by the restriction analysis where the 
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digested clones yielded the expected fragment banding patterns. Figure 3.13. shows the 
restriction profile obtained from restriction digest of the p2NILcdc48_Pac construct with 
different enzymes, all yielding the correct sizes. Notably, the PacI restriction digest yielded a 
doublet band due to the presence of two fragments that were closely related in size. Figure 
3.14. shows the restriction profile obtained from restriction digest of the p2NILftsI_Pac 
construct with different enzymes, no missing or aberrant bands were observed. Analysis of 
the constructs by sequencing revealed that no mutations were accumulated (data not shown) 
which further confirmed the integrity of the constructs for subsequent use in mutant 
generation. 
 
Figure 3.13: Restriction profile of the p2NILcdc48_Pac knockout construct. (A) Genome map of mc
2
155 
indicating the position of cdc48 gene within the genome. The strategy employed for construction of the 
knockout vector is also shown. (B) Plasmid map of the final p2NILcdc48_Pac knockout construct used for 
transformation. (C) 0.8% agarose gel indicating expected DNA band sizes, lane (1) DNA marker III 
(Fermentas), lane (2) uncut construct control, lane (3) BspHI, lane (4) BsrGI, lane(5) NcoI, lane (6) PacI, lane 
(7) SmaI, lane (8) XmnI. (D) Table showing restriction enzymes used for profiling and the expected fragment 
sizes. * in lane 6 indicates that the two fragments run together as indicated by the bright single band. 
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Figure 3.14: Restriction profile of the p2NILftsI_Pac knockout construct. (A) Genome map of mc
2
155 
indicating the position of ftsI gene within the genome. The strategy employed for construction of the knockout 
vector is also shown. (B) Plasmid map of the final p2NILftsI_Pac knockout construct used for transformation. 
(C) 0.8% agarose gel indicating expected DNA band sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut 
construct control, lane (3) AatII, lane (4) BglII, lane(5) BspHI, lane (6) BsrGI, lane (7) NruI, lane (8) XmnI. (D) 
Table showing restriction enzymes used for profiling and the expected fragment sizes. * in lane 3 indicates the 
extra band as a result of the enzyme‟s star activity. 
 
3.2.2. Generation of cdc48 and ftsI deletion mutant strains in Msm  
3.2.2.1 Generation of Msm ∆cdc48 strain 
The two-step allelic exchange by homologous recombination method was employed for 
deletion of the cdc48 gene in Msm following the protocol outlined in section 2.9.2. The 
p2NILcdc48_Pac knockout construct was electroporated into the parental mc
2
155 strain as 
per protocol outlined in 2.7.2. Integration of p2NILcdc48_Pac construct into the genome of 
mc
2
155 by homologous recombination resulted in generation of cdc48 SCO strains. 
Following generation of an SCO strain, an unmarked ∆cdc48 mutant (represented by white 
antibiotic-sensitive colonies) was generated as described in section 2.9.2. The putative cdc48 
deletion mutants were identified by PCR screening as per the protocol in section 2.6.1.1. and 
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further verified by Southern blot analysis as indicated in section 2.9.3. Ten white colonies 
were picked for PCR screening to identify potential clones. The PCR strategy used to screen 
knockout mutants involved the use of primers that amplify the full length cdc48 gene. In the 
wildtype strains, a full length amplicon of 2238 bp is expected. In the knockout mutants, only 
a small region of the gene is amplified due to part of the gene being deleted, which would 
result in generation of a smaller fragment of 198 bp, indicating the presence of the mutant 
allele. PCR screening (Figure 3. 15B) revealed the presence of five potential cdc48 deletion 
mutant strains (clones 2, 4, 6, 7 and 10) as determined by the presence of the 198 bp band, 
representing the mutant allele (∆cdc48) in comparison to a 2338 bp band of the wildtype 
allele (Figure 3.15). 
 
Figure 3.15: PCR screening of ∆cdc48 deletion mutants. (A) Schematic representation of genomic maps of 
the wildtype and mutant cdc48 region. Primer binding sites (arrows) and expected amplicon sizes are shown. F 
= forward primer. R = reverse primer. (B) PCR screen of cdc48 deletion. Lane (1) DNA marker VI, lane (2) no 
DNA control, lane (3) p2NILcdc48_Pac knockout construct, (4) wildtype, lane (5) SCO, lane (6-15) possible 
mutants  1-10. 
Three of the potential ∆cdc48 strains (clones 2, 4 and 6) were taken forward for further 
analysis by Southern blotting. Southern blot analysis was conducted to confirm the genotype 
of ∆cdc48 strains. Genomic DNA of mc2155, ∆cdc48 and SCO strains was digested with 
BamHI and Southern blot analysis was conducted on these strains as per protocol in section 
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2.9.3. Wildtype mc
2
155 strain displayed expected fragment sizes of 3334 bp and 2495 bp, the 
SCO strain displayed 3913 bp, 3334 bp and 461 bp fragments and both the ∆cdc48 strains 
displayed expected 3334 bp and 461 bp fragments confirming that the ∆cdc48 strain retains 
the truncated copy of the cdc48 gene (Figure 3.16). 
 
Figure 3.16: Southern blot analysis of Msm ∆cdc48 strain. (A) Genomic map of mc2155 strain showing 
expected fragment sizes for the wildtype cdc48 allele. (B) Genomic map of ∆cdc48 mutant strain showing 
expected fragment sizes for the mutant cdc48 allele. (C) Southern blot showing BamHI digested DNA fragments 
bound by the designed cdc48 specific probe (represented by orange rectangles in A and B). lane (1) mc
2
155, 
lane (2) SCO, lane (3-5) ∆cdc48 strains.  
3.2.2.2. Generation of Msm ∆ftsI strain 
For deletion of the ftsI gene in Msm, the two-step allelic exchange by homologous 
recombination procedure was conducted as per protocol outlined in section 2.9.2. The 
p2NILftsI_Pac knockout construct was electroporated into the parental mc
2
155 strain as per 
protocol outlined in 2.7.2., which resulted in integration of the construct into the genome of 
mc
2
155 by homologous recombination generating ftsI SCO strains. Following generation of 
SCO strain, attempts were made to generate an unmarked ∆ftsI mutant (represented by white 
antibiotic-sensitive colonies) as described in section 2.9.2. PCR screening was conducted to 
identify possible ftsI deletion mutants as per protocol in section 2.6.1.1. White colonies were 
picked for PCR screening to identify potential clones. The same PCR strategy used to screen 
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the above cdc48 knockout mutants was also employed for this experiment, whereby 
amplification of the ftsI gene in the wildtype strain would result in a full length amplicon of 
1947 bp as expected while in the knockout mutants, only a small region of the gene would be 
amplified due to part of the gene being deleted yielding a smaller fragment of 198 bp. 
Initially, 10 colonies were screened and all the clones in this screen appeared to be wildtype 
revertants as confirmed by the presence of a 1947 bp band found in lanes 6-15 (Figure 3. 
17B). Additional clones (50) were screened and no potential mutants were revealed. All the 
remaining clones had reverted to the wildtype genotype and others retained the SCO 
genotype as confirmed by the presence of both the wildtype and mutant allele bands (data not 
shown). The observed SCO genotype post sucrose counter selection suggests that the strains 
had been subjected to compensatory mutation in the lacZ and sacB genes, which allowed for 
growth in the presence of sucrose. These observations highlighted the possibility that ftsI is 
essential and could not be targeted for gene deletion. In order to test for this, additional 45 
white colonies were screened and none of them revealed the mutant genotype (results not 
shown), thus confirming that ftsI is essential for growth in vitro. 
 
Figure 3.17: PCR screening of ∆ftsI deletion mutants. (A) Schematic representation of genomic maps of 
wildtype and mutant ftsI region. Primer binding sites (arrows) and expected amplicon sizes are shown. F = 
forward primer. R = reverse primer. (B) PCR screen of ftsI deletion. Lane (1) DNA marker VI, lane (2) no DNA 
control, lane (3) p2NILftsI_Pac knockout construct, (4) wildtype, lane (5) SCO, lane (6-15) clone 1-10. 
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3.2.3. Genetic complementation of ∆cdc48 strain 
Genetic complementation of the ∆cdc48 strain was conducted to confirm that any phenotypic 
variation observed from the mutant strain was only due to loss of the functional copy of the 
gene and not due to polar effects. This was accomplished by reintroducing a functional copy 
of cdc48 gene in the background of the mutant strain (see section 2.10.). 
3.2.3.1. Construction of the cdc48 complementation vector 
The cdc48 complementation vector was constructed by amplifying the wildtype cdc48 allele 
and the 200 bp upstream native cdc48 promoter region by PCR, followed by cloning of the 
amplicons into the pMV306H integrating vector as per protocol outlined in section 2.6.6. 
Subsequent clones were screened and a single positive clone was selected, verified by 
restriction analysis as outlined in section 2.6.2. (Figure 3.18D) and further confirmed by 
sequencing (results not shown). Figure 3.18. demonstrates that the restriction profile obtained 
from restriction digest of the pMV306Hcdc48 yielded correct sizes. Sequencing results 
revealed no mutations, thus confirming the integrity of the construct. 
 
See figure legend on the next page. 
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Figure 3.18: Restriction profile of the pMV306Hcdc48 construct. (A) Genome map of mc
2
155 indicating the 
location of cdc48 gene within the genome. The strategy employed for construction of the complementation 
vector is also shown. (B) Plasmid map of the final pMV306Hcdc48 construct used for transformation. (C) Table 
showing restriction enzymes used for profiling and the expected fragment sizes. (D) 0.8% agarose gel indicating 
expected DNA band sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) 
Acc65I, lane (4) BglII, lane(5) BsrGI, lane (6) NcoI, lane (7) NotI, lane (8) NruI.  
3.2.3.2. Generation of ∆cdc48 complemented strain (∆cdc48::cdc48) 
The pMV306Hcdc48 construct was electroporated into the ∆cdc48 strain following the 
protocol in section 2.7.2. to generate the ∆cdc48::cdc48 complemented strain. The pMV306H 
vector allows for integration of the functional cdc48 gene into the attB site in the genome of 
mycobacteria. To confirm that integration of the complementing gene was successful, PCR 
screening was performed to confirm site-specific integration of the construct (Figure 3.19). 
Primers were targeted to the att region where the observed PCR products of 282 bp and 320 
bp confirmed that the pMV306Hcdc48 construct had integrated at the correct site (Figure 
3.19). 
 
Figure 3.19: PCR confirmation of site-specific integration of pMV306Hcdc48 into ∆cdc48 mutant. (A) 
Schematic representation of Msm chromosome showing pMV306Hcdc48 integrated into the attB site. Primer 
binding sites (arrows) and expected amplicon sizes are shown. (B) PCR reaction with attBS2 + attL4 primer set. 
(C) PCR reaction with attL2 + attBS1 primer set. Lane (1) Marker VI, lane (2) no DNA control, lane (3) 
wildtype, lane (4) ∆cdc48, lane (5-12) potential clones carrying pMV306Hcdc48 complementation vector. 
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3.2.4. Generation of ftsI deletion mutant in the merodiploid strain  
Following unsuccessful attempts of generating a ftsI gene knockout mutant by allelic 
exchange, another method was employed to evaluate the physiological role of the ftsI gene 
product in Msm. This method allows for inactivation of the wildtype copy of the gene in the 
presence of a second copy of the gene (termed the wildtype complementing gene) located 
elsewhere in the genome. A strain carrying two copies of a gene in this conformation is 
referred to as a merodiploid strain. In this way, the wildtype complementing gene expressed 
from the native promoter on the integrating vector, allows for deletion of the native copy. To 
achieve this, a ftsI complementation vector was first constructed and then integrated into the 
genome of ftsI SCO strain, generating a merodiploid strain (Figure 2.6). Following this, the 
merodiploid strain was subjected to counter-selection for DCOs as per standard protocol. 
 
3.2.4.1. Construction of ftsI complementation vector 
For construction of the complementation vector, the wildtype ftsI allele was amplified by 
PCR including the 200 bp native ftsI promoter region, followed by cloning of the amplicons 
into the pMV306H integrating vector as per the protocol outlined in section 2.6.6. Subsequent 
clones were screened and a single positive clone was selected, verified by restriction analysis 
as outlined in section 2.6.2. (Figure 3.20D) and further confirmed by sequencing (results not 
shown). Restriction enzymes used for profiling the pMV306HftsI construct yielded the 
expected banding patterns with the exception of AatII, which had an extra band (Figure 3.20). 
Analysis of the construct by sequencing further confirmed the integrity of the construct for 
subsequent use in generation of the complement strain. This suggests that the extra AatII 
band is the result of an unmapped site in the vector backbone.  
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Figure 3.20: Restriction profile of the pMV306HftsI construct. (A) Genome map of mc
2
155 indicating the 
location of ftsI gene within the genome. The strategy employed for construction of the complementation vector 
is also shown. (B) Plasmid map of the final pMV306HftsI construct used for transformation. (C) Table showing 
restriction enzymes used for profiling and the expected fragment sizes. (D) 0.8% agarose gel indicating expected 
DNA band sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) 
Acc65I, lane(5) BamHI, lane (6) BglII, lane (7) EcoRI, lane (8) PvuI. 
 
3.2.4.2. Generation of ∆ftsI mutant strain in the merodiploid background 
To generate ftsI mutant, a merodiploid strain was first generated by electroporating the 
pMV306HftsI complementation vector into the previously generated ftsI SCO recombinant 
strain, following the protocol outlined in section 2.7.2. A schematic representation of this 
approach is shown in Figure 2.6. This was then followed by extraction of genomic DNA from 
the resultant merodiploid strain as per protocol in section 2.5.2.1, and the DNA was then used 
for PCR screening as indicated in section 2.6.1.1. to confirm successful integration of 
complementation vector into the SCO recombinant strain. PCR screening confirmed the 
correct interaction of the construct as indicated by observed expected bands (Figure 3.21). 
Five of the selected colonies for PCR screen appeared to exhibit correct integration pattern. 
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Figure 3.21: PCR confirmation of site-specific integration of pMV306HftsI into ftsI SCO strain. (A) 
Schematic representation of Msm chromosome showing pMV306HftsI integrated into the attB site. Primer 
binding sites (arrows) and expected amplicon sizes are shown (B) PCR reaction with attL2 + attBS1 primer set. 
(C) PCR reaction with attBS2 + attL4 primer set. Lane (1) Marker VI, lane (2-8) potential clones carrying 
pMV306HftsI complementation vector. Lane (9) wildtype, lane (10) no DNA control. The band in lane 9 of 
figure C is probably due to template contamination. 
 
Following this, the strain was subjected to counter-selection for DCO strains as per the 
protocol outlined in section 2.12. White colonies were picked for PCR screening to identify 
potential clones containing the mutant allele. One hundred and forty colonies were screened 
and no potential mutants were revealed (data not shown). Most of the screened clones had 
reverted to the wildtype genotype and others retained the SCO genotype. It was unclear why 
an ftsI mutant could not be generated in the merodiploid strain and no further attempts were 
made to delete this gene.  
3.2.5. Phenotypic characterization of ∆cdc48 mutant 
To investigate the role of the cdc48 gene in cell growth, division and structural maintenance 
of Msm, a number of assays were carried out on the ∆cdc48 strain to compare against the 
wildtype and complemented strains. This included analyses of growth kinetics, cell 
permeability/ integrity, cell morphology and division by use of cell wall staining chemical 
probes and different forms of microscopy. 
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3.2.5.1. The role of Cdc48 in regulating Msm growth kinetics 
To evaluate the role of Cdc48 in regulating Msm growth kinetics, growth analyses were 
carried out on the wildtype mc
2155, the ∆cdc48 mutant and the complemented derivative 
strains. Growth kinetics were determined by the use of growth curves conducted in triplicate 
and growth assays were set up as described in section 2.13.1. The data revealed that Cdc48 is 
dispensable for growth and plays no significant role in regulating Msm growth kinetics as 
indicated by the slight, but non-significant (p˃0.05) delay in growth kinetics of the ∆cdc48 
strain, particularly during the exponential growth phase (Figure 3.22). As observed in Figure 
3.22, the complemented strain struggled to grow compared to the mutant and wildtype strains 
and this could be due to the effect of Hyg antibiotic present in the media, which was used to 
grow the strain and select for the complementing vector. 
 
Figure 3.22: Growth kinetics of the ∆cdc48 strain in comparison to the wildtype and complemented 
strains. Growth analyses were conducted by measuring the increase in optical density (OD600) of the cultures at 
three hour intervals over 30 hours and the data was then used to generate scatter plots. The data shown represent 
the means of three independent replicates and the error bars represent standard error obtained from standard 
deviation of the triplicates. Unpaired student T-test was used with ** representing p-value ˃ 0.05. 
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3.2.5.2. Cdc48 plays a role in antibiotic sensitivity and cell wall permeability 
In addition to determining the role of Cdc48 in Msm growth kinetics, we investigated whether 
loss of cdc48 gene affected the susceptibility of Msm to various drugs. This was done by 
assessing the minimum inhibitory concentrations (MICs) for selected cell wall targeting 
antibiotics in the ∆cdc48 mutant in comparison to the parental mc2155 strain and the 
∆cdc48::cdc48 genetically complemented strain. The MIC is described as the antibiotic 
concentration that gives visible growth inhibition. The assay was prepared as per the protocol 
in section 2.13.2. The results revealed that loss of cdc48 resulted in a 4-fold increase in 
susceptibility to amoxicillin, a cell wall targeting antibiotic that inhibits cell wall biosynthesis 
by inhibiting transpeptidases that catalyze peptidoglycan cross-linking (Table 3.5 and Figure 
3.23).  A 2-fold increase in susceptibility is generally not considered significant. However, 
repeatedly the ∆cdc48 strain displayed an increase in susceptibility to other cell wall targeting 
antibiotics such as D-cycloserine and vancomycin, suggesting that the difference might be 
significant (Figure 3.23).  
Table 3.5: MICs (µg/ml) of the wildtype, ∆cdc48 and ∆cdc48::cdc48 strains. Shown in 
brackets is the fold increase in drug susceptibility of the ∆cdc48 mutant over wildtype. 
 MIC (µg/ml)* 
Drug  Wildtype ∆cdc48 ∆cdc48::cdc48 
Amoxycillin 32 10.67 (3) 26.67 
D-cycloserine 6.25 3.13 (2) 6.25 
Ethambutol 0.27 0.4 (-) 0.27 
Imepenem 100 100 (0) 100 
Isoniazid 100 100 (0) 100 
Teicoplanin 12.5 12.5 (0) 12.5 
Vancomycin 0.1 0.05 (2) 0.1 
*Fold change over the MIC observed in wildtype is shown in parenthesis 
 
 
84 
 
 
Figure 3.23: Minimum inhibitory concentrations (MICs) of the ∆cdc48 strain in comparison to the 
wildtype and complemented strains. The strains were exposed to drug treatment for 7 days from which the 
MIC was determined for different antibiotics. The ∆cdc48 strain showed increased susceptibility to amoxicillin, 
D-cycloserine and vancomycin. The data shown represent the means of three independent replicates and the 
error bars represent standard error obtained from standard deviation of the triplicate experiments.  Unpaired 
student T-test was used with p-value ˂0.05 considered significant *, p-value ˃ 0.05 ** non-significant. 
The intrinsic resistance of mycobacteria to various antibiotics is mostly attributed to their 
relatively impermeable cell wall, which provides a barrier to foreign compounds and limits 
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drug uptake (Brennan and Nikaido, 1995). As the ∆cdc48 mutant exhibited increased 
susceptibility to selected antibiotics, we hypothesized that this strain may have a weakened 
cell wall, which is more permeable to compounds thus facilitating drug uptake. To further 
evaluate this, the ethidium bromide (EtBr) uptake/ diffusion assay was performed as outlined 
in section 2.13.3. In this assay, accumulation of EtBr is assessed in relation to cell wall 
permeability. EtBr is highly fluorescent inside the cell and emits weak fluorescence outside 
the cell. From the results obtained, the ∆cdc48 strain seemed to be more permeable, 
compared to the wildtype as indicated by the increased fluorescence observed for this strain 
indicating high EtBr accumulation (Figure 3.24). Overall, these results revealed that loss of 
cdc48 may have led to an increase in susceptibility to cell wall targeting antibiotics and 
enhanced cell permeability, but the results are not yet amenable to a statistical assessment of 
the data.  
 
Figure 3.24: ∆cdc48 cell wall permeability assessment. Cell wall permeability was monitored by quantifying 
accumulation of EtBr (5 µg/ml) into the cells of the ∆cdc48 mutant strain, wildtype and complemented strains 
over an hour. The data shown represent one experiment, see appendix C19 for the other two.  Unpaired student 
T-test was used with. *: p-value ˂0.05, using technical replicates from one experiment. Time limitations 
precluded further repetition.  
3.2.5.3. Microscopic analyses 
SEM and fluorescence microscopy (in conjunction with various fluorescent chemical probes) 
were employed as described in section 2.13.4. to evaluate the overall structure of ∆cdc48 
individual cells in comparison to wildtype and complemented strains.  These analyses were 
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carried out to investigate the possible role of Cdc48 in maintaining a number of cellular 
processes. Examination of ∆cdc48 cell surface morphology by SEM revealed distinct 
morphological defects in comparison to the wildtype, including formation of V-shaped cells, 
pole bulging cells, kinking and chaining cells as shown in Figure 3.25. The observed 
phenotypes that were robustly different in ∆cdc48 and wildtype were quantified. Cells with 
pole bulges (indicated by blue arrows in Figure 3.25) occurred more frequently in the ∆cdc48 
mutant strain and a significant number of cells in the mutant strain were short and V-shaped 
(indicated by the green arrow in Figure 3.25) compared to rod shaped cells in the wildtype 
mc2155 strain, Figure 3.26. Chaining cells with multiple septal bridges (depicted by red 
arrows in Figure 3.25) were also observed however, there was no significant difference 
between the number of these cells in the wildtype and mutant strain and this could possibly 
be due to a limited number of cells quantified (Figure 3.26). These observed phenotypes point 
to a possible role of Cdc48 in maintaining cell growth, division and cell shape. 
Figure 3.25: SEM micrographs of wildtype mc
2155 and ∆cdc48 strains. Loss of cdc48 results in cell 
morphological defects such as formation of short V-shaped cells (green arrows), chaining cells (red arrows), 
cells with pole bulges (blue arrows) and kinks (yellow arrows). 100 cells were viewed per replicates. 
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Figure 3.26: Quantification of the ∆cdc48 morphological defects revealed by SEM in comparison to 
wildtype. The graph, which is representative of two experiments, shows a significant increase in the frequency 
of cells possessing pole bulges and V-shaped cells in the mutant strain. A notable increase in the frequency of 
cells with kinking phenotype was also observed. Error bars represent standard error obtained from standard 
deviation of the replicates. n= 156 cells were viewed per replicates, *: p ˂ 0.05, **: p ˃ 0.05.  
In addition to SEM, fluorescent microscopy was performed to assess the role of Cdc48 in cell 
division by evaluating localization of new PG synthesis. This was achieved by the use of cell 
wall staining chemical probes as described in section 2.13.4.1 and 2.13.4.2. Staining of the 
cell wall in vivo with fluorescent D-alanine analogue that is incorporated into the PG layer by 
click chemistry allowed for labelling of sites of new PG synthesis.  Mycobacteria grow by 
incorporating newly synthesized PG subunits at the cell poles and/or septum (Brown et al., 
2011). Deletion of cdc48 did not result in impaired PG synthesis as this growth pattern was 
retained in the ∆cdc48 mutant and there were no differences in septal and polar staining as 
observed in Figure 3.27. However, the ∆cdc48 strain seemed to have slightly reduced polar 
staining when compared to the wildtype and the complemented strain. These phenotypes 
were quantified and we observed that approximately 90 % of cells for all three strains showed 
polar PG localization and the remaining cells had both polar and septal localization, or had 
diffused staining (Figure 3.28). Notably, the ∆cdc48 strain had some cells that were slightly 
shorter than those of the wildtype hence we further quantified cell length by measuring polar 
distance within the cells. There was no difference in cell length, with high frequency of cells 
falling within the range of 2.1-4 µm corresponding to the normal size of Msm (Figure 3.29). 
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In addition to PG staining, the MA layer was also stained using a DMN-Trehalose stain 
which is composed of trehalose attached to a solvatochromic dye. This probe fluoresces when 
DMN-Tre is converted to trehalose monomycolate and incorporated into the bacterial cell 
wall (Kamariza et al., 2018). DMN-Tre staining revealed formation of multiple septa in the 
∆cdc48 strain (Figure 3.30). Taken together, these phenotypes revealed that the last stages of 
cell division were arrested in the ∆cdc48 mutant. Collectively, these results show that 
deletion of cdc48 does not lead to PG synthesis and cell elongation impairment hence 
synthesis of new PG continues in the mutant strain however, the last steps of cell separation 
are defective. 
 
Figure 3.27: Microscopic analysis of the PG-synthesis ability of the ∆cdc48 strain in comparison to the 
wildtype and ∆cdc48::cdc48 strains.  Assessment of PG synthesis was achieved by labelling of the PG with 
the fluorescent D-alanine analogue by click chemistry and sites of PG incorporation were visualized by 
fluorescent microscopy. New PG subunits localize to the poles in all three stains as shown by the fluorescent 
green spots at the poles. 100 cells were assessed for each experiment. The arrows indicate the sites of new PG 
incorporation. 
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Figure 3.28: Quantification of the staining patterns revealed by microscopic analysis of the PG-synthesis 
ability of the ∆cdc48 strain, the wildtype and ∆cdc48::cdc48 strains . New PG synthesis localized to the 
poles in 85% of the cells. Less than 10% of the cells displayed both septal and polar PG localization, while 
others had a diffused staining pattern. The graph represents three independent experiments. Errors bars indicate 
standard error obtained from standard deviation of the triplicate experiments. n=100. **: p ˃0.05. The white 
arrows indicate the sites of new PG incorporation 
 
Figure 3.29: Cell length quantification in the ∆cdc48 mutant. The size of the bacterial cells was measured 
from pole to pole. The graph shows change in cell length distribution observed in the wildtype, ∆cdc48 and 
∆cdc48::cdc48 strains. In general, a large number of cells had cell sizes within the range of 2.1-4 µm. There was 
no significant difference in ∆cdc48 and wildtype cells across all measured size ranges. The graph represents 
three independent experiments. Errors bars indicate standard error obtained from standard deviation of the 
triplicate experiments. n=100. **: p ˃0.05. 
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Figure 3.30: Microscopic analysis of ∆cdc48 strain phenotypes in comparison to the wildtype and 
∆cdc48::cdc48 strains after DMN-Trehalose staining.  Assessment of cell division defects was achieved by 
labelling of the cell wall with the DMN-trehalose stain. Fluorescent microscopy revealed formation of multiple 
septa in the ∆cdc48 mutant strain compared to the single septum observed in the wildtype and ∆cdc48::cdc48 
strain. 100 cells were assessed per experiment. The arrows indicate the sites of septal formation. 
3.2.5.4. Localization of FtsZ in the ∆cdc48 mutant 
Bacterial cell division is a dynamic process requiring a spatially coordinated invagination of 
the cell membrane and cell wall (Kumar et al., 2010). This process is mediated by FtsZ 
filaments that recruit septal PG-synthesizing enzymes to the division site (Typas et al., 2012). 
As cell wall morphology analysis in the ∆cdc48 mutant revealed formation of cellular chains 
and cells with abnormal septa suggestive of cell separation arrest, we further investigated cell 
division using FtsZ as a division reporter. This was achieved by assessing localization of 
GFP-tagged derivative of FtsZ in the wildtype and mutant strains as described in section 2.14. 
Localization of FtsZ_GFP in the ∆cdc48 mutant confirmed the formation of multiple septa, as 
indicated by the presence of multiple foci (Figure 3.31 and 3.32). This confirmed the 
presence of cellular chains consisting of multiple cells, separated by septal bridges. The 
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number of septa per bacterium was quantified and it was observed that 40 % of ∆cdc48 cells 
contained at least three septa in contrast to only 2 % for wildtype as shown in Figure 3.32. 
The proportion of cells that had at least one septum was 99 % in the wildtype and 
approximately 60 % in the ∆cdc48 mutant. 
 
Figure 3.31: Localization of FtsZ_GFP in the ∆cdc48 mutant in comparison to the wildtype. (A) In the 
wildtype mc
2
155 strain, FtsZ_GFP localized to the division site as displayed by the formation of a single mid-
cell foci (white arrow). (B) FtsZ_GFP displayed a punctate localization pattern in the mutant strain (white 
arrows). 100 cells were assessed per experiment. 
 
Figure 3.32: Quantification of FtsZ_GFP in vivo localization patterns. The graph shows that 99 % and 60% 
of cells displayed FtsZ_GFP mid-cell localization in the wildtype and mutant strains, respectively. In the ∆cdc48 
mutant, 40 % of cells exhibited punctate FtsZ_GFP localization pattern as shown by formation of multiple foci. 
n=100 Error bars represent standard error obtained from standard deviation. *: p ˂ 0.05. 
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4. Discussion 
TB continues to be a significant public health burden and the leading cause of death 
worldwide despite the availability of treatment (WHO, 2015). The alarming rise of drug 
resistance has compromised the efficacy of current anti-TB therapies. In addition, the 
intrinsic resistance of mycobacteria to most antimicrobial agents has further given rise to 
challenges in TB treatment. This intrinsic resistance is attributed to the impermeable nature of 
the mycobacterial cell wall, which provides a barrier to toxic substances and limits the 
diffusion of drugs into the cell (Brennan and Nikaido, 1995). Considering this, there is an 
urgent need for new and highly effective therapeutics. In this context, the mycobacterial cell 
wall has been identified as a potential drug target for development of anti-TB drugs, 
particularly the PG layer. The coordination of PG remodelling is crucial for bacterial growth 
and division, as well as maintenance of structural integrity, disruption of which could result 
in cell death. Furthermore, disturbances in PG metabolism can lead to increased cell wall 
permeability due to compromised cell wall integrity, eventually giving rise to antibiotic 
susceptibility (Kieser et al., 2015a). Therefore, understanding mycobacterial cell wall 
biosynthesis and identifying key protein complexes that underlie cell growth and division is 
crucial for the development of novel anti-TB drugs. 
The constant growth and division of the cell requires continuous remodelling of the PG layer 
to allow for a range of functions, including the insertion of newly synthesized units (Peters et 
al., 2016). This process is facilitated by multiple enzymes and tight coordination of the 
activity of these enzymes is required to maintain bacterial cell shape, structural integrity and 
cell viability (Cava et al., 2013). This study focuses on D,D-CPases, a set of enzymes 
involved in regulating the amount of PG cross-links by trimming pentapeptides in the newly 
synthesized PG to tetrapeptides, via removal of the terminal D-alanine (Peters et al., 2016). 
D,D-CPases are present in high protein copy number per cell, when compared to their HMM 
counterparts and they have been implicated in maintenance of bacterial cell shape (Nelson 
and Young, 2001). In E. coli all 7 D,D-CPases are dispensable for cell survival, with the 
exception of PBP5, and deletion of these enzymes does not affect cell growth or morphology 
(Nelson and Young, 2001). Collective studies conducted in our lab demonstrated that Msm 
encodes four D,D-CPase homologues, which during growth are expressed in varying 
abundance, and deletion of these enzymes resulted in no growth or morphological defects, 
with the exception of MSMEG_6113,  which could not be deleted as it is essential for 
mycobacterial growth (Ealand et al., unpublished). Several studies have revealed the 
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existence of protein-protein interaction complexes that are pivotal to a number of 
mycobacterial cellular processes. PBPs have been proposed to act in a complex to fully exert 
their function in cell growth and division (Sauvage et al., 2008). To further expand our 
knowledge on the functional roles of the essential MSMEG_6113 and the highly expressed 
(in terms of transcript abundance) MSMEG_2433, additional studies were conducted to 
establish a foundation for investigating whether these D,D-CPases exert their functions as 
individual proteins or whether they form part of protein complexes in mycobacteria. These 
studies revealed that MSMEG_6113 and MSMEG_2433 interact with key regulators of cell 
division and elongation (D. Ralefeta and R. Asmal, unpublished). Considering these findings, 
we sought to further interrogate the role of the two D,D-CPases through protein interaction 
and genetic knockout studies in Msm. 
Two previous MSc studies, by D. Ralefeta and R. Asmal, identified D,D-CPase interacting 
partners using either bacterial or yeast 2-hybrid systems respectively. In this study, we sought 
to confirm the interacting partners for MSMEG_6113 and MSMEG_2433 that were 
previously identified by Mr. D. Ralefeta using full length clones. The roles of MSMEG_6113 
and MSMEG_2433 in mycobacterial physiology were further investigated by confirming 
interaction between the two D,D-CPases and their identified putative partnering proteins as 
well as characterizing these partners. Confirmation of these interacting partners was achieved 
by the use of M-PFC assay. Whilst numerous partners were confirmed, only four partners 
(two for each) were taken forward due to time constrains. In addition, only a subset of 
MSMEG_6113 partners were further characterized through gene knockout studies as 
MSMEG_6113 is considered to be essential. 
Interaction of MSMEG_6113 and MSMEG_2433 with HMM PBPs  
HMM PBPs participate in PG synthesis through glycosyltransferase activities and 
transpeptidase activities and they have been shown to play a role in cell elongation and 
septation (Ghosh et al., 2008). In this study, we report that the transpeptidase domain of Msm 
D,D-CPases is responsible for mediating interaction between D,D-CPases and HMM PBPs. 
Our data suggest that FtsI, a class B PBP and PonA1, a class A PBP, bind to the PG 
hydrolase domain of MSMEG_6113 and MSMEG_2433 respectively. These individual 
interactions form complexes, possibly involved in PG synthesis and hydrolysis during cell 
growth and division. In E. coli, a PG synthase PBP1B has been shown to interact with a lytic 
transglycosylase MltA and structural protein MipA, providing evidence that PG-synthesizing 
94 
 
and hydrolyzing complexes assemble to facilitate PG elongation and mid-cell septation 
(Vollmer et al., 1999). Multiple interactions between PG remodelling enzymes with different 
functions have also been identified in mycobacteria (Hett et al., 2008; Hett et al., 2010). 
FtsI, is one of the essential septasomal components for cell division in mycobacteria and 
related organisms (Weiss et al., 1999; Wissel et al., 2004; Datta et al., 2006). The essentiality 
of this gene for mycobacterial viability was demonstrated in this study where generation of 
ftsI deletion mutant by allelic exchange was not possible, confirming that the gene is essential 
for in vitro growth. Consistent with these results is the observation that Mtb ftsI counterpart is 
essential for growth as determined by transposon mutagenesis (Sassetti et al., 2003). In E. 
coli, localization of FtsI to the division site is seen at later stages of cell growth and 
throughout septation (Weiss et al., 1999). Moreover, its localization to the division site is 
dependent on FtsZ and other intervening Fts proteins suggesting that FtsI is recruited to the 
septal ring through a cascade of protein-protein interactions involved in divisome assembly 
(Buddelmeijer and Beckwith, 2002; Wissel et al., 2004). A multiprotein interaction complex 
containing FtsI-FtsW-FtsZ has been identified in mycobacteria and this complex is proposed 
to regulate the initiation of septation (Datta et al, 2006). Interaction between the C-tail of 
FtsW and FtsZ strengthens FtsW and FtsI interaction, providing a link between septal PG 
biosynthesis and cell division (Datta et al., 2006). FtsI has also been demonstrated to 
associate with Wag31 (the polar anchor protein) during transitioning of the division septum 
to the pole (Mukherjee et al., 2009). Herein we demonstrate a novel interaction between 
MSMGE_6113 and FtsI in Msm. This interaction suggests that MSMEG_6113 may be 
involved in regulating septal PG hydrolysis during the process of cytokinesis, considering 
that FtsI is involved in initiation of septation.  
PonA1 is a major determinant of polar growth in mycobacteria and the rate of polar growth is 
modulated by phosphorylation (Kieser et al., 2015a). In Msm, PonA1 predominantly localizes 
to the cell poles where it promotes PG expansion and localizes occasionally at the septum 
during cell division (Hett et al., 2010; Kieser et al., 2015a). PonA1 is involved in regulation 
of a number of cellular processes in mycobacteria including spatial establishment of the new 
pole growth and maintenance of cell shape and length, both of which are required for normal 
mycobacterial growth and are critical during Mtb infection (Kieser et al., 2015a). Depletion 
of ponA1 in mycobacteria results in growth defects and formation of cells with morphological 
abnormalities (Hett et al., 2010, Kieser et al., 2015a), suggesting that PonA1 is important for 
maintaining cell wall synthesis. In addition, alteration in PonA1 activity results in changes in 
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antibiotic susceptibility in both Msm and Mtb (Kieser et al., 2015a). Similar to FtsI, PonA1 
has also been found to form protein interaction complexes. For instance, it interacts with the 
essential PG hydrolase RipA, where it modulates the activity of RipA during cytokinesis 
(Hett et al., 2010). In another study it was reported to associate with L,D-transpeptidase LdtB 
in Mtb, suggesting that PBPs work together with transpeptidases to synthesize new PG during 
growth (Kieser et al., 2015b). The identified interaction between PonA1 and MSMEG_2433 
in this study indicates that MSMEG_2433 may be recruited to the poles by PonA1 following 
organization of a new pole, where MSMEG_2433 is involved in PG hydrolysis during 
elongation.  
Interaction of MSMEG_6113 and MSMEG_2433 with AAA+ protein family 
Members of the AAA+ protein family are commonly referred to as AAA+ proteases and are 
prevalent in all taxa (Alhuwaider and Dougan, 2017). This family of proteases use common 
structural and operational mechanisms to perform diverse biological functions in the cell, 
including protein quality control, proteolysis, protein and nucleic acid translocation, 
membrane fusion, DNA replication and recombination, transcription regulation, biogenesis of 
organelles and remodelling of macromolecular complexes (Neuwald et al., 1999; Ogura and 
Wilkinson, 2001; Erzberger and Berger, 2006). The molecular mechanisms of these proteins 
and how they function in mycobacteria are still at the early stages of discovery. Recent work 
has highlighted the significance of AAA proteases in the physiology of mycobacteria and 
several mycobacterial AAA proteases have been biochemically characterized, including the 
essential zinc metalloprotease FtsH (Anilkumar et al., 2004; Srinivasan et al., 2006), the 
proteasome ATPase Rv2115c (Darwin et al., 2005), the essential casein lytic protein (Clp) 
proteases ClpC1 and ClpX (Schmitz and Sauer, 2014) and Msm0858/Cdc48 (Unciuleac et 
al., 2016). In this study, we focus on Msm FtsH and Cdc48. 
The role of FtsH is poorly understood in mycobacteria, nevertheless, based on E. coli FtsH 
mutant strain complementation experiments, it appears that mycobacterial FtsH shares 
overlapping substrate specificity with E. coli FtsH, as it can recognize heterologous substrates 
such as heat shock transcription factor σ32, SecY proteins and the phage λ CII repressor 
protein (Anilkumar et al., 2004; Srinivasan et al., 2006). Amino acid sequence alignment 
demonstrated that Msm FtsH shares conserved regions with that of E. coli as the two share 
48.4 % identity at the amino acid sequence level. Based on these observations, FtsH is 
proposed to play a role in quality control mechanisms in mycobacteria, enabling regulation of 
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protein complex activities by controlling the availability of specific integral and cytoplasmic 
proteins and/or their degradation rate (Anilkumar et al., 2004; Srinivasan et al., 2006). In B. 
subtilis, GFP tagged derivative of FtsH displays mid-cell localization in dividing vegetative 
cells (Wehrl et al., 2000) suggesting a possible role for this protease in septal biogenesis. In 
addition to septal localization, Anilkumar and colleagues demonstrated that in E. coli, the cell 
division protein FtsZ is subjected to degradation by FtsH in vitro, pointing to an additional 
role for FtsH as a negative regulator of FtsZ (Anilkumar et al. 2001). This is further 
substantiated by the observed reduced intracellular levels of FtsZ in Mtb FtsH-overexpressing 
strain (Kiran et al., 2009). In Mtb, expression levels of FtsH are upregulated upon exposure to 
reactive nitrogen and oxygen intermediates, as well as growth in macrophages (Kiran et al., 
2009). In addition, a FtsH overexpression strain displays growth defects and reduced viability 
ex vivo and in vitro, pointing to the fact that FtsH plays a crucial role in stress response 
pathways and cell survival (Kiran et al., 2009). Considering that MSMEG_2433 interacts 
with FtsH in Msm, it is possible that the former is involved in septal PG hydrolysis where its 
activity is regulated by FtsH, which in turn interacts with FtsZ and could directly regulate the 
levels of FtsZ by its proteolytic activity. We propose that a MSMEG_2433-FtsH-FtsZ 
complex regulates initiation of septation in mycobacteria. However, our explanations in this 
regard are speculative and require further investigation. 
The cell division protein Cdc48 is relatively uncharacterized in prokaryotic cells. It belongs 
to the same family of proteins as FtsH, which is involved in a number of cellular processes in 
mycobacteria including regulation of FtsZ. One of the key functions of Cdc48 is to maintain 
protein homeostasis via a network of protein quality control processes (Meyer et al., 2012). 
Cdc48 shares conserved motifs with FtsH but it is unclear whether this protein retains a 
proteolytic mechanism to facilitate similar cellular processes as FtsH. However, there is a 
possibility that Cdc48 could directly play a role in regulating FtsZ levels or indirectly 
influence FtsZ levels by degrading other proteins that stabilize FtsZ. Herein we demonstrate 
interaction between MSMEG_6113 and Cdc48 and propose that MSMEG_6113 is involved 
in cellular pathways that mediate the correct septal placement during cell division through 
interaction with Cdc48. Given that Cdc48 is not well characterized in bacteria, we 
investigated its role in the physiology of mycobacteria through gene knockout studies and our 
results support our hypothesis of a possible MSMEG_6113-Cdc48-FtsZ complex, which 
links PG synthesis and cell division. As with FtsI, this hypothesis requires further 
investigation. 
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Deletion of cdc48 from the genome of Msm resulted in no significant defects in cell survival 
and bacterial growth kinetics, confirming that this gene is not essential for mycobacterial 
growth and survival in vitro. These results are supported by previous findings from a high 
density mutagenesis screen that demonstrated that the Mtb homologue of cdc48 was non- 
essential for growth in vitro (Sassetti et al., 2003; Griffin et al., 2011). However, the 
enhanced sensitivity to amoxicillin, D-cycloserine and vancomycin as well as a probable 
increase in cell wall permeability that prevails when Cdc48 is deleted, suggests a possible 
role for Cdc48 in maintaining cell wall integrity. Cdc48 possibly maintains the integrity of 
the cell wall by regulating the amount and/or the activity of MSMEG_6113. In the absence of 
Cdc48, the transpeptidase activity of MSMEG_6113 may be dysregulated, resulting in a 
decrease in cross-links formation due to the unavailability of the tetrapeptide substrate 
required by HMM PBPs and/or L,D- transpeptidases. This could lead to a weakened cell wall 
with increased permeability to antibiotics. In mycobacteria, loss of endopeptidase activity of 
RipA and RipC results in increased susceptibility to lysozyme (Mavrici et al., 2014, 
Martinelli and Pavelka, 2016). In addition, deletion of RipA and RipB causes enhanced 
sensitivity to erythromycin, rifampicin and vancomycin (Mavrici et al., 2014, Martinelli and 
Pavelka, 2016). Kieser and colleagues (2015b) demonstrated that the inactivation of LdtMt2 
and PonA2 causes enhanced sensitivity to teicoplanin and meropenem, while PonA1 deletion 
increases sensitivity to ethambutol. Our study and these previous findings indicate that 
disruption of cell wall integrity increases cell wall permeability and also results in enhanced 
antibiotic sensitivity. Figure 4.1 illustrates the proposed model for Cdc48 function in 
mycobacteria. 
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Figure 4.1: Proposed model of Cdc48 function in mycobacterial physiology: Cdc48 forms a protein complex 
with MSMEG_6113, a D,D-CPase involved in PG hydrolysis. (A) When Cdc48 is present, it regulates the 
activity and/or amount of MSMEG_6113 which functions to modulate the degree of PG cross-links by trimming 
pentapeptides in the newly synthesized PG to tetrapeptides. The generated tetrapeptides are then used as 
substrates for formation of 3-3 and 3-4 cross-links by Ldts and HMM PBPs respectively, resulting in a thick, 
rigid PG layer. (B) When the Cdc48-MSMEG_6113 complex is disrupted by deletion/inactivation of Cdc48, the 
hydrolase activity of MSMEG_6113 gets dysregulated, resulting in accumulation of pentapeptides which might 
form inappropriate (red line) cross-links or an overall decrease in PG cross-links due to the absence of the 
substrate. This then causes the PG layer to lose its structural and morphological integrity, giving rise to the 
defects observed. This explanation is largely speculative and requires further validation. Figure drawn by 
student. 
Microscopic analyses of the ∆cdc48 deletion strain revealed the presence of morphological 
defects such as cells with globular bulges, multiple septa and formation of chains suggesting 
that Cdc48 is required for proper coordination of cell separation. Localization of new PG 
synthesis revealed no defects in PG synthesis as the ∆cdc48 deletion strain retained polar 
and/or septal PG localization patterns. However, the last stages of cell division were arrested, 
particularly cell separation. In the PBP5 mutant, formation of cells with chains (similar to 
∆cdc48 phenotype) was observed and this phenotype was thought to be due to an increase in 
pentapeptide side-chain levels, which caused formation of inappropriate inter-strand peptide 
cross-links (Nelson and Young, 2001). The production of cells with globular bulges in the 
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∆cdc48 deletion strain phenocopies the morphology of PonA1 depleted strain. This 
morphological defect is characteristic of dysregulated and/or increased PG hydrolytic 
activity, causing loss of structural integrity. Bulbous regions in the PonA1 depleted strain is 
indicative of increased cell wall hydrolysis and loss of morphological and structural integrity 
(Hett et al., 2010). Recent findings demonstrated that the absence of non-classical 
transpeptidases, which catalyse the predominant 3-3 cross-links in PG, LdtA and LdtB, leads 
to production of short bulging cells (Schoonmaker et al., 2014). RipA requires proteolytic 
cleavage for its full catalytic activity to degrade septal PG and separate daughter cells 
(Ruggiero et al., 2010; Chao et al., 2013). In mycobacteria, this hydrolase has been shown to 
be activated through interaction with RpfB (Hett et al., 2008) and more recently, Botella and 
colleagues demonstrated that the periplasmic protease MarP, activates RipA during acid 
stress (Botella et al., 2017). Based on our interaction work and the observed phenotypes, we 
propose that Cdc48 is involved in PG hydrolysis where it regulates the activity of 
MSMEG_6113 and possibly other hydrolases involved in septal PG degradation to facilitate 
cell separation. Given that the role of Cdc48 in cell division has not been elucidated, our 
explanations in this regard require further validations. 
To further investigate division defects in our mutants, we assessed localization of GFP tagged 
derivative of FtsZ in Msm. Polymerization of FtsZ into a ring-like structure initiates 
septation. The FtsZ ring functions as a scaffold for downstream septal PG remodelling 
enzymes and it produces the energy required for constriction of the membrane during cell 
division (Hett et al., 2008). The observation of multiple FtsZ rings in the ∆cdc48 deletion 
strain indicates failure to coordinate cell division. Formation of multiple FtsZ rings in this 
strain could results from FtsZ misplacement or dysregulated FtsZ levels due to the absence of 
putative FtsZ regulator proposed in this study, Cdc48. These results support the Cdc48-Ftsz 
protein complex proposed earlier herein, where Cdc48 regulates FtsZ levels directly or 
indirectly by degrading FtsZ stabilizing proteins. However, further analysis of these results is 
needed to validate the presence of the proposed complex in coordinating mycobacterial cell 
growth and division, as well as elucidating the mechanism by which Cdc48 regulates FtsZ. 
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5. Conclusion and future studies 
5.1. Conclusion 
Careful coordination of cell wall remodelling is critical for mycobacterial growth and 
division. Collectively, this MSc demonstrates the presence of protein-protein interaction 
complexes containing PG synthases and hydrolases, as well as proteases, which function 
together to facilitate both growth and division. Our results confirm that D,D-CPases exert 
their function through interaction with other proteins in the cell and are required for 
maintaining cell wall integrity. This is the first study to identify Cdc48 as part of the 
regulatory mechanism that controls mycobacterial growth and division. This was evidenced 
by lack of coordinated cell division and dysregulated cell wall integrity in the absence of this 
protein. Our study highlights that identification and disruption of key protein complexes 
could present a mechanism to block cell growth and thus identify possible drug targets that 
can be exploited for the development of new TB drugs. 
5.2. Future Studies 
Future work will entail interrogation of the functional roles of the remaining D,D-CPase 
interacting partners through gene knockout/knockdown studies. Co-localization of the 
identified partners would also be useful do elucidate the mechanisms by which these proteins 
function together to coordinate crucial cellular processes. As our results revealed the 
existence of MSMEG_6113 and Cdc48 protein complex, and a possible role of Cdc48 in 
regulating the activity of MSMEG_6113 during PG hydrolysis, assessment of the behaviour 
of MSMEG_6113 in the absence of Cdc48 would provide further support for the putative role 
of Cdc48 in division regulation. 
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6. Appendices 
Appendix A – Media and Solutions 
Table A1. Media and supplements 
Media / 
Supplement 
Components 
Luria- Bertani 
Agar (LA) 
5 g yeast extract, 10 g tryptone, 10 g NaCl and 1.5 g agar dissolved in 1L 
sdH2O. 
Luria- Bertani 
Broth (LB) 
5 g yeast extract, 10 g tryptone and 10 g NaCl dissolved in 1L sdH2O. 
2xTY 10 g yeast extract, 16 g tryptone and 10 g NaCl dissolved in 1L sdH2O. 
Middlebrook 
7H9 
4.7 g Difco Middlebrook 7H9 powder and 2ml glycerol dissolved in 986 
ml sdH2O. Autoclave. 10 ml 100 X glucose salts and 2 ml Tween80. 
Middlebrook 
7H10 
19 g Difco Middlebrook 7H10 powder and 5ml glycerol dissolved in 985 
ml sdH2O. Autoclave. 10 ml 100 X glucose salts.  
Glucose salts 
(100X) 
20 g glucose and 8.5 g NaCl dissolved in 100 ml sdH2O. 
Tween80 (25%) 10 ml Tween80 dissolved in 40 ml sdH2O. 
Sucrose (75%) 75 g sucrose dissolved in 100 ml sdH2O 
X-gal (2)% 1 g X- gal dissolved in 50 ml deionized DMF 
 
Table A2. Solutions used for E. coli plasmid DNA extractions 
Solution Composition 
Solution I 50 mM glucose, 25 mM Tris- HCl (pH 8) and 10 mM EDTA dissolved in 
sdH2O. Autoclave. 
Solution II 1% SDS and 0.2 M NaOH dissolved in sdH2O. 
Solution III 3 M Potassium acetate and 11.5% acetic acid dissolved in sdH2O. 
 
Table A3. Solutions used for Msm DNA extractions   
Solutions  Composition 
TE buffer 10 mM Tris- HCl (pH 8) and 10 mM EDTA dissolved in sdH2O. 
Autoclave. 
CTAB/NaCl 4.1% NaCl and 10% N – acetyl- N, N, N – trimethyl ammonium bromide 
dissolved in sdH2O. Filter sterilize.  
 
 Table A.4 Solutions used for DNA precipitation  
Solution Composition 
Chloroform: 
Isoamyl alcohol 
24 ml chloroform and 1ml isoamyl alcohol. 
Sodium Acetate 3 M sodium acetate dissolved in sdH2O (pH5.2). Autoclave. 
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Table A5. Solutions used for DNA electrophoresis   
Solution Composition 
TAE 50 X stock solution: 242 g Tris base 57.1 ml glacial acetic and 100 ml 
EDTA (pH 8) made up to 1L with sdH2O. 
Ethidium Bromide 10 mg/ml dissolved in sdH2O. 
 
Table A6. Agarose gel recipes 
Gel percentage Amount of agarose (g) in 50 ml TAE 
0.8 0.4 
1 0.5 
2 1 
 
Table A7. Solutions used for preparation of E. coli competent cells  
Solution  Composition  
TfbI  30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium 
chloride, 50 mM manganese chloride and 15% v/v glycerol made up in 
sdH2O. Adjusted to pH 5.8 with acetic acid. 
TfbII 10 mM rubidium chloride, 75 mM calcium chloride, 10 mM MOPS and 
15% v/v glycerol made up in sdH2O. Adjusted to pH 6.5 with diluted 
NAOH.  
 
Table A8. Southern blot solutions 
Solution Composition 
Denaturation solution 1.5 M NaCl and 0.5 M NaOH dissolved in sdH2O. 
Depurination solution 0.25 M HCl dissolved in sdH2O. 
TBE (1X) 100 ml 10 X Tris-Borate-EDTA (Sigma) dissolved in 900 ml 
sdH2O. 
SSC (20X) 0.3 M Sodium citrate and 3 M NaCl dissolved in sdH2O. 
SDS (10%) 10 g SDS powder dissolved in 100 ml sdH2O. 
Solution 1 0.1% SDS and 2 X SSC dissolved in sdH2O. 
Solution 2 0.1% SDS and 0.5 X SSC dissolved in sdH2O. 
Maleic Acid Buffer 1.5 M NaCl and 1 M Maleic acid dissolved in sdH2O. Adjusted to 
pH 7.5 with NaOH pellets. 
Wash buffer 0.1 M Maleic Acid Buffer and 0.3% Tween20. 
Blocking solution 
(Roche) 
1 X blocking solutions dissolved in Maleic Acid Butter. 
Detection buffer 0.1 M NaCl and 0.1 M Tris-HCl dissolved in sdH2O (pH 9.5) 
Antibody solution 
(Roche) 
Dilute 1: 10000 in blocking solution. 
CSPD ( Roche) Disodium 3-(4-methoxysoiro {1, 2-dioxetane-3, 2‟-(5‟-chloro) 
tricycle [3.3.1.1
3,7
] decan}-4-yl)phenyl phosphate. 
Stripping solution 0.2 M NaOH and 0.1% SDS dissolved in sdH2O. 
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Appendix B: Primers 
Table B1: Primers used for generation of full length partners for M-PFC assay 
Primer pair Primer sequence Restriction 
site 
MSMEG_2433_F 
MSMEG_2433_R 
CGCGCGGAATTCATGTGGAGGTACGCCTTCGGG 
GCGCGCAAGCTTTCAGAGCGCCCCGATGCTCGC 
EcoRI 
HindIII 
MSMEG_6900_F 
MSMEG_6900_R 
CGCGCGCAGCTGATGCCGCCCGACGACCGGTTG 
GCGCGCAAGCTTTCACGGAGGCGGCGGGGCTCC 
PvuII 
HindIII 
MSMEG_4227_F 
MSMEG_4227_R 
CGCGCGCTGCAGATGAACAAGGGTTCGCGGGAC 
GCGCGCAAGCTTTCATGACGCCTTCTTCCGTGC 
PstI 
HindIII 
MSMEG_0031_F 
MSMEG_0031_R 
CGCGCGGGATCCATGAACACCTCACTGCGCCGG 
GCGCGCAAGCTTTCATGAACCCTCCCGCAGCGC 
BamHI 
HindIII 
MSMEG_6105_F 
MSMEG_6105_R 
CGCGCGGGATCCATGAACCGGAAAAATGTTATC 
GCGCGCAAGCTTTCAGCCGTGCGGGTTCGACCG 
BamHI 
HindIII 
MSMEG_6113_F 
MSMEG_6113_R 
CGCGCGGAATTCATGAGCGATAGGCTGACGCGC 
GCGCGCAAGCTTTCATGCGCCGCATCCGCAGCT 
EcoRI 
HindIII 
MSMEG_4233_F 
MSMEG_4233_R 
CGCGCGGGATCCATGAGCCGGCGGGGCGACCGT 
GCGCGCAAGCTTTCAGGTGGCCTGCAATGTCAA 
BamHI 
HindIII 
MSMEG_0858_F 
MSMEG_0858_R 
CGCGCGCAGCTGGGAAGGTGACATGTCGCAGGG 
GCGCGCAAGCTTTCGTCGAGGGTCAACGCTTCT 
PvuII 
HindIII 
MSMEG_5637_F 
MSMEG_5637_R 
CGCGCGCTGCAGATGTACAGCATGCGCAGGTCG 
GCGCGCAAGCTTTCATCTGGTGAACGTCCCCGT 
PstI 
HindIII 
MSMEG_0365_F 
MSMEG_0365_R 
CGCGCGCAGCTGATGCCGGGTTCGATCTTTGAG 
GCGCGC AAGCTTTCATCTCACCGGCACCCGCGG 
PvuII 
HindIII 
MSMEG_6112_F 
MSMEG_6112_R 
CGCGCGCTGCAGATGAGCCGGCCCACCATGACC 
GCGCGCAAGCTTTCACAGCACGCGATCGATCCA 
PstI 
HindIII 
*The underlined region indicates the restriction site used for cloning.  
Table B2: Primers used for domain truncation  
Primer pair Primer sequence Restriction 
site 
MSMEG_2433SP_F CGCGCGCAGCTGATGTGGAGGTACGCCTTCGGG PvuII 
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MSMEG_2433SP_R GCGCGCAAGCTTCGCGCGGGCGACGGGCACTGC HindIII 
MSMEG_2433TP_F 
MSMEG_2433TP_R 
CGCGCGCAGCTGGGTCGGATCGGTGGCCCCGCC 
GCGCGCAAGCTTGCCGTACATCATCGCGATCAC 
PvuII 
HindIII 
MSMEG_2433CT_F 
MSMEG_2433CT_R 
CGCGCGCAGCTGCTGGTGAAAGAGGGCGGGCCG 
GCGCGCAAGCTTTCAGAGCGCCCCGATGCTCGC 
PvuII 
HindIII 
MSMEG_6113SP_F 
MSMEG_6113SP_R 
CGCGCGCAGCTGATGAGCGATAGGCTGACGCGC 
GCGCGCAAGCTTCGCGGCGGCGACGACGGCGAC 
PvuII 
HindIII 
MSMEG_6113LR_F 
MSMEG_6113LR_R 
CGCGCGCAGCTGGCCCTGTTCACCGGCAAACAC 
GCGCGCAAGCTTGTGGGCTGTGTGCGCCCACCG 
PvuII 
HindIII 
MSMEG_6113TP_F 
MSMEG_6113TP_R 
CGCGCGGAATTCCACCGTGGAATCGCGGCGGTC 
GCGCGCAAGCTTTCATGCGCCGCATCCGCAGCT 
EcoRI 
HindIII 
 *The underlined region indicates the restriction site used for cloning.  
Table B3: Primers used for amplification of genes for mutant generation 
Primer pair Primer sequence Restriction 
site 
MSMEG_0858US_F 
MSMEG_0858US_R 
GTGGGTACCTCCAGCATTCCCCCGATG 
GTGAGATCTCAGCGCGGAGGTGTTCAG 
Acc65I 
BglII 
MSMEG_0858DS_F 
MSMEG_0858DS_R 
GTGAGATCTGTCACGGCCGCCGACGTC 
GTGAAGCTTTGGGCAGAACCGTGTTGG 
BglII 
HindIII 
MSMEG_4233US_F 
MSMEG_4233US_R 
GTGAAGCTTGGCGCACCGGCGGCCATC 
GTGAGATCTCACGCGGGTACGCCGGGT 
HindIII 
BglII 
MSMEG_4233DS_F 
MSMEG_4233DS_R 
GTGAGATCTGCGCCGTTGTTCCACGAG 
GTGGGTACC CCTTTACCCGCGATCAGC 
BglII 
Acc65I 
*The underlined region indicates the restriction site used for cloning.  
Table B4: Primers used for amplification of genes for mutant complementation 
Primer pair Primer sequence Restriction 
site 
MSMEG_0858cmp_F 
MSMEG_0858cmp_R 
GCGCGCGATATCCATCGTGATCATGGTCATCAT 
GCGCGCGATATCCTAACGCTTCTCGGCGAACTC 
EcoRV 
EcoRV 
MSMEG_4233cmp_F 
MSMEG_4233cmp_R 
GCGCGCGATATCCCGTTGGCGACGCCACAGGCG 
GCGCGCGATATCTCAGGTGGCCTGCAATGTCAA 
EcoRV 
EcoRV 
*The underlined region indicates the restriction site used for cloning.  
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Table B5: Primers used for confirmation of site specific integration of complementing 
vector 
Primer pair Primer sequence Restriction 
site 
attBS2 
attL4 
ACAGGATTTGAACCTGCGGC 
AATTCTTGCAGACCCCTGGA 
None 
attBS1 
attL1 
ACGTGGCGGTCCCTACCG 
CTTGGATCCTCCCGCTGCGC 
None 
 
Appendix C: Figures 
 
 
Figure C1: Restriction profile of pUAB300. (A) 0.8% agarose gel indicating expected DNA band sizes, lane 
(1) DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) AatII, lane (4) Acc65I, lane(5) BglII, 
lane (6) EcoRI, lane (7) NruI, lane (8) XhoI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of pUAB300 vector. 
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Figure C2: Restriction profile of pUAB400. (A) 0.8% agarose gel indicating expected DNA band sizes, lane 
(1) DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) NruI, lane (4) NspI, lane (5) PstI, lane 
(6) PvuI, lane (7) SmaI, lane (8) XhoI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of pUAB400 vector. 
 
 
Figure C3: Restriction profile of pUAB400::2433. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) HindIII, lane (4) PstI, lane (5) 
PvuI, lane (6) SmaI, lane (7) XhoI. (B) Table showing restriction enzymes used for profiling and the expected 
fragment sizes. (C) Plasmid map of the final pUAB400::2433 construct used for transformation. 
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Figure C4: Restriction profile of pUAB300::6900. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) Acc65I, lane (4) AscI, lane (5) 
BglII, lane (6) EcoRI, lane (7) XhoI. (B) Table showing restriction enzymes used for profiling and the expected 
fragment sizes. (C) Plasmid map of the final pUAB300::6900 construct used for transformation. 
 
 
Figure C5: Restriction profile of pUAB300::4227. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) Acc65I, lane (5) 
BamHI, lane (6) BglII, lane (7) EcoRI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of the final pUAB300::4227 construct used for transformation. 
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Figure C6: Restriction profile of pUAB300::0031. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) Acc65I, lane (5) 
BglII, lane (6) BspHI, lane (7) EcoRI. (B) Table showing restriction enzymes used for profiling and the expected 
fragment sizes. (C) Plasmid map of the final pUAB300::0031 construct used for transformation. 
 
Figure C7: Restriction profile of pUAB300::6105. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) Acc65I, lane (5) 
BglII, lane (6) EcoRI, lane (7) NotI, lane (8) SmaI. (B) Table showing restriction enzymes used for profiling and 
the expected fragment sizes. (C) Plasmid map of the final pUAB300::6105 construct used for transformation. 
NotI digest yielded aberrant bands shown by * in figure A lane 7. 
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Figure C8: Restriction profile of pUAB400::6113. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) PstI, lane (4) SmaI, lane (5) 
SphI, lane (6) XbaI, lane (7) XhoI. (B) Table showing restriction enzymes used for profiling and the expected 
fragment sizes. (C) Plasmid map of the final pUAB400::6113 construct used for transformation. SphI digest 
yielded an extra band due to the enzyme star activity. 
  
Figure C9: Restriction profile of pUAB300::4233. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) Acc65I, lane(5) 
NruI, lane (6) BglII, lane (7) XhoI. (B) Table showing restriction enzymes used for profiling and the 
expectedfragment sizes. (C) Plasmid map of the final pUAB300::4233 construct used for transformation. A 
partial digest by NruI was observed in lane 5 as indicated by additional light bands. 
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Figure C10: Restriction profile of pUAB300::0858. (A) 0.8% agarose gel indicating expected DNA band 
sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) BamHI, lane (4) BglII, 
lane (5) EcoRI, lane (6) NruI, lane (7) XbaI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of the final pUAB300::0858 construct used for transformation. 
 
Figure C11: Restriction profile of pUAB300::5637. (A) 0.8% agarose gel indicating expected DNA band 
sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) EcoRI, lane (4) Acc65I, 
lane(5) AatII, lane (6) BglII, lane (7) XhoI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of the final pUAB300::5637 construct used for transformation. 
Additional light bands in lanes 5 and 6 are most likely the result of partial digests.  
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Figure C12: Restriction profile of pUAB300::0365. (A) 0.8% agarose gel indicating expected DNA band 
sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) AatII, lane (4) BamHI, 
lane(5) BglII, lane (6) EcoRI, lane (7) XhoI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of the final pUAB300::0365 construct used for transformation. 
Additional light bands in lane 4 are most likely the result of partial digests. 
 
Figure C13: Restriction profile of pUAB300::6112. (A) 0.8% agarose gel indicating expected DNA band 
sizes, lane (1) DNA marker III (Fermentas), lane (2) uncut construct control, lane (3) XhoI, lane (4) EcoRI, 
lane(5) BglII, lane (6) AatII, lane (7) NruI, lane (8) PvuII. (B) Table showing restriction enzymes used for 
profiling and the expected fragment sizes. (C) Plasmid map of the final pUAB300::6112 construct used for 
transformation. Additional light bands in lanes 5 and 7 are most likely the result of partial digests. 
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Figure C14: Restriction profile of p2NIL. (A) 0.8% agarose gel indicating expected DNA band sizes, lane (1) 
DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) Acc65I, lane (4) AccI, lane(5) BamHI, lane 
(6) BspHI, lane (7) PvuI. (B) Table showing restriction enzymes used for profiling and the expected fragment 
sizes. (C) Plasmid map of the p2NIL vector. 
  
Figure C15: Restriction profile of p2NILcdc48. (A) 0.8% agarose gel indicating expected DNA band sizes, 
lane (1) DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) Acc65I, lane (4) BamHI, lane(5) 
BspHI, lane (6) EcoRI, lane (7) NotI, lane (8) XmnI. (B) Table showing restriction enzymes used for profiling 
and the expected fragment sizes. (C) Plasmid map of the final p2NILcdc48 construct used for transformation. 
113 
 
 
Figure C16: Restriction profile of p2NILftsI. (A) 0.8% agarose gel indicating expected DNA band sizes, lane 
(1) DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) BspHI, lane (4) MluI, lane(5) NotI, lane 
(6) PacI, lane (7) PvuI, lane (8) XmnI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of the final p2NILftsI construct used for transformation. 
 
Figure C17: Restriction profile of pGOAL17. (A) 0.8% agarose gel indicating expected DNA band sizes, lane 
(1) DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) AatII, lane (4) Acc65II, lane(5) AccI, 
lane (6) BamHI, lane (7) BsrGI, lane (8) NruI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of pGOAL17 vector. * in lane 5 shows that AccI digest yielded 
aberrant bands most likely the results of the enzyme mapping to the vector backbone and not the region of 
interest. * in lane 7 indicates that the two fragments run together as indicated by the bright single band. 
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Figure C18: Restriction profile of pMV306H. (A) 0.8% agarose gel indicating expected DNA band sizes, lane 
(1) DNA marker III (Fermentas), lane (2) uncut vector control, lane (3) Acc65I, lane (4) BamHI, lane(5) BglII, 
lane (6) MscI, lane (7) EcoRI, lane (8) PstI. (B) Table showing restriction enzymes used for profiling and the 
expected fragment sizes. (C) Plasmid map of pMV306H vector. 
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Figure C19: ∆cdc48 cell wall permeability assessment. Cell wall permeability was monitored by quantifying 
accumulation of EtBr (5 µg/ml) into the cells of the ∆cdc48 mutant strain, wildtype and complemented strains 
over an hour. (A) The data obtained from experiment 2.  (B) The data obtained from experiment 3. 
Appendix D: DNA molecular weight markers 
 
Figure D1: DNA molecular weight markers used in this study.  
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